

(19) World Intellectual Property Organization  
International Bureau(43) International Publication Date  
7 February 2002 (07.02.2002)

PCT

(10) International Publication Number  
WO 02/10355 A2

(51) International Patent Classification: C12N 9/00

(21) International Application Number: PCT/DK01/00488

(22) International Filing Date: 12 July 2001 (12.07.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
 PA 2000 01160 1 August 2000 (01.08.2000) DK  
 PA 2000 01354 12 September 2000 (12.09.2000) DK  
 PA 2000 01687 10 November 2000 (10.11.2000) DK  
 PA 2001 00655 26 April 2001 (26.04.2001) DK

(71) Applicant: NOVOZYMES A/S [DK/DK]; Kroghshøjvej  
 36, DK-2880 Bagsvaerd (DK).

(72) Inventors: THISTED, Thomas; Rungsted Bytove 9, 1.  
 35, DK-2900 Rungsted Kyst (DK); KJÆRHUUS, Søren;  
 Kongensdalvej 47, DK-2720 Vanløse (DK); ANDERSEN,  
 Carsten; Højeholst Vange 162, DK-3500 Værløse (DK);  
 FUGLSANG, Claus, CRONE; Poppelbøj 43, DK-2950  
 Nivå (DK).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,  
 AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
 CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
 GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
 LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,  
 MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK,  
 SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW,

(84) Designated States (regional): ARIPO patent (GH, GM,  
 KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian  
 patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European  
 patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,  
 IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,  
 CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

## Published:

--- without international search report and to be republished  
 upon receipt of that report

--- with sequence listing part of description published sepa-  
 rately in electronic form and available upon request from  
 the International Bureau

For two-letter codes and other abbreviations, refer to the "Guid-  
 ance Notes on Codes and Abbreviations" appearing at the begin-  
 ning of each regular issue of the PCT Gazette.

WO 02/10355 A2

(54) Title: ALPHA-AMYLASE MUTANTS WITH ALTERED PROPERTIES

(57) Abstract: The present invention relates to variants (mutants) of parent Termamyl-like alpha-amylases, which variant has alpha-amylase activity and exhibits altered stability, in particular at high temperatures and/or at low pH relative, and/or low Ca2+ to the parent alpha-amylase.

## Alpha-amylase mutants with altered properties

### FIELD OF THE INVENTION

The present invention relates to variants (mutants) of parent Termamyl-like alpha-amylases, which variant has alpha-amylase activity and exhibits an alteration in at least one of the following properties relative to said parent alpha-amylase: stability under, e.g., high temperature and/or low pH conditions, in particular at low calcium concentrations. The variant of the invention are suitable for starch conversion, ethanol production, laundry wash, dish wash, hard surface cleaning, textile desizing, and/or sweetener production.

### BACKGROUND OF THE INVENTION

Alpha-Amylases (alpha-1,4-glucan-4-glucanohydrolases, E.C. 3.2.1.1) constitute a group of enzymes, which catalyze hydrolysis of starch and other linear and branched 1,4-glucosidic oligo- and polysaccharides.

### BRIEF DISCLOSURE OF THE INVENTION

The object of the present invention is to provide Termamyl-like amylases which variants in comparison to the corresponding parent alpha-amylase, i.e., un-mutated alpha-amylase, has alpha-amylase activity and exhibits an alteration in at least one of the following properties relative to said parent alpha-amylase: stability under, e.g., high temperature and/or low pH conditions, in particular at low calcium concentrations.

### Nomenclature

In the present description and claims, the conventional one-letter and three-letter codes for amino acid residues are

used. For ease of reference, alpha-amylase variants of the invention are described by use of the following nomenclature:

Original amino acid(s): position(s): substituted amino acid(s)

According to this nomenclature, for instance the substitution of alanine for asparagine in position 30 is shown as:

Ala30Asn or A30N

a deletion of alanine in the same position is shown as:

Ala30\* or A30\*

and insertion of an additional amino acid residue, such as lysine, is shown as:

Ala30AlaLys or A30AK

A deletion of a consecutive stretch of amino acid residues, such as amino acid residues 30-33, is indicated as (30-33)\* or  
Δ(A30-N33).

Where a specific alpha-amylase contains a "deletion" in comparison with other alpha-amylases and an insertion is made in such a position this is indicated as:

\*36Asp or \*36D

for insertion of an aspartic acid in position 36.

Multiple mutations are separated by plus signs, i.e.:

Ala30Asp + Glu34Ser or A30N+E34S

representing mutations in positions 30 and 34 substituting alanine and glutamic acid for asparagine and serine, respectively.

When one or more alternative amino acid residues may be inserted in a given position it is indicated as

A30N,E or

A30N or A30E

Furthermore, when a position suitable for modification is identified herein without any specific modification being suggested, it is to be understood that any amino acid residue may be substituted for the amino acid residue present in the

position. Thus, for instance, when a modification of an alanine in position 30 is mentioned, but not specified, it is to be understood that the alanine may be deleted or substituted for any other amino acid, i.e., any one of:

5 R,N,D,A,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V.

Further, "A30X" means any one of the following substitutions:

A30R, A30N, A30D, A30C, A30Q, A30E, A30G, A30H, A30I, A30L, A30K, A30M, A30F, A30P, A30S, A30T, A30W, A30Y, or A30 V; or in short: A30R,N,D,C,Q,E,G,H,I,L,K,M,F,P,S,T,W,Y,V.

10 If the parent enzyme - used for the numbering - already has the amino acid residue in question suggested for substitution in that position the following nomenclature is used:

"X30N" or "X30N,V" in the case where for instance one or N or V is present in the wildtype.

15 Thus, it means that other corresponding parent enzymes are substituted to an "Asn" or "Val" in position 30.

#### BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is an alignment of the amino acid sequences of  
20 five parent Termamyl-like alpha-amylases. The numbers on the extreme left designate the respective amino acid sequences as follows:

1: SEQ ID NO: 4 (SP722)

2: SEQ ID NO: 2 (SP690)

25 3: SEQ ID NO: 10 (BAN)

4: SEQ ID NO: 8 (BLA)

5: SEQ ID NO: 6 (BSG).

#### DETAILED DISCLOSURE OF THE INVENTION

30 The object of the present invention is to provide Termamyl-like amylases, which variants have alpha-amylase activity and exhibits altered stability at high temperatures and/or at low pH, in particular at low calcium concentrations.

## Termamyl-like alpha-amylases

A number of alpha-amylases produced by *Bacillus* spp. are highly homologous (identical) on the amino acid level.

- s The identity of a number of known *Bacillus* alpha-amylases can be found in the below Table 1:

Table 1

	Percent identity	707	AP137	BAN	BSG	SP690	SP722	AA560	Termamyl
			8						1
707	100.0		86.4	66.9	66.5	87.6	86.2	95.5	68.1
AP1378	86.4		100.0	67.1	68.1	95.1	86.6	86.0	69.4
BAN	66.9		67.1	100.0	65.6	67.1	68.8	66.9	80.7
BSG	66.5		68.1	65.6	100.0	67.9	67.1	66.3	65.4
SP690	87.6		95.1	67.1	67.9	100.0	87.2	87.0	69.2
SP722	86.2		86.6	68.8	67.1	87.2	100.0	86.8	70.8
AA560	95.5		86.0	66.9	66.3	87.0	86.8	100.0	68.3
Termamyl	68.1		69.4	80.7	65.4	69.2	70.8	68.3	100.0

10

- For instance, the *B. licheniformis* alpha-amylase comprising the amino acid sequence shown in SEQ ID NO: 8 (commercially available as Termamyl™) has been found to be about 81% homologous with the *B. amyloliquefaciens* alpha-amylase comprising the amino acid sequence shown in SEQ ID NO: 10 and about 65% homologous with the *B. stearothermophilus* alpha-amylase (BSG) comprising the amino acid sequence shown in SEQ ID NO: 6. Further homologous alpha-amylases include SP690 and SP722 disclosed in WO 95/26397 and further depicted in SEQ ID NO: 2 and SEQ ID NO: 4, respectively, herein. Other amylases are the AA560 alpha-amylase derived from *Bacillus* sp. and shown in SEQ ID NO: 12, and the #707 alpha-amylase derived from *Bacillus* sp., shown in SEQ ID NO: 13 and described by Tsukamoto et al., Biochemical and Biophysical Research Communications, 151 (1988), pp. 25-31.
- 25

The KSM AP1378 alpha-amylase is disclosed in WO 97/00324 (from KAO Corporation).

Still further homologous alpha-amylases include the alpha-amylase produced by the *B. licheniformis* strain described in EP 0252666 (ATCC 27811), and the alpha-amylases identified in WO 91/00353 and WO 94/18314. Other commercial Termamyl-like alpha-amylases are comprised in the products sold under the following tradenames: Optitherm™ and Takatherm™ (Solvay); Maxamyl™ (available from Gist-brocades/Genencor), Spezyme AA™ and Spezyme Delta AATM (available from Genencor), and Keistase™ (available from Daiwa), Dex 10, GC 521 (available from Genencor) and Ultraphlow (from Enzyme Biosystems).

Because of the substantial homology found between these alpha-amylases, they are considered to belong to the same class of alpha-amylases, namely the class of "Termamyl-like alpha-amylases".

Accordingly, in the present context, the term "Termamyl-like" alpha-amylase" is intended to indicate an alpha-amylase, in particular *Bacillus* alpha-amylase, which, at the amino acid level, exhibits a substantial identity to Termamyl™, i.e., the *B. licheniformis* alpha-amylase having the amino acid sequence shown in SEQ ID NO: 8, herein.

In other words, all the following alpha-amylases, which has the amino acid sequences shown in SEQ ID NOS: 2, 4, 6, 8, 10, 12 and 13 herein are considered to be "Termamyl-like alpha-amylase". Other Termamyl-like alpha-amylases are alpha-amylases i) which displays at least 60%, such as at least 70%, e.g., at least 75%, or at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, at least 99% homology (identity) with at least one of said amino acid sequences shown in SEQ ID NOS: 2, 4, 6, 8, 10, 12, and 13, and/or is encoded by a DNA sequence which hybridizes to the DNA

sequences encoding the above-specified alpha-amylases which are apparent from SEQ ID NOS: 1, 3, 5, 7, 9, and of the present specification (which encoding sequences encode the amino acid sequences shown in SEQ ID NOS: 2, 4, 6, 8, 10 and 12 herein, respectively).

### Homology

The homology may be determined as the degree of identity between the two sequences indicating a derivation of the first sequence from the second. The homology may suitably be determined by means of computer programs known in the art such as GAP provided in the GCG program package (described above). Thus, Gap GCGv8 may be used with the default scoring matrix for identity and the following default parameters: GAP creation penalty of 5.0 and GAP extension penalty of 0.3, respectively for nucleic acidic sequence comparison, and GAP creation penalty of 3.0 and GAP extension penalty of 0.1, respectively, for protein sequence comparison. GAP uses the method of Needleman and Wunsch, (1970), J.Mol. Biol. 48, p.443-453, to make alignments and to calculate the identity.

A structural alignment between Termamyl (SEQ ID NO: 8) and, e.g., another alpha-amylase may be used to identify equivalent/corresponding positions in other Termamyl-like alpha-amylases. One method of obtaining said structural alignment is to use the Pile Up programme from the GCG package using default values of gap penalties, i.e., a gap creation penalty of 3.0 and gap extension penalty of 0.1. Other structural alignment methods include the hydrophobic cluster analysis (Gaboriaud et al., (1987), FEBS LETTERS 224, pp. 149-155) and reverse threading (Huber, T; Torda, AE, PROTEIN SCIENCE Vol. 7, No. 1 pp. 142-149 (1998).

Hybridisation

The oligonucleotide probe used in the characterisation of the Termamyl-like alpha-amylase above may suitably be prepared on the basis of the full or partial nucleotide or amino acid sequence of the alpha-amylase in question.

Suitable conditions for testing hybridisation involve pre-soaking in 5xSSC and prehybridizing for 1 hour at 40°C in a solution of 20% formamide, 5xDenhardt's solution, 50mM sodium phosphate, pH 6.8, and 50mg of denatured sonicated calf thymus DNA, followed by hybridisation in the same solution supplemented with 100 mM ATP for 18 hours at 40°C, followed by three times washing of the filter in 2xSSC, 0.2% SDS at 40°C for 30 minutes (low stringency), preferred at 50°C (medium stringency), more preferably at 65°C (high stringency), even more preferably at 75°C (very high stringency). More details about the hybridisation method can be found in Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd Ed., Cold Spring Harbor, 1989.

In the present context, "derived from" is intended not only to indicate an alpha-amylase produced or producible by a strain of the organism in question, but also an alpha-amylase encoded by a DNA sequence isolated from such strain and produced in a host organism transformed with said DNA sequence. Finally, the term is intended to indicate an alpha-amylase, which is encoded by a DNA sequence of synthetic and/or cDNA origin and which has the identifying characteristics of the alpha-amylase in question. The term is also intended to indicate that the parent alpha-amylase may be a variant of a naturally occurring alpha-amylase, i.e., a variant, which is the result of a modification (insertion, substitution, deletion) of one or more amino acid residues of the naturally occurring alpha-amylase.



Parent Termamyl-like Alpha-amylases

According to the invention all Termamyl-like alpha-amylases, as defined above, may be used as the parent (i.e., backbone) alpha-amylase. In a preferred embodiment of the invention the parent alpha-amylase is derived from *B. licheniformis*, e.g., one of those referred to above, such as the *B. licheniformis* alpha-amylase having the amino acid sequence shown in SEQ ID NO: 8.

Parent hybrid Termamyl-like Alpha-amylases

The parent alpha-amylase (i.e., backbone alpha-amylase) may also be a hybrid alpha-amylase, i.e., an alpha-amylase, which comprises a combination of partial amino acid sequences derived from at least two alpha-amylases.

The parent hybrid alpha-amylase may be one, which on the basis of amino acid homology (identity) and/or DNA hybridization (as defined above) can be determined to belong to the Termamyl-like alpha-amylase family. In this case, the hybrid alpha-amylase is typically composed of at least one part of a Termamyl-like alpha-amylase and part(s) of one or more other alpha-amylases selected from Termamyl-like alpha-amylases or non-Termamyl-like alpha-amylases of microbial (bacterial or fungal) and/or mammalian origin.

Thus, the parent hybrid alpha-amylase may comprise a combination of partial amino acid sequences deriving from at least two Termamyl-like alpha-amylases, or from at least one Termamyl-like and at least one non-Termamyl-like bacterial alpha-amylase, or from at least one Termamyl-like and at least one fungal alpha-amylase. The Termamyl-like alpha-amylase from which a partial amino acid sequence derives, may be any of the specific Termamyl-like alpha-amylase referred to herein.

For instance, the parent alpha-amylase may comprise a C-terminal part of an alpha-amylase derived from a strain of *B. licheniformis*, and a N-terminal part of an alpha-amylase derived from a strain of *B. amyloliquefaciens* or from a strain of *B. stearothermophilus*. For instance, the parent alpha-amylase may comprise at least 430 amino acid residues of the C-terminal part of the *B. licheniformis* alpha-amylase, and may, e.g., comprise a) an amino acid segment corresponding to the 37 N-terminal amino acid residues of the *B. amyloliquefaciens* alpha-amylase having the amino acid sequence shown in SEQ ID NO: 10 and an amino acid segment corresponding to the 445 C-terminal amino acid residues of the *B. licheniformis* alpha-amylase having the amino acid sequence shown in SEQ ID NO: 8, or a hybrid Termamyl-like alpha-amylase being identical to the Termamyl sequence, i.e., the *Bacillus licheniformis* alpha-amylase shown in SEQ ID NO: 8, except that the N-terminal 35 amino acid residues (of the mature protein) has been replaced by the N-terminal 33 residues of BAN (mature protein), i.e., the *Bacillus amyloliquefaciens* alpha-amylase shown in SEQ ID NO: 10; or b) an amino acid segment corresponding to the 68 N-terminal amino acid residues of the *B. stearothermophilus* alpha-amylase having the amino acid sequence shown in SEQ ID NO: 6 and an amino acid segment corresponding to the 415 C-terminal amino acid residues of the *B. licheniformis* alpha-amylase having the amino acid sequence shown in SEQ ID NO: 8.

Another suitable parent hybrid alpha-amylase is the one previously described in WO 96/23874 (from Novo Nordisk) constituting the N-terminus of BAN, *Bacillus amyloliquefaciens* alpha-amylase (amino acids 1-300 of the mature protein) and the C-terminus from Termamyl (amino acids 301-483 of the mature protein).

In a preferred embodiment of the invention the parent Termamyl-like alpha-amylase is a hybrid alpha-amylase of SEQ ID NO: 8 and SEQ ID NO: 10. Specifically, the parent hybrid Termamyl-like alpha-amylase may be a hybrid alpha-amylase comprising the 445 C-terminal amino acid residues of the B. licheniformis alpha-amylase shown in SEQ ID NO: 8 and the 37 N-terminal amino acid residues of the alpha-amylase derived from B. amyloliquefaciens shown in SEQ ID NO: 10, which may suitably further have the following mutations:

10 H156Y+A181T+N190F+A209V+Q264S (using the numbering in SEQ ID NO: 8). The latter mentioned hybrid is used in the examples below and is referred to as LE174.

Other specifically contemplated parent alpha-amylase include LE174 with fewer mutations, i.e., the right above mentioned hybrid having the following mutations:

15 A181T+N190F+A209V+Q264S; N190F+A209V+Q264S; A209V+Q264S; Q264S; H156Y+N190F+A209V+Q264S; H156Y+A209V+Q264S; H156Y+Q264S; H156Y+A181T+A209V+Q264S; H156Y+A181T+Q264S; H156Y+Q264S; H156Y+A181T+N190F+Q264S; H156Y+A181T+N190F;

20 H156Y+A181T+N190F+A209V. These hybrids are also considered to be part of the invention.

In a preferred embodiment the parent Termamyl-like alpha amylase is LE174, SP722, or AA560 including any of LE174+G48A+T49I+G107A+I201F; LE174+M197L;

25 LE174+G48A+T49I+G107A+M197L+I201F, or SP722+D183\*+G184\*;

SP722+D183\*+G184\*+N195F; SP722+D183\*+G184\*+M202L; SP722+D183\*+G184\*+N195F+M202L; BSG+I181\*+G182\*;

BSG+I181\*+G182\*+N193F; BSG+I181\*+G182\*+M200L; BSG+I181\*+G182\*+N193F+M200L;

30 AA560+D183\*+G184\*; AA560+D183\*+G184\*+N195F; AA560+D183\*+G184\*+M202L; AA560+D183\*+G184\*+N195F+M202L.

Other parent alpha-amylases contemplated include LE429, which is LE174 with an additional substitution in I201F.

According to the invention LE335 is the alpha-amylase, which in comparison to LE429 has additional substitutions in T49I+G107A; LE399 is LE335+G48A, i.e., LE174, with G48A+T49I+G107A+I201F.

5

#### Altered properties

The following section discusses the relationship between mutations, which are present in variants of the invention, and desirable alterations in properties (relative to those of a parent Termamyl-like alpha-amylase), which may result therefrom.

As mentioned above the invention relates to Termamyl-like alpha-amylases with altered properties (as mentioned above), in particular at high temperatures and/or at low pH, in particular at low calcium concentrations.

In the context of the present invention "high temperature" means temperatures from 70-120°C, preferably 80-100°C, especially 85-95°C.

In the context of the present invention the term "low pH" means from a pH in the range from 4-6, preferably 4.2-5.5, especially 4.5-5.

In the context of the present invention the term "high pH" means from a pH in the range from 8-11, especially 8.5-10.6.

In the context of the present invention the term "low calcium concentration" means free calcium levels lower than 60 ppm, preferably 40 ppm, more preferably 25 ppm, especially 5 ppm calcium.

Parent Termamyl-like alpha-amylase specifically contemplated in connection with going through the specifically contemplated altered properties are the above mentioned parent Termamyl-like alpha-amylase and parent hydrid Termamyl-like alpha-amylases.

The Termamyl® alpha-amylase is used as the starting point, but corresponding positions in, e.g., the SP722, BSG, BAN, AA560, SP690, KSM AP1378, and #707 should be understood as disclosed and specifically contemplated too.

- 5 In a preferred embodiment the variant of the invention has in particular at high temperatures and/or at low pH.

In an aspect the invention relates to variant with altered properties as mentioned above.

- In the first aspect a variant of a parent Termamyl-like  
10 alpha-amylase, comprising an alteration at one or more positions (using SEQ ID NO: 8 for the amino acid numbering) selected from the group of:

49, 60, 104, 132, 161, 170, 176, 179, 180, 181, 183, 200, 203,  
204, 207, 212, 237, 239, 250, 280, 298, 318, 374, 385, 393,  
15 402, 406, 427, 430, 440, 444, 447, 482,

wherein

(a) the alteration(s) are independently

- (i) an insertion of an amino acid downstream of the amino  
acid which occupies the position,  
20 (ii) a deletion of the amino acid which occupies the  
position, or  
(iii) a substitution of the amino acid which occupies the  
position with a different amino acid,

- (b) the variant has alpha-amylase activity and (c) each  
25 position corresponds to a position of the amino acid sequence  
of the parent Termamyl-like alpha-amylase having the amino  
acid sequence shown in SEQ ID NO: 8.

In Termamyl® (SEQ ID NO: 8) such corresponding positions  
are:

- 30 T49; D60; N104; E132; D161; K170; K176; G179; K180; A181; D183;  
D200; Y203; D204; D207; I212; K237; S239; E250; N280; Q298;  
L318; Q374; E385; Q393; Y402; H406; L427 D430; V440; N444; E447;  
Q482.

In SP722 (SEQ ID NO: 4) the corresponding positions are:

T51; D62; N106; D134; D163; Q172; K179; G184; K185; A186;  
D188; D205; M208; D209; X212; L217, K242, S244, N255, N285,  
S303, M323; D387, N395; Y404; H408; I429; D432; V442; K446;  
5 Q449; K484.

Corresponding positions in other parent alpha-amylases can be found by alignment as described above and shown in the alignment in Fig. 1.

In a preferred embodiment the variant of the invention  
10 (using SEQ ID NO: 8 (Termamyl™) for the numbering) has one or more of the following substitutions:

T49I; D60N; N104D; E132A,V,P; D161N; K170Q; K176R; G179N; K180T;  
A181N; D183N; D200N; X203Y; D204S; D207V,E,L,G; X212I; K237F;  
S239W; E250G,F; N280S; X298Q; L318M; Q374R; E385V; Q393R; Y402F;  
15 H406L,W; L427I D430N; V440A; N444R,K; E447Q,K; Q482K.

In a preferred embodiment the variant of the invention (using SEQ ID NO: 4 (SP722) for the numbering) has one or more of the following substitutions:

T51I; D62N; N106D; D134A,V,P; D163N; X172Q; K179R; G184N;  
20 K185T; A186N; D188N; D205N; M208Y; D209S; X212V,E,L,G; L217I,  
K242P, S244W, N255G,F, N285S, S303Q, X323M; D387V, N395R;  
Y404F; H406L,W; X429I; D432N; V442A; X446R,K; X449Q,K; X484K,  
using SEQ ID NO: 4 (SP722) for the numbering.

Preferred double, triple and multi-mutations - using SEQ ID  
25 NO: 8 as the basis for the numbering - are selected from the group consisting of:

T49I+D60N; T49I+D60N+E132A; T49I+D60N+E132V;  
T49I+D60N+E132V+K170Q; T49I+D60N+E132A+K170Q;  
T49I+D60N+E132V+K170Q+K176R; T49I+D60N+E132A+K170Q+K176R;  
30 T49I+D60N+E132V+K170Q+K176R+D207V;  
T49I+D60N+E132A+K170Q+K176R+D207V;  
T49I+D60N+E132V+K170Q+K176R+D207E;  
T49I+D60N+E132A+K170Q+K176R+D207E;

- T49I+D60N+E132V+K170Q+K176R+D207V+E250G;  
T49I+D60N+E132A+K170Q+K176R+D207V+E250G;  
T49I+D60N+E132V+K170Q+K176R+D207E+E250G;  
T49I+D60N+E132A+K170Q+K176R+D207E+E250G;  
5 T49I+D60N+E132V+K170Q+K176R+D207E+E250G+N280S;  
T49I+D60N+E132A+K170Q+K176R+D207E+E250G+N280S;  
T49I+D60N+E132V+K170Q+K176R+D207V+E250G+N280S;  
T49I+D60N+E132A+K170Q+K176R+D207V+E250G+N280S;  
T49I+D60N+E132V+K170Q+K176R+D207V+E250G+N280S+L318M;  
10 T49I+D60N+E132A+K170Q+K176R+D207V+E250G+N280S+L318M;  
T49I+D60N+E132V+K170Q+K176R+D207E+E250G+N280S+L318M;  
T49I+D60N+E132A+K170Q+K176R+D207E+E250G+N280S+L318M;  
T49I+D60N+E132V+K170Q+K176R+D207V+E250G+N280S+L318M+Q374R;  
T49I+D60N+E132A+K170Q+K176R+D207V+E250G+N280S+L318M+Q374R;  
15 T49I+D60N+E132V+K170Q+K176R+D207E+E250G+N280S+L318M+Q374R;  
T49I+D60N+E132A+K170Q+K176R+D207E+E250G+N280S+L318M+Q374R;  
T49I+D60N+E132V+K170Q+K176R+D207V+E250G+N280S+L318M+Q374R+  
E385V;  
T49I+D60N+E132A+K170Q+K176R+D207V+E250G+N280S+L318M+Q374R+  
20 E385V;  
T49I+D60N+E132V+K170Q+K176R+D207E+E250G+N280S+L318M+Q374R+  
E385V;  
T49I+D60N+E132A+K170Q+K176R+D207E+E250G+N280S+L318M+Q374R+  
E385V;  
25 T49I+D60N+E132V+K170Q+K176R+D207V+E250G+N280S+L318M+Q373R+  
E385V+Q393R;  
T49I+D60N+E132A+K170Q+K176R+D207V+E250G+N280S+L318M+Q374R+  
E385V+Q393R;  
T49I+D60N+E132V+K170Q+K176R+D207E+E250G+N280S+L318M+Q374R+  
30 E385V+Q393R;  
T49I+D60N+E132A+K170Q+K176R+D207E+E250G+N280S+L318M+Q374R+E385  
V+ Q393R;

- T49I+D60N+E132V+K170Q+K176R+D207V+E250G+N280S+L318M+Q373R+  
E385V+Q393R+Y402F;  
T49I+D60N+E132A+K170Q+K176R+D207V+E250G+N280S+L318M+Q374R+  
E385V+Q393R+Y402F;  
5 T49I+D60N+E132V+K170Q+K176R+D207E+E250G+N280S+L318M+Q374R+  
E385V+Q393R+Y402F;  
T49I+D60N+E132A+K170Q+K176R+D207E+E250G+N280S+L318M+Q374R+E385  
V+ Q393R+Y402F;  
T49I+D60N+E132V+K170Q+K176R+D207V+E250G+N280S+L318M+Q373R+  
10 E385V+Q393R+Y402F+H406L;  
T49I+D60N+E132A+K170Q+K176R+D207V+E250G+N280S+L318M+Q374R+  
E385V+Q393R+Y402F+H406L;  
T49I+D60N+E132V+K170Q+K176R+D207E+E250G+N280S+L318M+Q374R+  
E385V+Q393R+Y402F+H406L;  
15 T49I+D60N+E132A+K170Q+K176R+D207E+E250G+N280S+L318M+Q374R+E385  
V+ Q393R+Y402F+H406L;  
T49I+D60N+E132V+K170Q+K176R+D207V+E250G+N280S+L318M+Q373R+  
E385V+Q393R+Y402F+H406L+L427I;  
T49I+D60N+E132A+K170Q+K176R+D207V+E250G+N280S+L318M+Q374R+  
20 E385V+Q393R+Y402F+H406L+L427I;  
T49I+D60N+E132V+K170Q+K176R+D207E+E250G+N280S+L318M+Q374R+  
E385V+Q393R+Y402F+H406L+L427I;  
T49I+D60N+E132A+K170Q+K176R+D207E+E250G+N280S+L318M+Q374R+E385  
V+ Q393R+Y402F+H406L+L427I;  
25 T49I+D60N+E132V+K170Q+K176R+D207V+E250G+N280S+L318M+Q373R+  
E385V+Q393R+Y402F+H406L+L427I+V440A;  
T49I+D60N+E132A+K170Q+K176R+D207V+E250G+N280S+L318M+Q374R+  
E385V+Q393R+Y402F+H406L+L427I+V440A;  
T49I+D60N+E132V+K170Q+K176R+D207E+E250G+N280S+L318M+Q374R+  
30 E385V+Q393R+Y402F+H406L+L427I+V440A;  
T49I+D60N+E132A+K170Q+K176R+D207E+E250G+N280S+L318M+Q374R+E385  
V+ Q393R+Y402F+H406L+L427I+V440A;



- D60N+E132A; D60N+E132V; D60N+E132V+K170Q; D60N+E132A+K170Q;  
D60N+E132V+K170Q+K176R; T49I+D60N+E132A+K170Q+K176R;  
D60N+E132V+K170Q+K176R+D207V;  
T49I+D60N+E132A+K170Q+K176R+D207V;  
5 D60N+E132V+K170Q+K176R+D207E;  
T49I+D60N+E132A+K170Q+K176R+D207E;  
D60N+E132V+K170Q+K176R+D207V+E250G;  
D60N+E132A+K170Q+K176R+D207V+E250G;  
D60N+E132V+K170Q+K176R+D207E+E250G;  
10 D60N+E132A+K170Q+K176R+D207E+E250G;  
D60N+E132V+K170Q+K176R+D207V+E250G+N280S;  
D60N+E132A+K170Q+K176R+D207V+E250G+N280S;  
D60N+E132V+K170Q+K176R+D207E+E250G+N280S;  
D60N+E132A+K170Q+K176R+D207E+E250G+N280S;  
15 D60N+E132V+K170Q+K176R+D207V+E250G+N280S+L318M;  
D60N+E132A+K170Q+K176R+D207V+E250G+N280S+L318M;  
D60N+E132V+K170Q+K176R+D207E+E250G+N280S+L318M;  
D60N+E132A+K170Q+K176R+D207E+E250G+N280S+L318M;  
D60N+E132V+K170Q+K176R+D207V+E250G+N280S+L318M+Q374R;  
20 D60N+E132A+K170Q+K176R+D207V+E250G+N280S+L318M+Q374R;  
D60N+E132V+K170Q+K176R+D207E+E250G+N280S+L318M+Q374R;  
D60N+E132A+K170Q+K176R+D207E+E250G+N280S+L318M+Q374R;  
D60N+E132V+K170Q+K176R+D207E+E250G+N280S+L318M+Q374R+E385V;  
D60N+E132A+K170Q+K176R+D207E+E250G+N280S+L318M+Q374R+E385V;  
25 D60N+E132V+K170Q+K176R+D207E+E250G+N280S+L318M+Q374R+E385V;  
D60N+E132A+K170Q+K176R+D207E+E250G+N280S+L318M+Q374R+E385V;  
D60N+E132V+K170Q+K176R+D207V+E250G+N280S+L318M+Q373R+  
E385V+Q393R+Y402F;  
D60N+E132A+K170Q+K176R+D207V+E250G+N280S+L318M+Q374R+  
30 E385V+Q393R+Y402F;  
D60N+E132V+K170Q+K176R+D207E+E250G+N280S+L318M+Q374R+  
E385V+Q393R+Y402F;

- D60N+E132A+K170Q+K176R+D207E+E250G+N280S+L318M+Q374R+E385V+  
Q393R+Y402F;  
D60N+E132V+K170Q+K176R+D207V+E250G+N280S+L318M+Q373R+  
E385V+Q393R+Y402F+H406L;  
5 D60N+E132A+K170Q+K176R+D207V+E250G+N280S+L318M+Q374R+  
E385V+Q393R+Y402F+H406L;  
D60N+E132V+K170Q+K176R+D207E+E250G+N280S+L318M+Q374R+  
E385V+Q393R+Y402F+H406L;  
D60N+E132A+K170Q+K176R+D207E+E250G+N280S+L318M+Q374R+E385V+  
10 Q393R+Y402F+H406L;  
D60N+E132V+K170Q+K176R+D207V+E250G+N280S+L318M+Q373R+  
E385V+Q393R+Y402F+H406L+L427I;  
D60N+E132A+K170Q+K176R+D207V+E250G+N280S+L318M+Q374R+  
E385V+Q393R+Y402F+H406L+L427I;  
15 D60N+E132V+K170Q+K176R+D207E+E250G+N280S+L318M+Q374R+  
E385V+Q393R+Y402F+H406L+L427I;  
D60N+E132A+K170Q+K176R+D207E+E250G+N280S+L318M+Q374R+E385V+  
Q393R+Y402F+H406L+L427I;  
D60N+E132V+K170Q+K176R+D207V+E250G+N280S+L318M+Q373R+  
20 E385V+Q393R+Y402F+H406L+L427I+V440A;  
D60N+E132A+K170Q+K176R+D207V+E250G+N280S+L318M+Q374R+  
E385V+Q393R+Y402F+H406L+L427I+V440A;  
D60N+E132V+K170Q+K176R+D207E+E250G+N280S+L318M+Q374R+  
E385V+Q393R+Y402F+H406L+L427I+V440A;  
25 D60N+E132A+K170Q+K176R+D207E+E250G+N280S+L318M+Q374R+E385V+  
Q393R+Y402F+H406L+L427I+V440A;  
E132V+K170Q; E132A+K170Q; E132V+K170Q+K176R;  
E132A+K170Q+K176R;  
E132V+K170Q+K176R+D207V; E132A+K170Q+K176R+D207V;  
30 E132V+K170Q+K176R+D207E; E132A+K170Q+K176R+D207E;  
E132V+K170Q+K176R+D207V+E250G; E132A+K170Q+K176R+D207V+E250G;  
E132V+K170Q+K176R+D207E+E250G; E132A+K170Q+K176R+D207E+E250G;

- E132V+K170Q+K176R+D207E+E250G+N280S;  
E132A+K170Q+K176R+D207E+E250G+N280S;  
E132V+K170Q+K176R+D207V+E250G+N280S;  
E132A+K170Q+K176R+D207V+E250G+N280S;  
5 E132V+K170Q+K176R+D207V+E250G+N280S+L318M;  
E132A+K170Q+K176R+D207V+E250G+N280S+L318M;  
E132V+K170Q+K176R+D207E+E250G+N280S+L318M;  
E132A+K170Q+K176R+D207E+E250G+N280S+L318M;  
E132V+K170Q+K176R+D207V+E250G+N280S+L318M+Q374R;  
10 E132A+K170Q+K176R+D207V+E250G+N280S+L318M+Q374R;  
E132V+K170Q+K176R+D207E+E250G+N280S+L318M+Q374R;  
E132A+K170Q+K176R+D207E+E250G+N280S+L318M+Q374R;  
E132V+K170Q+K176R+D207V+E250G+N280S+L318M+Q374R+E385V;  
E132A+K170Q+K176R+D207V+E250G+N280S+L318M+Q374R+E385V;  
15 E132V+K170Q+K176R+D207E+E250G+N280S+L318M+Q374R+E385V;  
E132A+K170Q+K176R+D207E+E250G+N280S+L318M+Q374R+E385V;  
E132V+K170Q+K176R+D207V+E250G+N280S+L318M+Q373R+E385V+Q393R;  
E132A+K170Q+K176R+D207V+E250G+N280S+L318M+Q374R+E385V+Q393R;  
E132V+K170Q+K176R+D207E+E250G+N280S+L318M+Q374R+E385V+Q393R;  
20 E132A+K170Q+K176R+D207E+E250G+N280S+L318M+Q374R+E385V+Q393R;  
E132V+K170Q+K176R+D207V+E250G+N280S+L318M+Q373R+  
E385V+Q393R+Y402F;  
E132A+K170Q+K176R+D207V+E250G+N280S+L318M+Q374R+  
E385V+Q393R+Y402F;  
25 E132V+K170Q+K176R+D207E+E250G+N280S+L318M+Q374R+  
E385V+Q393R+Y402F;  
E132A+K170Q+K176R+D207E+E250G+N280S+L318M+Q374R+E385V+  
Q393R+Y402F;  
E132V+K170Q+K176R+D207V+E250G+N280S+L318M+Q373R+  
30 E385V+Q393R+Y402F+H406L;  
E132A+K170Q+K176R+D207V+E250G+N280S+L318M+Q374R+  
E385V+Q393R+Y402F+H406L;

- E132V+K170Q+K176R+D207E+E250G+N280S+L318M+Q374R+  
 E385V+Q393R+Y402F+H406L;  
 E132A+K170Q+K176R+D207E+E250G+N280S+L318M+Q374R+E385V+  
 Q393R+Y402F+H406L;  
 5 E132V+K170Q+K176R+D207V+E250G+N280S+L318M+Q373R+  
 E385V+Q393R+Y402F+H406L+L427I;  
 E132A+K170Q+K176R+D207V+E250G+N280S+L318M+Q374R+  
 E385V+Q393R+Y402F+H406L+L427I;  
 E132V+K170Q+K176R+D207E+E250G+N280S+L318M+Q374R+  
 10 E385V+Q393R+Y402F+H406L+L427I;  
 E132A+K170Q+K176R+D207E+E250G+N280S+L318M+Q374R+E385V+  
 Q393R+Y402F+H406L+L427I;  
 E132V+K170Q+K176R+D207V+E250G+N280S+L318M+Q373R+  
 E385V+Q393R+Y402F+H406L+L427I+V440A;  
 15 E132A+K170Q+K176R+D207V+E250G+N280S+L318M+Q374R+  
 E385V+Q393R+Y402F+H406L+L427I+V440A;  
 E132V+K170Q+K176R+D207E+E250G+N280S+L318M+Q374R+  
 E385V+Q393R+Y402F+H406L+L427I+V440A;  
 E132A+K170Q+K176R+D207E+E250G+N280S+L318M+Q374R+E385V+  
 20 Q393R+Y402F+H406L+L427I+V440A;  
 K170Q+K176R; K170Q+K176R+D207V; K170Q+K176R+D207E;  
 K170Q+K176R+D207V+E250G; K170Q+K176R+D207E+E250G;  
 K170Q+K176R+D207V+E250G+N280S; K170Q+K176R+D207E+E250G+N280S;  
 K170Q+K176R+D207E+E250G+N280S+L318M;  
 25 K170Q+K176R+D207V+E250G+N280S+L318M;  
 K170Q+K176R+D207E+E250G+N280S+L318M+Q374R;  
 K170Q+K176R+D207V+E250G+N280S+L318M+Q374R;  
 K170Q+K176R+D207E+E250G+N280S+L318M+Q374R+E385V;  
 K170Q+K176R+D207V+E250G+N280S+L318M+Q374R+E385V;  
 30 K170Q+K176R+D207V+E250G+N280S+L318M+Q374R+E385V+Q393R;  
 K170Q+K176R+D207E+E250G+N280S+L318M+Q374R+E385V+Q393R;  
 K170Q+K176R+D207V+E250G+N280S+L318M+Q374R+E385V+Q393R+Y402F;  
 K170Q+K176R+D207E+E250G+N280S+L318M+Q374R+E385V+Q393R+Y402F;

- K170Q+K176R+D207V+E250G+N280S+L318M+Q373R+385V+Q393R+Y402F+H406L;  
L;  
K170Q+K176R+D207E+E250G+N280S+L318M+Q374R+  
E385V+Q393R+Y402F+H406L;  
5 K170Q+K176R+D207V+E250G+N280S+L318M+Q373R+  
E385V+Q393R+Y402F+H406L+L427I;  
K170Q+K176R+D207E+E250G+N280S+L318M+Q374R+  
E385V+Q393R+Y402F+H406L+L427I;  
K170Q+K176R+D207V+E250G+N280S+L318M+Q373R+  
10 E385V+Q393R+Y402F+H406L+L427I+V440A;  
K170Q+K176R+D207E+E250G+N280S+L318M+Q374R+  
E385V+Q393R+Y402F+H406L+L427I+V440A;  
K176R+D207V; K176R+D207E; K176R+D207V+E250G;  
K176R+D207E+E250G; K176R+D207V+E250G+N280S;  
15 K176R+D207E+E250G+N280S; K176R+D207E+E250G+N280S+L318M;  
K176R+D207V+E250G+N280S+L318M;  
K176R+D207E+E250G+N280S+L318M+Q374R;  
K176R+D207V+E250G+N280S+L318M+Q374R;  
K176R+D207E+E250G+N280S+L318M+Q374R+E385V;  
20 K176R+D207V+E250G+N280S+L318M+Q374R+E385V;  
K176R+D207V+E250G+N280S+L318M+Q374R+E385V+Q393R;  
K176R+D207E+E250G+N280S+L318M+Q374R+E385V+Q393R;  
K176R+D207V+E250G+N280S+L318M+Q374R+E385V+Q393R+Y402F;  
K176R+D207E+E250G+N280S+L318M+Q374R+E385V+Q393R+Y402F;  
25 K176R+D207V+E250G+N280S+L318M+Q374R+E385V+Q393R+Y402F+H406L;  
K176R+D207V+E250G+N280S+L318M+Q374R+  
E385V+Q393R+Y402F+H406L+L427I;  
K176R+D207E+E250G+N280S+L318M+Q374R+  
E385V+Q393R+Y402F+H406L+L427I;  
30 K176R+D207V+E250G+N280S+L318M+Q373R+  
E385V+Q393R+Y402F+H406L+L427I+V440A;  
K176R+D207E+E250G+N280S+L318M+Q374R+  
E385V+Q393R+Y402F+H406L+L427I+V440A;

- D207V+E250G; D207E+E250G;  
D207V+E250G+N280S; D207E+E250G+N280S+L318M;  
D207V+E250G+N280S+L318M; D207E+E250G+N280S+L318M+Q374R;  
D207V+E250G+N280S+L318M+Q374R;  
5 D207E+E250G+N280S+L318M+Q374R+E385V;  
D207V+E250G+N280S+L318M+Q374R+E385V;  
D207V+E250G+N280S+L318M+Q374R+E385V+Q393R;  
D207E+E250G+N280S+L318M+Q374R+E385V+Q393R;  
D207V+E250G+N280S+L318M+Q374R+E385V+Q393R+Y402F;  
10 D207E+E250G+N280S+L318M+Q374R+E385V+Q393R+Y402F;  
D207V+E250G+N280S+L318M+Q374R+E385V+Q393R+Y402F+H406L;  
D207E+E250G+N280S+L318M+Q374R+E385V+Q393R+Y402F+H406L;  
D207V+E250G+N280S+L318M+Q374R+E385V+Q393R+Y402F+H406L+L427I;  
D207E+E250G+N280S+L318M+Q374R+E385V+Q393R+Y402F+H406L+L427I;  
15 D207V+E250G+N280S+L318M+Q374R+E385V+Q393R+Y402F+H406L+L427I+V440  
A;  
D207E+E250G+N280S+L318M+Q374R+E385V+Q393R+Y402F+H406L+L427I+  
V440A; E250G+N280S; E250G+N280S+L318M;  
E250G+N280S+L318M+Q374R;  
20 E250G+N280S+L318M+Q374R+E385V;  
E250G+N280S+L318M+Q374R+E385V+Q393R;  
E250G+N280S+L318M+Q374R+E385V+Q393R+Y402F;  
E250G+N280S+L318M+Q374R+E385V+Q393R+Y402F+H406L;  
E250G+N280S+L318M+Q374R+E385V+Q393R+Y402F+H406L+L427I;  
25 E250G+N280S+L318M+Q374R+E385V+Q393R+Y402F+H406L+L427I+V440A;  
N280S+L318M; N280S+L318M+Q374R; N280S+L318M+Q374R+E385V;  
N280S+L318M+Q374R+E385V+Q393R;  
N280S+L318M+Q374R+E385V+Q393R+Y402F;  
N280S+L318M+Q374R+E385V+Q393R+Y402F+H406L;  
30 N280S+L318M+Q374R+E385V+Q393R+Y402F+H406L+L427I;  
N280S+L318M+Q374R+E385V+Q393R+Y402F+H406L+L427I+V440A;  
L318M+Q374R; L318M+Q374R+E385V; L318M+Q374R+E385V+Q393R;

- L318M+Q374R+E385V+Q393R+Y402F;  
L318M+Q374R+E385V+Q393R+Y402F+H406L;  
L318M+Q374R+E385V+Q393R+Y402F+H406L+L427I;  
L318M+Q374R+E385V+Q393R+Y402F+H406L+L427I+V440A;  
5 Q374R+E385V; Q374R+E385V+Q393R; Q374R+E385V+Q393R+Y402F;  
Q374R+E385V+Q393R+Y402F+H406L;  
Q374R+E385V+Q393R+Y402F+H406L+L427I;  
Q374R+E385V+Q393R+Y402F+H406L+L427I+V440A;  
E385V+Q393R; E385V+Q393R+Y402F; E385V+Q393R+Y402F+H406L;  
10 E385V+Q393R+Y402F+H406L+L427I;  
E385V+Q393R+Y402F+H406L+L427I+V440A;  
Q393R+Y402F; Q393R+Y402F+H406L; Q393R+Y402F+H406L+L427I;  
Q393R+Y402F+H406L+L427I+V440A; Y402F+H406L;  
Y402F+H406L+L427I; Y402F+H406L+L427I+V440A; H406L+L427I;  
15 H406L+L427I+V440A; L427I+V440A;  
N104D+D161N+G179N+K180T+A181N+D183N+D200N+D204S+K237P+S239W+  
H406W+D430N+N444K+E447Q+Q482K;  
D161N+G179N+K180T+A181N+D183N+D200N+D204S+K237P+S239W+H406W+  
D430N+N444K+E447Q+Q482K;  
20 D161N+A181N+D183N+D200N+D204S+K237P+S239W+H406W+  
D430N+N444K+E447Q+Q482K;  
D161N+A181N+D183N+D200N+D204S+K237P+S239W+H406W+  
D430N+E447Q+Q482K;  
N104D+D161N+G179N+K180T+A181N+D183N+D200N+D204S+K237P+S239W+  
25 H406W+D430N+E447Q+Q482K;  
D161N+G179N+K180T+A181N+D183N+D200N+D204S+K237P+S239W+H406W+  
D430N+E447Q+Q482K;  
N104D+D161N+G179N+K180T+A181N+D183N+D200N+D204S+K237P+S239W+  
H406W+D430N;  
30 D161N+G179N+K180T+A181N+D183N+D200N+D204S+K237P+S239W+H406W+  
D430N;  
H406W+D430N; N444K+E447Q+Q482K; E447Q+Q482K;  
N104D+D161N+G179N+K180T+A181N+D183N+D200N+D204S+K237P+S239W+

- H406W+D430N+N444R+N444K+E447K+Q482K;  
 D161N+G179N+K180T+A181N+D183N+D200N+D204S+K237P+S239W+H406W+  
 D430N+N444R+N444K+E447K+Q482K;  
 N104D+D161N+G179N+K180T+A181N+D183N+D200N+D204S+K237P+S239W;  
 5 D161N+G179N+K180T+A181N+D183N+D200N+D204S+K237P+S239W;  
 H406W+D430N; N444K+E447K+Q482K; E447K+Q482K;  
 N104D+D161N+A181N+D183N+D200N+D204S+K237P+S239W;  
 N104D+D161N+A181N+D183N+D200N+D204S+K237P;  
 N104D+D161N+A181N+D183N+D200N+D204S;  
 10 D161N+A181N+D183N+D200N+D204S+K237P+S239W;  
 D161N+A181N+D183N+D200N+D204S+K237P;  
 D161N+A181N+D183N+D200N+D204S; K237P+S239W, using SEQ ID NO: 8  
 for the numbering.

- In a preferred embodiment the variant has the following  
 15 substitutions: K170Q+D207V+N280S; R132A+D207V;  
 D207E+E250G+H406L+L427I; D207V+L318M; D60N+D207V+L318M;  
 T49I+E132V+V440A; T49I+K176R+D207V+Y402F; Q374R+E385V+Q393R;  
 N190F+A209V+Q264S; G48A+T49I+G107A+I201F; T49I+G107A+I201F;  
 G48A+T49I+I201F; G48A+T49I+G107A; T49I+I201F; T49I+G107A;  
 20 G48A+T49I;  
 D161N+G179N+K180T+A181N+D183N+D200N+D204S+K237P+S239W+H406W+  
 D430N+N444K+E447Q+Q482K using SEQ ID NO: 8 for the numbering.  
 Specific variant include: LE399; LE174+G48A+T49I+G107A;  
 LE174+G48A+T49I+I201F; LE174+G48A+G107A+I201F;  
 25 LE174+T49I+G107A+I201F; LE174+G48A+T49I; LE174+G48A;  
 LE174+G107A+I201F; LE174+I201F, are specifically contemplated  
 variants of the invention.

#### Stability

- 30 In the context of the present invention, mutations  
 (including amino acid substitutions and deletion) of  
 importance with respect to achieving altered stability, in  
 particular improved stability (i.e., higher or lower), at



especially high temperatures (i.e., 70-120°C) and/or extreme pH (i.e. low or high pH, i.e, pH 4-6 or pH 8-11, respectively), in particular at free (i.e., unbound, therefore in solution) calcium concentrations below 60 ppm, include any of the mutations listed in the "Altered properties" section. The stability may be determined as described in the "Materials & Methods" section below.

#### General mutations in variants of the invention

10 A variant of the invention may in one embodiment comprise one or more modifications in addition to those outlined above. Thus, it may be advantageous that one or more Proline (Pro) residues present in the part of the alpha-amylase variant which is modified is/are replaced with a non-Proline residue 15 which may be any of the possible, naturally occurring non-Proline residues, and which preferably is an Alanine, Glycine, Serine, Threonine, Valine or Leucine.

Analogously, in one embodiment one or more Cysteine residues present in the parent alpha-amylase may be replaced 20 with a non-Cysteine residue such as Serine, Alanine, Threonine, Glycine, Valine or Leucine.

Furthermore, a variant of the invention may - either as the only modification or in combination with any of the above outlined modifications - be modified so that one or more Asp 25 and/or Glu present in an amino acid fragment corresponding to the amino acid fragment 185-209 of SEQ ID NO: 10 is replaced by an Asn and/or Gln, respectively. Also of interest is the replacement, in the Termamyl-like alpha-amylase, of one or more of the Lys residues present in an amino acid fragment 30 corresponding to the amino acid fragment 185-209 of SEQ ID NO: 10 by an Arg.

It is to be understood that the present invention encompasses variants incorporating two or more of the above outlined modifications.

Furthermore, it may be advantageous to introduce mutations  
5 in one or more of the following positions (using SEQ ID NO: 8 (Termamyl) for the numbering):

M15, V128, A111, H133, W138, T149, M197, N188, A209, A210, H405, T412, in particular the following single, double or triple or multi mutations:

- 10 M15X, in particular M15T,L;  
V128X, in particular V128E;  
H133X, in particular H133Y;  
N188X, in particular N188S,T,P;  
M197X, in particular M197T,L;  
15 A209X, in particular A209V;  
M197T/W138F; M197T/W138Y; M15T/H133Y/N188S;  
M15/V128E/H133Y/N188S; E119C/S130C; D124C/R127C; H133Y/T149I;  
G475R, H133Y/S187D; H133Y/A209V.

20 Methods for preparing alpha-amylase variants of the invention

Several methods for introducing mutations into genes are known in the art. After a brief description of cloning of alpha-amylase-encoding DNA sequences, methods for generating mutations at specific sites within the alpha-amylase-encoding  
25 sequence will be described.

Cloning a DNA sequence encoding an alpha-amylase

The DNA sequence encoding a parent alpha-amylase may be isolated from any cell or microorganism producing the alpha-  
30 amylase in question, using various methods well known in the art. First, a genomic DNA and/or cDNA library should be constructed using chromosomal DNA or messenger RNA from the organism that produces the alpha-amylase to be studied. Then,

if the amino acid sequence of the alpha-amylase is known, homologous, labeled oligonucleotide probes may be synthesized and used to identify alpha-amylase-encoding clones from a genomic library prepared from the organism in question. Alternatively, a labeled oligonucleotide probe containing sequences homologous to a known alpha-amylase gene could be used as a probe to identify alpha-amylase-encoding clones, using hybridization and washing conditions of lower stringency.

Yet another method for identifying alpha-amylase-encoding clones would involve inserting fragments of genomic DNA into an expression vector, such as a plasmid, transforming alpha-amylase-negative bacteria with the resulting genomic DNA library, and then plating the transformed bacteria onto agar containing a substrate for alpha-amylase, thereby allowing clones expressing the alpha-amylase to be identified.

Alternatively, the DNA sequence encoding the enzyme may be prepared synthetically by established standard methods, e.g., the phosphoramidite method described by S.L. Beaucage and M.H. Caruthers, Tetrahedron Letters 22, 1981, pp. 1859-1869, or the method described by Matthes et al., The EMBO J. 3, 1984, pp. 801-805. In the phosphoramidite method, oligonucleotides are synthesized, e.g., in an automatic DNA synthesizer, purified, annealed, ligated and cloned in appropriate vectors.

Finally, the DNA sequence may be of mixed genomic and synthetic origin, mixed synthetic and cDNA origin or mixed genomic and cDNA origin, prepared by ligating fragments of synthetic, genomic or cDNA origin (as appropriate, the fragments corresponding to various parts of the entire DNA sequence), in accordance with standard techniques. The DNA sequence may also be prepared by polymerase chain reaction (PCR) using specific primers, for instance as described in US 4,683,202 or R.K. Saiki et al., Science 239, 1988, pp. 487-491.

#### Site-directed mutagenesis

Once an alpha-amylase-encoding DNA sequence has been isolated, and desirable sites for mutation identified, mutations may be introduced using synthetic oligonucleotides. These oligonucleotides contain nucleotide sequences flanking the desired mutation sites; mutant nucleotides are inserted during oligonucleotide synthesis. In a specific method, a single-stranded gap of DNA, bridging the alpha-amylase-encoding sequence, is created in a vector carrying the alpha-amylase gene. Then the synthetic nucleotide, bearing the desired mutation, is annealed to a homologous portion of the single-stranded DNA. The remaining gap is then filled in with DNA polymerase I (Klenow fragment) and the construct is ligated using T4 ligase. A specific example of this method is described in Morinaga et.al. (1984). US 4,760,025 disclose the introduction of oligonucleotides encoding multiple mutations by performing minor alterations of the cassette. However, an even greater variety of mutations can be introduced at any one time by the Morinaga method, because a multitude of oligonucleotides, of various lengths, can be introduced.

Another method for introducing mutations into alpha-amylase-encoding DNA sequences is described in Nelson and Long

(1989). It involves the 3-step generation of a PCR fragment containing the desired mutation introduced by using a chemically synthesized DNA strand as one of the primers in the PCR reactions. From the PCR-generated fragment, a DNA fragment  
5 carrying the mutation may be isolated by cleavage with restriction endonucleases and reinserted into an expression plasmid.

Alternative methods for providing variants of the invention include gene shuffling, e.g., as described in WO 95/22625  
10 (from Affymax Technologies N.V.) or in WO 96/00343 (from Novo Nordisk A/S), or other corresponding techniques resulting in a hybrid enzyme comprising the mutation(s), e.g., substitution(s) and/or deletion(s), in question. Examples of parent alpha-amylases, which suitably may be used for  
15 providing a hybrid with the desired mutations(s) according to the invention include the KSM-K36 and KSM-K38 alpha-amylases disclosed in EP 1,022,334 (hereby incorporated by reference).

#### Expression of alpha-amylase variants

20 According to the invention, a DNA sequence encoding the variant produced by methods described above, or by any alternative methods known in the art, can be expressed, in enzyme form, using an expression vector which typically includes control sequences encoding a promoter, operator,  
25 ribosome binding site, translation initiation signal, and, optionally, a repressor gene or various activator genes.

The recombinant expression vector carrying the DNA sequence encoding an alpha-amylase variant of the invention may be any vector, which may conveniently be subjected to recombinant DNA  
30 procedures, and the choice of vector will often depend on the host cell into which it is to be introduced. Thus, the vector may be an autonomously replicating vector, i.e., a vector which exists as an extrachromosomal entity, the replication of

which is independent of chromosomal replication, e.g., a plasmid, a bacteriophage or an extrachromosomal element, minichromosome or an artificial chromosome. Alternatively, the vector may be one which, when introduced into a host cell, is  
5 integrated into the host cell genome and replicated together with the chromosome(s) into which it has been integrated.

In the vector, the DNA sequence should be operably connected to a suitable promoter sequence. The promoter may be any DNA sequence, which shows transcriptional activity in the  
10 host cell of choice and may be derived from genes encoding proteins either homologous or heterologous to the host cell. Examples of suitable promoters for directing the transcription of the DNA sequence encoding an alpha-amylase variant of the invention, especially in a bacterial host, are the promoter of  
15 the lac operon of *E.coli*, the *Streptomyces coelicolor* agarase gene *dagA* promoters, the promoters of the *Bacillus licheniformis* alpha-amylase gene (*amyL*), the promoters of the *Bacillus stearothermophilus* maltogenic amylase gene (*amyM*), the promoters of the *Bacillus amyloliquefaciens* alpha-amylase  
20 (*amyQ*), the promoters of the *Bacillus subtilis* *xylA* and *xylB* genes etc. For transcription in a fungal host, examples of useful promoters are those derived from the gene encoding *A. oryzae* TAKA amylase, *Rhizomucor miehei* aspartic proteinase, *A. niger* neutral alpha-amylase, *A. niger* acid stable alpha-  
25 amylase, *A. niger* glucoamylase, *Rhizomucor miehei* lipase, *A. oryzae* alkaline protease, *A. oryzae* triose phosphate isomerase or *A. nidulans* acetamidase.

The expression vector of the invention may also comprise a suitable transcription terminator and, in eukaryotes, poly-  
30 adenylation sequences operably connected to the DNA sequence encoding the alpha-amylase variant of the invention. Termination and polyadenylation sequences may suitably be derived from the same sources as the promoter.

The vector may further comprise a DNA sequence enabling the vector to replicate in the host cell in question. Examples of such sequences are the origins of replication of plasmids pUC19, pACYC177, pUB110, pE194, pAMB1 and pIJ702.

5 The vector may also comprise a selectable marker, e.g. a gene the product of which complements a defect in the host cell, such as the *dal* genes from *B. subtilis* or *B. licheniformis*, or one which confers antibiotic resistance such as ampicillin, kanamycin, chloramphenicol or tetracycline resistance. Furthermore, the vector may comprise *Aspergillus* selection markers such as *amdS*, *argB*, *niaD* and *sC*, a marker giving rise to hygromycin resistance, or the selection may be accomplished by co-transformation, e.g., as described in WO 91/17243.

15 While intracellular expression may be advantageous in some respects, e.g., when using certain bacteria as host cells, it is generally preferred that the expression is extracellular. In general, the *Bacillus* alpha-amylases mentioned herein comprise a prerregion permitting secretion of the expressed protease into the culture medium. If desirable, this prerregion 20 may be replaced by a different prerregion or signal sequence, conveniently accomplished by substitution of the DNA sequences encoding the respective prerregions.

The procedures used to ligate the DNA construct of the invention encoding an alpha-amylase variant, the promoter, 25 terminator and other elements, respectively, and to insert them into suitable vectors containing the information necessary for replication, are well known to persons skilled in the art (cf., for instance, Sambrook et al., *Molecular Cloning: A Laboratory Manual*, 2nd Ed., Cold Spring Harbor, 1989).

30 The cell of the invention, either comprising a DNA construct or an expression vector of the invention as defined above, is advantageously used as a host cell in the

recombinant production of an alpha-amylase variant of the invention. The cell may be transformed with the DNA construct of the invention encoding the variant, conveniently by integrating the DNA construct (in one or more copies) in the host chromosome. This integration is generally considered to be an advantage as the DNA sequence is more likely to be stably maintained in the cell. Integration of the DNA constructs into the host chromosome may be performed according to conventional methods, e.g., by homologous or heterologous recombination. Alternatively, the cell may be transformed with an expression vector as described above in connection with the different types of host cells.

The cell of the invention may be a cell of a higher organism such as a mammal or an insect, but is preferably a microbial cell, e.g., a bacterial or a fungal (including yeast) cell.

Examples of suitable bacteria are Gram-positive bacteria such as *Bacillus subtilis*, *Bacillus licheniformis*, *Bacillus lentus*, *Bacillus brevis*, *Bacillus stearothermophilus*, *Bacillus alkalophilus*, *Bacillus amyloliquefaciens*, *Bacillus coagulans*, *Bacillus circulans*, *Bacillus lautus*, *Bacillus megaterium*, *Bacillus thuringiensis*, or *Streptomyces lividans* or *Streptomyces murinus*, or gramnegative bacteria such as *E.coli*. The transformation of the bacteria may, for instance, be effected by protoplast transformation or by using competent cells in a manner known per se.

The yeast organism may favorably be selected from a species of *Saccharomyces* or *Schizosaccharomyces*, e.g. *Saccharomyces cerevisiae*. The filamentous fungus may advantageously belong to a species of *Aspergillus*, e.g., *Aspergillus oryzae* or *Aspergillus niger*. Fungal cells may be transformed by a process involving protoplast formation and transformation of the protoplasts followed by regeneration of the cell wall in a



manner known per se. A suitable procedure for transformation of *Aspergillus* host cells is described in EP 238 023.

In a yet further aspect, the present invention relates to a method of producing an alpha-amylase variant of the invention, which method comprises cultivating a host cell as described above under conditions conducive to the production of the variant and recovering the variant from the cells and/or culture medium.

The medium used to cultivate the cells may be any conventional medium suitable for growing the host cell in question and obtaining expression of the alpha-amylase variant of the invention. Suitable media are available from commercial suppliers or may be prepared according to published recipes (e.g., as described in catalogues of the American Type Culture Collection).

The alpha-amylase variant secreted from the host cells may conveniently be recovered from the culture medium by well-known procedures, including separating the cells from the medium by centrifugation or filtration, and precipitating proteinaceous components of the medium by means of a salt such as ammonium sulphate, followed by the use of chromatographic procedures such as ion exchange chromatography, affinity chromatography, or the like.

## 25 Industrial Applications

The alpha-amylase variants of this invention possess valuable properties allowing for a variety of industrial applications. In particular, enzyme variants of the invention are applicable as a component in washing, dishwashing, and hard surface cleaning detergent compositions.

Variant of the invention with altered properties may be used for starch processes, in particular starch conversion, especially liquefaction of starch (see, e.g., US 3,912,590, EP

patent publications Nos. 252 730 and 63 909, WO 99/19467, and WO 96/28567 all references hereby incorporated by reference). Also contemplated are compositions for starch conversion purposes, which may beside the variant of the invention also comprise a  
5 AMG, pullulanase, and other alpha-amylases.

Further, variants of the invention are also particularly useful in the production of sweeteners and ethanol (see, e.g., US patent no. 5,231,017 hereby incorporated by reference), such as fuel, drinking and industrial ethanol, from starch or whole  
10 grains.

A variant of the invention may also be used for textile desizing (see, e.g., WO 95/21247, US patent 4,643,736, EP 119,920 hereby incorporated by reference).

#### 15 Detergent compositions

As mentioned above, variants of the invention may suitably be incorporated in detergent compositions. Reference is made, for example, to WO 96/23874 and WO 97/07202 for further details concerning relevant ingredients of detergent  
20 compositions (such as laundry or dishwashing detergents), appropriate methods of formulating the variants in such detergent compositions, and for examples of relevant types of detergent compositions.

Detergent compositions comprising a variant of the invention  
25 may additionally comprise one or more other enzymes, such as a protease, a lipase, a peroxidase, another amylolytic enzyme, glucoamylase, maltogenic amylase, CGTase and/or a cellulase, mannanase (such as Mannaway<sup>™</sup> from Novozymes, Denmark)), pectinase, pectine lyase, cutinase, laccase, and/or another  
30 alpha-amylase.

Alpha-amylase variants of the invention may be incorporated in detergents at conventionally employed concentrations. It is at present contemplated that a variant of the invention may be

incorporated in an amount corresponding to 0.00001-10 mg (calculated as pure, active enzyme protein) of alpha-amylase per liter of wash/dishwash liquor using conventional dosing levels of detergent.

5

#### Compositions

The invention also related to composition comprising a variant of the invention, and in a preferred embodiment also a *B. stearothermophilus* alpha-amylase (BSG), in particular a  
10 variant thereof.

In another embodiment the composition comprises beside a variant of the invention a glucoamylase, in particular a glucoamylase originating from *Aspergillus niger* (e.g., the G1 or G2 *A. niger* AMG disclosed in Boel et al. (1984),  
15 "Glucoamylases G1 and G2 from *Aspergillus niger* are synthesized from two different but closely related mRNAs", EMBO J. 3 (5), p. 1097-1102, or a variant therefore, in particular a variant disclosed in WO 00/04136 or WO 01/04273 or the *Talaromyces emersonii* AMG disclosed in WO 99/28448.

20 A specific combination is LE399 and a variant disclosed in WO 00/04136 or WO 01/04273, in particular a variant with one or more of the following substitutions:

N9A, S56A, V59A, S119P, A246T, N313G, E342T, A393R, S394R, Y402F, E408R, in particular a variant with all mutation.

25 In an embodiment the composition of the invention also comprises a pullulanase, in particular a *Bacillus pullulanase*.

#### MATERIALS AND METHODS

Enzymes:

Bacillus licheniformis alpha-amylase shown in SEQ ID NO: 8 and also available from Novozymes.

- 5 AA560: SEQ ID NO: 12; disclosed in WO 00/60060; deposited on 25th January 1999 at DSMZ and assigned the DSMZ no. 12649. AA560 were deposited by the inventors under the terms of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure  
10 at Deutsche Sammlung von Microorganismen und Zellkulturen GmbH (DSMZ), Mascheroder Weg 1b, D-38124 Braunschweig DE.

LB medium (In 1 liter H<sub>2</sub>O: 10 g bacto-tryptone, 5 g bacto-yeast extract, 10 g NaCl, pH adjusted to 7.0 w. NaOH, autoclaved).

- 15 TY agar plates (In 1 liter H<sub>2</sub>O: 16 g bacto-tryptone, 10 g bacto-yeast extract, 5 g NaCl, pH adjusted to 7.0 w. NaOH, and 15 g bacto-agar is added prior to autoclaving).

10% Lugol solution (Iodine/Potassium iodine solution; made by 10-fold dil. in H<sub>2</sub>O of stock: Sigma Cat. no. L 6146).

- 20 Bacillus subtilis SHA273: see WO 95/10603

Plasmids

- pDN1528 contains the complete gene encoding Termamyl, amyL, the expression of which is directed by its own promoter.  
25 Further, the plasmid contains the origin of replication, ori, from plasmid pUB110 and the cat gene from plasmid pCI94 conferring resistance towards chloramphenicol. pDN1528 is shown in Fig. 9 of WO 96/23874.

- 30 Methods:

Low pH filter assay

Bacillus libraries are plated on a sandwich of cellulose acetate (OE 67, Schleicher & Schuell, Dassel, Germany) - and

nitrocellulose filters (Protran-Ba 85, Schleicher & Schuell, Dassel, Germany) on TY agar plates with 10 micro g/ml chloramphenicol at 37°C for at least 21 hours. The cellulose acetate layer is located on the TY agar plate.

5        Each filter sandwich is specifically marked with a needle after plating, but before incubation in order to be able to localize positive variants on the filter, and the nitrocellulose filter with bound variants is transferred to a container with citrate buffer, pH 4.5 and incubated at 80°C  
10 for 20 minutes (when screening for variants in the wild type backbone) or 85°C for 60 minutes (when screening for variants in the LE399 backbone). The cellulose acetate filters with colonies are stored on the TY-plates at room temperature until use. After incubation, residual activity is detected on assay  
15 plates containing 1% agarose, 0.2% starch in citrate buffer, pH 6.0. The assay plates with nitrocellulose filters are marked the same way as the filter sandwich and incubated for 2 hours at 50°C. After removal of the filters the assay plates are stained with 10% Lugol solution. Starch degrading variants  
20 are detected as white spots on dark blue background and then identified on the storage plates. Positive variants are re-screened twice under the same conditions as the first screen.

#### Secondary screening

25        Positive transformants after rescreening are picked from the storage plate and tested in a secondary plate assay. Positive transformants are grown for 22 hours at 37°C in 5 ml LB + chloramphenicol. The Bacillus culture of each positive transformant and as a control a clone expressing the  
30 corresponding backbone are incubated in citrate buffer, pH 4.5 at 90°C and samples are taken at 0, 10, 20, 30, 40, 60 and 80 minutes. A 3 micro liter sample is spotted on an assay plate.

The assay plate is stained with 10% Lugol solution. Improved variants are seen as variants with higher residual activity (detected as halos on the assay plate) than the backbone. The improved variants are determined by nucleotide sequencing.

5

Stability assay of unpurified variants:

Bacillus cultures expressing the variants to be analysed are grown for 21 hours at 37°C in 10 ml LB+chloramphenicol. 800 micro liter culture is mixed with 200 micro l citrate buffer, 10 pH 4.5. A number of 70 micro l aliquots corresponding to the number of sample time points are made in PCR tubes and incubated at 70°C (for variants in the wt backbone) or 90°C (for variants in LB399) for various time points (typically 5, 10, 15, 20, 25 and 30 minutes) in a PCR machine. The 0 min 15 sample is not incubated at high temperature. Activity in the sample is measured by transferring 20 micro l to 200 micro l of the alpha-amylase PNP-G7 substrate MPR3 ((Boehringer Mannheim Cat. no. 1660730) as described below under "Assays for Alpha-Amylase Activity". Results are plotted as percentage 20 activity (relative to the 0 time point) versus time, or stated as percentage residual activity after incubation for a certain period of time.

Fermentation and purification of alpha-amylase variants

25 A B. subtilis strain harbouring the relevant expression plasmid is streaked on a LB-agar plate with 10 micro g/ml kanamycin from -80°C stock, and grown overnight at 37°C. The colonies are transferred to 100 ml PS-1 media supplemented with 10 micro g/ml chloramphenicol in a 500 ml shaking flask.

30

## Composition of PS-1 medium:

	Pearl sugar	100 g/l
	Soy Bean Meal	40 g/l
	Na <sub>2</sub> HPO <sub>4</sub> , 12 H <sub>2</sub> O	10 g/l
5	Pluronic <sup>TM</sup> PE 6100	0.1 g/l
	CaCO <sub>3</sub>	5 g/l

The culture is shaken at 37°C at 270 rpm for 5 days.

Cells and cell debris are removed from the fermentation broth by centrifugation at 4500 rpm in 20-25 minutes. 10 Afterwards the supernatant is filtered to obtain a completely clear solution. The filtrate is concentrated and washed on a UF-filter (10000 cut off membrane) and the buffer is changed to 20mM Acetate pH 5.5. The UF-filtrate is applied on a S-sepharose F.F. and elution is carried out by step elution with 15 0.2M NaCl in the same buffer. The eluate is dialysed against 10mM Tris, pH 9.0 and applied on a Q-sepharose F.F. and eluted with a linear gradient from 0-0.3M NaCl over 6 column volumes. The fractions that contain the activity (measured by the Phadebas assay) are pooled, pH was adjusted to pH 7.5 and 20 remaining color was removed by a treatment with 0.5% W/vol. active coal in 5 minutes.

Stability determination of purified variants

All stability trials of purified variants are made using 25 the same set up. The method is as follows:

The enzyme is incubated under the relevant conditions (1-4). Samples are taken at various time points, e.g., after 0, 5, 10, 15 and 30 minutes and diluted 25 times (same dilution for all taken samples) in assay buffer (0.1M 50mM Britton buffer 30 pH 7.3) and the activity is measured using the Phadebas assay (Pharmacia) under standard conditions pH 7.3, 37°C.

The activity measured before incubation (0 minutes) is used as reference (100%). The decline in percent is calculated as a

function of the incubation time. The table shows the residual activity after, e.g., 30 minutes of incubation.

#### Specific activity determination

- 5 The specific activity is determined using the Phadebas assay (Pharmacia) as activity/mg enzyme. The manufactures instructions are followed (see also below under "Assay for  $\alpha$ -amylase activity").

#### 10 Assays for Alpha-Amylase Activity

##### 1. Phadebas assay

- Alpha-amylase activity is determined by a method employing Phadebas® tablets as substrate. Phadebas tablets (Phadebas® Amylase Test, supplied by Pharmacia Diagnostic) contain a  
15 cross-linked insoluble blue-colored starch polymer, which has been mixed with bovine serum albumin and a buffer substance and tabletted.

- For every single measurement one tablet is suspended in a tube containing 5 ml 50 mM Britton-Robinson buffer (50 mM  
20 acetic acid, 50 mM phosphoric acid, 50 mM boric acid, 0.1 mM  $\text{CaCl}_2$ , pH adjusted to the value of interest with NaOH). The test is performed in a water bath at the temperature of interest. The alpha-amylase to be tested is diluted in x ml of 50 mM Britton-Robinson buffer. 1 ml of this alpha-amylase  
25 solution is added to the 5 ml 50 mM Britton-Robinson buffer. The starch is hydrolyzed by the alpha-amylase giving soluble blue fragments. The absorbance of the resulting blue solution, measured spectrophotometrically at 620 nm, is a function of the alpha-amylase activity.

- 30 It is important that the measured 620 nm absorbance after 10 or 15 minutes of incubation (testing time) is in the range of 0.2 to 2.0 absorbance units at 620 nm. In this absorbance range there is linearity between activity and absorbance



(Lambert-Beer law). The dilution of the enzyme must therefore be adjusted to fit this criterion. Under a specified set of conditions (temp., pH, reaction time, buffer conditions) 1 mg of a given alpha-amylase will hydrolyze a certain amount of substrate and a blue colour will be produced. The colour intensity is measured at 620 nm. The measured absorbance is directly proportional to the specific activity (activity/mg of pure alpha-amylase protein) of the alpha-amylase in question under the given set of conditions.

10

## 2. Alternative method

Alpha-amylase activity is determined by a method employing the PNP-G7 substrate. PNP-G7 which is a abbreviation for p-nitrophenyl-alpha,D-maltoheptaoside is a blocked oligosaccharide which can be cleaved by an endo-amylase. Following the cleavage, the alpha-Glucosidase included in the kit digest the substrate to liberate a free PNP molecule which has a yellow colour and thus can be measured by visible spectrophotometry at  $\lambda=405\text{nm}$  (400-420 nm). Kits containing PNP-G7 substrate and alpha-Glucosidase is manufactured by Boehringer-Mannheim (cat. No.1054635).

To prepare the reagent solution 10 ml of substrate/buffer solution is added to 50 ml enzyme/buffer solution as recommended by the manufacturer. The assay is performed by transferring 20 micro l sample to a 96 well microtitre plate and incubating at 25°C. 200 micro l reagent solution pre-equilibrated to 25°C is added. The solution is mixed and pre-incubated 1 minute and absorption is measured every 30 sec. over 4 minutes at OD 405 nm in an ELISA reader.

The slope of the time dependent absorption-curve is directly proportional to the activity of the alpha-amylase in question under the given set of conditions.

## EXAMPLES

## Example 1.

Construction, by error-prone PCR mutagenesis, of *Bacillus licheniformis* alpha-amylase variants having an improved stability at low pH, high temperature and low calcium ion concentration compared to the parent enzyme.

Error-prone PCR mutagenesis and library construction

To improve the stability at low pH and low calcium concentration of the parent *Bacillus licheniformis* alpha-amylase, error-prone PCR mutagenesis was performed. The plasmid pDN1528 encoding the wild-type *Bacillus licheniformis* alpha-amylase gene was utilized as template to amplify this gene with primers: 22149: 5'-CGA TTG CTG ACG CTG TTA TTT GCG-  
10 3' (SEQID NO: 14) and 24814: 5'-GAT CAC CCG CGA TAC CGT C-3'  
15 (SEQ ID NO: 15) under PCR conditions where increased error rates leads to introduction of random point mutations. The PCR conditions utilized were: 10 mM Tris-HCl, pH 8.3, 50 mM KCl, 4 mM MgCl<sub>2</sub>, 0.3 mM MnCl<sub>2</sub>, 0.1mM dGTP/dATP, 0.5 mM dTTP/dCTP, and  
20 2.5 units Taq polymerase per 100 micro'l reaction.

The resultant PCR fragment was purified on gel and used in a PCR-based multimerization step with a gel purified vector fragment created by PCR amplification of pDN1528 with primers #24: 5'-GAA TGT ATG TCG GCC GGC AAA ACG CCG GTG A-3' (SEQ ID  
25 NO: 16) and #27: 5'-GCC GCC GCT GCT GCA GAA TGA GGC AGC AAG-3' (SEQ ID NO:17) forming an overlap to the insert fragment. The multimerization reaction was subsequently introduced into *B. subtilis* (Shafikhani et al., Biotechniques, 23 (1997), 304-310).

30

## Screening

The error-prone library described above was screened in the low pH filter assay (see "Materials & Methods"). Clones

testing positive upon rescreening was submitted to secondary screening for stability in the liquid assay described in Materials and Methods.

# 9 Results:

Increased stability at pH 4.5, 5 ppm calcium incubated at 90°C

Name	wt	LE488	LE489	7.19.1	8.9.1
Mutations	-	D207V	K170Q D207V N280S	E132A D207V	D207E E250G H406L L427I
Stability1 )	-	+	+	+	+

1) A "+" indicates significant increase in stability relative to wild type.

# 10 Increased stability at pH 4.5, 5 ppm calcium incubated at 90°C

Name	wt	LE491	LE492	LE493	LE494	19.3.1
Mutations	-	D60N D207V L318M	T49I E132V V440A	T49I K176R D207V Y402F	Q374R E385V Q393R	N190F A209V Q264S
Stability1 )	-	+	+	+	+	+

1) A "+" indicates significant increase in stability relative to wt.

Increased stability at pH 4.5, 5 ppm calcium incubated at 90°C

Name	wt	E132-1	D207-7	D207-6	E250-8
Mutations	-	E132P	D207L	D207G	E250F
Stability1 )	-	+	+	+	+

15 1) A "+" indicates significant increase in stability relative to wt.

## Example 2

Transfer, by site-directed mutagenesis, of a selection of mutations from Example 1 to a new (non-wild type) backbone to improve stability at low pH and low calcium ion concentration compared to the parent enzyme.

Site-directed mutagenesis

Mutations from LE493 (K176R+D207V+Y402F) were transferred to LE399 yielding LE495. This was performed by the overlap PCR method (Kirchhoff and Desrosiers, PCR Methods and Applications, 2 (1993), 301-304). 2 overlapping PCR fragments were generated by amplification of the LE399 template with the primers: Fragment A: #312 Mut176 5'-CCC GAA AGC TGA ACC GCA TCT ATA GGT TTC AAG GGA AGA CTT GGG ATT-3' (SEQ ID NO: 18) (mutated codon indicated in bold) and #296 D207overlap 5'-AGG ATG GTC ATA ATC AAA GTC GG-3' (SEQ ID NO: 19); Fragment B: #313 Mut207 5'-CCG ACT TTG ATT ATG ACC ATC CTG TTG TCG TAG CAG AGA TTA AGA GAT GGG G-3' (SEQ ID NO: 20) and #314 Mut402 5'-CGA CAA TGT CAT GGT GGT CGA AAA AAT CAT GCT GTG CTC CGT ACG-3' (SEQ ID NO: 21). Fragments A and B were mixed in equimolar ratios and subsequently the full-length fragment was amplified with the external primers: #312 Mut176 and #314 Mut402. This fragment was used in a multimerization reaction with the vector PCR fragment created with the primers #296 Y402multi 5'-TTT CGA CCA CCA TGA CAT TGT CG-3' (SEQ ID NO: 22) and #305 399Multi176 5'-TAT AGA TGC GGT TCA GCT TTC GGG-3' (SEQ ID NO: 23) on template LE399 as described above. The multimerization reaction was subsequently transformed into *E. subtilis*. Clones were screened for stability in the assay mentioned above. The presence of the mutations from LE493 in several clones with increased stability was confirmed by sequencing.

LE 497 was obtained in a similar manner by amplifying the LE399 encoding template with primers #312 Mut176 and #314 Mut402 and using the resulting PCR fragment in a multimerization reaction with a vector fragment obtained by PCR amplification of the LE399 template with the primers #295 Y402multi and #305 399Multi176.

#### Results:

Stabilization of LE399 variant at pH 4.5, 5ppm calcium  
10 incubated at 90oC

Name	LE399	LE495	LE497
Mutations	- (backbone)	K176R D207V Y402P	K176R Y402P
Stability1)	-	+	+

1) A "+" indicates significant increase in stability relative to backbone.

## CLAIMS

1. A variant of a parent Termamyl-like alpha-amylase, comprising an alteration at one or more positions selected from the group of:  
49, 60, 104, 132, 161, 170, 176, 179, 180, 181, 183, 200, 203, 204, 207, 212, 237, 239, 250, 280, 298, 318, 374, 385, 393, 402, 406, 427, 430, 440, 444, 447, 482,  
wherein
- 10 (a) the alteration(s) are independently  
(i) an insertion of an amino acid downstream of the amino acid which occupies the position,  
(ii) a deletion of the amino acid which occupies the position, or  
15 (iii) a substitution of the amino acid which occupies the position with a different amino acid,  
(b) the variant has alpha-amylase activity and (c) each position corresponds to a position of the amino acid sequence of the parent Termamyl-like alpha-amylase having the amino  
20 acid sequence shown in SEQ ID NO: 8.
2. The variant of claim 1, which variant has one or more of the following mutations: T49I; D60N; N104D; E132A,V,P; D161N; K170Q; K176R; G179N; K180T; A181N; D183N; D200N; X203Y; D204S;  
25 D207V,E,L,G; X212I; K237P; S239W; E250G,F; N280S; X298Q; L318M; Q374R; E385V; Q393R; Y402F; H406L,W; L427I D430N; V440A; N444R,K; E447Q,K; Q482K using SEQ ID NO: 8 for the numbering.
3. The variant of claim 1 or 2, wherein the variant has the  
30 following mutations: K170Q+D207V+N280S; E132A+D207V; D207E+E250G+H406L+L427I; D207V+L318M; D60N+D207V+L318M; T49I+E132V+V440A; T49I+K176R+D207V+Y402F; Q374R+E385V+Q393R; N190F+A209V+Q264S; G48A+T49I+G107A+I201F; T49I+G107A+I201F;

- G48A+T49I+I201F; G48A+T49I+G107A; T49I+I201F; T49I+G107A;  
G48A+T49I;  
N104D+D161N+G179N+K180T+A181N+D183N+D200N+D204S+K237P+S239W+  
H406W+D430N+N444K+E447Q+Q482K;
- 5 D161N+G179N+K180T+A181N+D183N+D200N+D204S+K237P+S239W+H406W+  
D430N+N444K+E447Q+Q482K;  
D161N+A181N+D183N+D200N+D204S+K237P+S239W+H406W+  
D430N+N444K+E447Q+Q482K;  
D161N+A181N+D183N+D200N+D204S+K237P+S239W+H406W+
- 10 D430N+E447Q+Q482K;  
N104D+D161N+G179N+K180T+A181N+D183N+D200N+D204S+K237P+S239W+  
H406W+D430N+E447Q+Q482K;  
D161N+G179N+K180T+A181N+D183N+D200N+D204S+K237P+S239W+H406W+  
D430N+E447Q+Q482K;
- 15 N104D+D161N+G179N+K180T+A181N+D183N+D200N+D204S+K237P+S239W+  
H406W+D430N;  
D161N+G179N+K180T+A181N+D183N+D200N+D204S+K237P+S239W+H406W+  
D430N;  
H406W+D430N; N444K+E447Q+Q482K; E447Q+Q482K;
- 20 N104D+D161N+G179N+K180T+A181N+D183N+D200N+D204S+K237P+S239W+  
H406W+D430N+N444R+N444K+E447K+Q482K;  
D161N+G179N+K180T+A181N+D183N+D200N+D204S+K237P+S239W+H406W+  
D430N+N444R+N444K+E447K+Q482K;  
N104D+D161N+G179N+K180T+A181N+D183N+D200N+D204S+K237P+S239W;
- 25 D161N+G179N+K180T+A181N+D183N+D200N+D204S+K237P+S239W;  
H406W+D430N; N444K+E447K+Q482K; E447K+Q482K;  
N104D+D161N+A181N+D183N+D200N+D204S+K237P+S239W;  
N104D+D161N+A181N+D183N+D200N+D204S+K237P;  
N104D+D161N+A181N+D183N+D200N+D204S;
- 30 D161N+A181N+D183N+D200N+D204S+K237P+S239W;  
D161N+A181N+D183N+D200N+D204S+K237P;  
D161N+A181N+D183N+D200N+D204S; K237P+S239W, using SEQ ID NO: 8  
for the numbering.

4. The variant of any of claims 1-3, wherein the parent Termamyl-like alpha-amylase is derived from a strain of *B. licheniformis* (SEQ ID NO: 8), *B. amyloliquefaciens* (SEQ ID NO: 10), *B. stearothermophilus* (SEQ ID NO: 6).

5. The variant of any of claims 1-4, wherein the parent Termamyl-like amylase is any of:

LE174; LE174+G48A+T49I+G107A+I201F; LE174+M197L;  
10 LE174+G48A+T49I+G107A+M197L+I201F.

6. The variant of claim 1, wherein the variant is mutated in one or more of the following positions: T51I; D62N; N106D; D134A,V,F; D163N; X172Q; K179R; G184N; K185T; A186N; D188N;  
15 D205N; M208Y; D209S; X212V,E,L,G; L217I, K242P, S244W, N255G,F, N285S, S303Q, X323M; D387V, N395R; Y404F; H408L,W; X429I; D432N; V442A; X446R,K; X449Q,K; X484K, using SEQ ID NO: 4 (SP722) for the numbering.

20 7. The variant of claim 1 or 6, wherein the variant has the following mutations: E212V+N285S; D134A+E212V; N255G+H408L+X429I; E212V+X323M; D62N+E212V+X323M; T51I+D134V+V442A; T51I+K179R+E212V+Y404F; D387V+N395R; N195F+X212V+K269S, when using SEQ ID NO: 4 (SP722) for the  
25 numbering.

8. The variant of any of claims 1-7, wherein the parent Termamyl-like alpha-amylase is selected from the group comprising: SP690 (SEQ ID NO: 2); SP722 (SEQ ID NO: 4; AA560  
30 (SEQ ID NO: 12); #707 alpha-amylase (SEQ ID NO: 13); KSM-AP1378.



9. The variant of any of claims 1-8, wherein the parent Termamyl-like amylase is any of: SP722+D183\*+G184\*;  
SP722+D183\*+G184\*+N195F; SP722+D183\*+G184\*+M202L;  
SP722+D183\*+G184\*+N195F+M202L; BSG+I181\*+G182\*;  
5 BSG+I181\*+G182\*+N193F; BSG+I181\*+G182\*+M200L;  
BSG+I181\*+G182\*+N193F+M200L;  
AA560+D183\*+G184\*;  
AA560+D183\*+G184\*+N195F;  
AA560+D183\*+G184\*+M202L;  
AA560+D183\*+G184\*+N195F+M202L.
- 10 10. The variant of any of claims 1-9, wherein the parent Termamyl-like alpha-amylase has an amino acid sequence which has a degree of identity to SEQ ID NO: 8 of at least 60%, preferably 70%, more preferably at least 80%, even more preferably at least about 90%, even more preferably at least 95%, even more  
15 preferably at least 97%, and even more preferably at least 99%.
11. The variant of any of claims 1-10, wherein the parent Termamyl-like alpha-amylase is encoded by a nucleic acid sequence, which hybridizes under low, preferably medium,  
20 preferred high stringency conditions, with the nucleic acid sequence of SEQ ID NO: 7.
12. The variant of any of claims 1-11, which variant has altered stability, in particular at high temperatures from 70-  
25 120°C and/or low pH in the range from pH 4-6
13. A DNA construct comprising a DNA sequence encoding an alpha-amylase variant according to any one of claims 1-12.
- 30 14. A recombinant expression vector which carries a DNA construct according to claim 13.

15. A cell which is transformed with a DNA construct according to claim 13 or a vector according to claim 14.
16. The cell according to claim 15, which is a microorganism, preferably a bacterium or a fungus.
17. The cell according to claim 16, which cell is a gram-positive bacterium, such as *Bacillus subtilis*, *Bacillus licheniformis*, *Bacillus lentus*, *Bacillus brevis*, *Bacillus stearothermophilus*, *Bacillus alkalophilus*, *Bacillus amyloliquefaciens*, *Bacillus coagulans*, *Bacillus circulans*, *Bacillus lautus* or *Bacillus thuringiensis*.
18. A composition comprising an alpha-amylase variant of any of claims 1-12.
19. The composition of claim 18, further comprising a *B. stearothermophilus* (BSG) alpha-amylase, in particular SP961, particular in a ratio of 1:10 to 10:1, preferably 1:2.
20. The composition of claim 18 or 19, wherein the composition further comprises a glucoamylase, pullulanase and/or a phytase.
21. A detergent composition comprising an alpha-amylase variant according to any of claims 1-12.
22. A detergent composition of claim 21, which additionally comprises another enzyme such as a protease, a lipase, a peroxidase, another amylolytic enzyme, glucoamylase, maltogenic amylase, CGTase, mannanase, cutinase, laccase and/or a cellulase.

23. Use of an alpha-amylase variant according to any of claims 1-12 or a composition according to any of claims 18-20 for starch liquefaction.
- 5 24. Use of an alpha-amylase variant according to any of claims 1-12 or a composition according to claims 18-20 for ethanol production.
25. Use of an alpha-amylase variant according to any one of  
10 claims 1-12 or a composition according to claims 18-20 for washing and/or dishwashing.
26. Use of an alpha-amylase variant of any one of claims 1-12  
or a composition according to claims 18-20 for textile  
15 desizing.

1/3

```

1                                     50
1 HHNGTNGTMM QYFEWHLFND GNHWNRLRDD ASNLRNRGIT AIWIPPAAWK
2 HHNGTNGTMM QYFEWYLFND GNHWNRLRDD AANLKSKGIT AVWIPPAAWK
3 ...VNGTLM QYFEWYTFND GQHWKRLQND AEHLSDIGIT AVWIPPAYKG
4 ..ANLNGTLM QYFEWYMPND GQHWRRLLQND SAYLAEHGIT AVWIPPAYKG
5 .AAPFNGTMM QYFEWYLPDD GTLWTKVANE ANNLSLIGIT ALWLPPAYKG

51                                     100
1 TSQNDVGYGGA YDLYDLGEFN QKGTVRTKYG TSQLESIAH ALKNNGVQVY
2 TSQNDVGYGGA YDLYDLGEFN QKGTVRTKYG TRNQLQAAYT SLKNNGIQVY
3 LSQSDNGYGP YDLYDLGEFQ QKGTVRTKYG TKSELQDAIG SLHSRNVQVY
4 TSQADVGYGGA YDLYDLGEFH QKGTVRTKYG TKGELQSAIK SLHSRDINYV
5 TSRSDVGYGV YDLYDLGEFN QKGTVRTKYG TKAQYLQAIQ AAHAAGMQVY

101                                     150
1 GDVVMNHKGG ADATENVLAV EVNPNNRNQE ISGDYTTIAW TKFDFFPGRGN
2 GDVVMNHKGG ADGTEIVNAV EVNRSNRNQE TSGEYAIEAW TKFDFFPGRGN
3 GDVVLNHKAG ADATEDVTAV EVNPANRNQE TSEEYQIKAW TDFRFPGRGN
4 GDVVINHKGK ADATEDVTAV EVDPADRNKV ISGEHLIKAW THPHFPGRGS
5 ADVVFDHKGG ADGTEWVDAV EVNPSDRNQE ISGTYIQAW TKFDFFPGRGN

151                                     200
1 TYSDFKWRWY HFDGVDWDQS RQFQNRRIYKF RGDGKAWDWE VDSENGNYDY
2 NHSSPKWRWY HFDGTDWDQS RQLQNKIYKF RGTGKAWDWE VDTENGNYDY
3 TYSDFKWHWY HFDGADWDES RKL.SRIFKF RGGGKAWDWE VSSENGNYDY
4 TYSDFKWHWY HFDGTDWDES RKL.NRIYKF ..QGKAWDWE VSNENGNYDY
5 TYSSFKWRWY HFDGVDWDES RKL.SRIYKF RGICKAWDWE VDTENGNYDY

```

Fig. 1

2/3

	201		250
1	LMYADVDMDH	PEVVNELRRW	GEWYTNLTNL DGFRIDAVKH IKYSFTRDWL
2	LMYADVDMDH	PEVIHELRRW	GVWYTNLTNL DGFRIDAVKH IKYSFTRDWL
3	LMYADVVDYDH	PDVVAETKKW	GIWYANELSL DGFRIDAACH IKFSFLRDWV
4	LMYADIDYDH	PDVAAEIKRW	GTWYANELQL DGFRIDAVKH IKFSFLRDWV
5	LMYADLDMDH	PEVVTELKNW	GKWYVNTTNI DGFRIDAVKH IKFSFFPDWL
	251		300
1	THVRNATGKE	MFVAEAFWKV	DLGALENYLN KTNWNHVSVD VPLHYNLNYA
2	THVRNTTGKP	MFVAEAFWKV	DLGALENYLN KTSWNHSAPD VPLHYNLNYA
3	QAVRQATGKE	MFTVAEYQVN	NAGKLENYLN KTSFNQSVVD VPLHFNQAQ
4	NHVREKTGKE	MFTVAEYQVN	DLGALENYLN KTNFNHVSVD VPLHYQFHAA
5	SYVRSQTGKP	LFTVGREYWSY	DINKLENYIT KTDGTMSLFD APLHNKFYTA
	301		350
1	SNSGGNYDMA	KLLNGTVVQK	HPMHAVTFVD NHDSQPGESL ESFVQEWFKP
2	SNSGGYDMR	NILNGSVVQK	HPTHAVTFVD NHDSQPGESL ESFVQGWFKP
3	SSQGGGYDMR	RLLDGTVVSR	HPEKAVTFVE NHDTPQGQSL ESTVQTWFKP
4	STQGGGYDMR	KLLNGTVVSK	HPLKSVTFVD NHDTPQGQSL ESTVQTWFKP
5	SKSGGAFDMR	TLMTNTLMKD	QPTLAVTFVD NHDTEPGQAL QSWVDPNFKP
	351		400
1	LAYALILITRE	QGYPSPVFGD	YYGIPTHS.. .VPAMKAKID PILEARQNFA
2	LAYALVITRE	QGYPSPVFGD	YYGIPTHG.. .VPAMKSKID PLLQARQTFE
3	LAYAFILITRE	SGYPQVFGD	MYGKTGTSKP EIPSLKDNIE PILKARKEYA
4	LAYAFILITRE	SGYPQVFGD	MYGKTGDSQR EIPALKHKIE PILKARKQYA
5	LAYAFILITRE	EGYPCVFGD	YYGIPQYN.. .IPSLKSKID PLLIARRDYA
	401		450
1	YGTQHDYFDH	HNIIGWTREG	NTTHPNNSGLA TIMSDGPGGE KWMYVGQNK
2	YGTQHDYFDH	HDIIGWTREG	NSSHPNNSGLA TIMSDGPGGN KWMYVGKNKA
3	YGPQHDYIDH	PDVIGWTREG	DSSAAKSGLA ALITDGPGGG KRMVAGLKN
4	YGPQHDYFDH	HDIVGWTREG	DSSVANSGLA ALITDGPGGG KRMVVGQNA
5	YGTQHDYLDH	SDIIGWTREG	GTEKPGSGLA ALITDGPGGG KWMYVGQKHA

Fig. 1 (continued)

3/3

```

451
1  GQVWHDITGN KPCTVTINAD GWANFSVNGG SVSIWVKR.. .....
2  GQVWRDITGN RTGTVTINAD GWGNFSVNGG SVSVWVKQ.. .....
3  GETWYDITGN RSDTVKIGSD GWGEFHVNDG SVSIYVQ.. .....
4  GETWHDITGN RSEPVVINSE GWGEFHVNGG SVSIYVQR.. .....
5  GKVFYDLTGN RSDTVTINS D GWGEFKVNGG SVSVWVPRKT TVSTIARPI T 500

501                      519
1  .....
2  .....
3  .....
4  .....
5  TRPWTGEFVR WTEPRLVAW
```

Fig. 1 (continued)

## SEQUENCE LISTING

## SEQUENCE LISTING

&lt;110&gt; Novo Nordisk A/S

&lt;120&gt;

&lt;130&gt;

&lt;160&gt; 28

&lt;170&gt; PatentIn Ver. 2.1

&lt;210&gt; 1

&lt;211&gt; 1455

&lt;212&gt; DNA

&lt;213&gt; Bacillus sp.

&lt;220&gt;

&lt;221&gt; CD5

&lt;222&gt; (1)..(1455)

&lt;223&gt; SP690

&lt;400&gt; 1

```

cat cat aat gga aca aat ggt act atg atg caa tat ttc gaa tgg tat 48
His His Asn Gly Thr Asn Gly Thr Met Met Gln Tyr Phe Glu Trp Tyr
1 5 10 15

ttg cca aat gac ggg aat cat tgg aac agg ttg agg gat gac gca gct 96
Leu Pro Asn Asp Gly Asn His Trp Asn Arg Leu Arg Asp Asp Ala Ala
20 25 30

aac tta aag agt aaa ggg ata aca gct gta tgg atc cca cct gca tgg 144
Asn Leu Lys Ser Lys Gly Ile Thr Ala Val Trp Ile Pro Pro Ala Trp
35 40 45

aag ggg act tcc cag aat gat gta ggt tat gga gcc tat gat tta tat 192
Lys Gly Thr Ser Gln Asn Asp Val Gly Tyr Gly Ala Tyr Asp Leu Tyr
50 55 60

gat ctt gga gag ttt aac cag aag ggg acg gtt. cgt aca aaa tat gga 240
Asp Leu Gly Glu Phe Asn Gln Lys Gly Thr Val Arg Thr Lys Tyr Gly
65 70 75 80

aca cgc aac cag cta cag gct gcg gtg acc tct tta aaa aat aac ggc 288
Thr Arg Asn Gln Leu Gln Ala Ala Val Thr Ser Leu Lys Asn Asn Gly
85 90 95

att cag gta tat ggt gat gtc gtc atg aat cat aaa ggt gga gca gat 336
Ile Gln Val Tyr Gly Asp Val Val Met Asn His Lys Gly Gly Ala Asp
100 105 110

ggt acg gaa att gta aat gcg gta gaa gtg aat cgg agc aac cga aac 384
Gly Thr Glu Ile Val Asn Ala Val Glu Val Asn Arg Ser Asn Arg Asn
115 120 125

cag gaa acc tca gga gag tat gca ata gaa gcg tgg aca aag ttt gat 432
Gln Glu Thr Ser Gly Glu Tyr Ala Ile Glu Ala Trp Thr Lys Phe Asp
130 135 140

ttt cct gga aga gga aat aac cat tcc agc ttt aag tgg cgc tgg tat 480
Phe Pro Gly Arg Gly Asn Asn His Ser Ser Phe Lys Trp Arg Trp Tyr
145 150 155 160

cat ttt gat ggg aca gat tgg gat cag tca cgc cag ctt caa aac aaa 528
His Phe Asp Gly Thr Asp Trp Asp Gln Ser Arg Gln Leu Glu Asn Lys
165 170 175

ata tat aaa ttc agg gga aca ggc aag gcc tgg gac tgg gaa gtc gat 576

```

SEQUENCE LISTING																
Ile	Tyr	Lys	Phe	Arg	Gly	Thr	Gly	Lys	Ala	Trp	Asp	Trp	Glu	Val	Asp	
			180					185					190			
aca	gag	aat	ggc	aac	tat	gac	tat	ctt	atg	tat	gca	gac	gtg	gat	atg	624
Thr	Glu	Asn	Gly	Asn	Tyr	Asp	200	Leu	Met	Tyr	Ala	Asp	Val	Asp	Met	
			195									205				
gat	cac	cca	gaa	gta	ata	cat	gaa	ctt	aga	aac	tgg	gga	gtg	tgg	tat	672
Asp	His	Pro	Glu	Val	Ile	His	Glu	Leu	Arg	Asn	Trp	Gly	Val	Trp	Tyr	
			210			215					220					
acg	aat	aca	ctg	aac	ctt	gat	gga	ttt	aga	ata	gat	gca	gtg	aaa	cat	720
Thr	Asn	Thr	Leu	Asn	Leu	Asp	Gly	Phe	Arg	Ile	Asp	Ala	Val	Lys	His	
			225		230					235				240		
ata	aaa	tat	agc	ttt	acg	aga	gat	tgg	ctt	aca	cat	gtg	cgt	aac	acc	768
Ile	Lys	Tyr	Ser	Phe	Thr	Arg	Asp	Trp	Leu	Thr	His	Val	Arg	Asn	Thr	
				245					250					255		
aca	ggt	aaa	cca	atg	ttt	gca	gtg	gct	gag	ttt	tgg	aaa	aat	gac	ctt	816
Thr	Gly	Lys	Pro	Met	Phe	Ala	Val	Ala	Glu	Phe	Trp	Lys	Asn	Asp	Leu	
			260					265					270			
ggt	gca	att	gaa	aac	tat	ttg	aat	aaa	aca	agt	tgg	aat	cac	tcg	gtg	864
Gly	Ala	Ile	Glu	Asn	Tyr	Leu	Asn	Lys	Thr	Ser	Trp	Asn	His	Ser	Val	
			275				280					285				
ttt	gat	ggt	cct	ctc	cac	tat	aat	ttg	tac	aat	gca	tct	aat	agc	ggt	912
Phe	Asp	Val	Pro	Leu	His	Tyr	Asn	Leu	Tyr	Asn	Ala	Ser	Asn	Ser	Gly	
						295					300					
ggt	tat	tat	gat	atg	aga	aat	att	tta	aat	ggt	tct	gtg	gtg	caa	aaa	960
Gly	Tyr	Tyr	Asp	Met	Arg	Asn	Ile	Leu	Asn	Gly	Ser	Val	Val	Gln	Lys	
					310					315					320	
cat	cca	aca	cat	gcc	ggt	act	ttt	ggt	gat	aac	cat	gat	tct	cag	ccc	1008
His	Pro	Thr	His	Ala	Val	Thr	Phe	Val	Asp	Asn	His	Asp	Ser	Gln	Pro	
				325					330					335		
ggg	gaa	gca	ttg	gaa	tcc	ttt	ggt	caa	caa	tgg	ttt	aaa	cca	ctt	gca	1056
Gly	Glu	Ala	Leu	Glu	Ser	Phe	Val	Gln	Gln	Trp	Phe	Lys	Pro	Leu	Ala	
			340					345					350			
tat	gca	ttg	ggt	ctg	aca	agg	gaa	caa	ggt	tat	cct	tcc	gta	ttt	tat	1104
Tyr	Ala	Leu	Val	Leu	Thr	Arg	Glu	Gln	Gly	Tyr	Pro	Ser	Val	Phe	Tyr	
			355				360					365				
ggg	gat	tac	tac	ggt	atc	cca	acc	cat	ggt	ggt	ccg	gct	atg	aaa	tct	1152
Gly	Asp	Tyr	Tyr	Gly	Ile	Pro	Thr	His	Gly	Val	Pro	Ala	Met	Lys	Ser	
						375					380					
aaa	ata	gac	cct	ctt	ctg	cag	gca	cgt	caa	act	ttt	gcc	tat	ggt	acg	1200
Lys	Ile	Asp	Pro	Leu	Leu	Gln	Ala	Arg	Gln	Thr	Phe	Ala	Tyr	Gly	Thr	
					390					395					400	
cag	cat	gat	tac	ttt	gat	cat	cat	gat	att	atc	ggt	tgg	aca	aga	gag	1248
Gln	His	Asp	Tyr	Phe	Asp	His	His	Asp	Ile	Ile	Gly	Trp	Thr	Arg	Glu	
				405					410					415		
gga	aat	agc	tcc	cat	cca	aat	tca	ggc	ctt	gcc	acc	att	atg	tca	gat	1296
Gly	Asn	Ser	Ser	His	Pro	Asn	Ser	Gly	Leu	Ala	Thr	Ile	Met	Ser	Asp	
			420					425					430			
ggt	cca	ggt	ggt	aac	aaa	tgg	atg	tat	gtg	ggg	aaa	aat	aaa	gcg	gga	1344
Gly	Pro	Gly	Gly	Asn	Lys	Trp	Met	Tyr	Val	Gly	Lys	Asn	Lys	Ala	Gly	
			435			440						445				
caa	gtt	tgg	aga	gat	att	acc	gga	aat	agg	aca	ggc	acc	gtc	aca	att	1392



## SEQUENCE LISTING

Gln Val Trp Arg Asp Ile Thr Gly Asn Arg Thr Gly Thr Val Thr Ile  
 450 455 460

aat gca gac gga tgg ggt aat ttc tct gtt aat gga ggg tcc gtt tgg 1440  
 Asn Ala Asp Gly Trp Gly Asn Phe Ser Val Asn Gly Gly Ser Val Ser 480  
 465 470 475 480

ggt tgg gtg aag caa 1455  
 Val Trp Val Lys Gln 485

<210> 2  
 <211> 485  
 <212> PRT  
 <213> Bacillus sp.

<400> 2  
 His His Asn Gly Thr Asn Gly Thr Met Met Gln Tyr Phe Glu Trp Tyr  
 1 5 10 15

Leu Pro Asn Asp Gly Asn His Trp Asn Arg Leu Arg Asp Asp Ala Ala  
 20 25 30

Asn Leu Lys Ser Lys Gly Ile Thr Ala Val Trp Ile Pro Pro Ala Trp  
 35 40 45

Lys Gly Thr Ser Gln Asn Asp Val Gly Tyr Gly Ala Tyr Asp Leu Tyr  
 50 55 60

Asp Leu Gly Glu Phe Asn Gln Lys Gly Thr Val Arg Thr Lys Tyr Gly  
 65 70 75 80

Thr Arg Asn Gln Leu Gln Ala Ala Val Thr Ser Leu Lys Asn Asn Gly  
 85 90 95

Ile Gln Val Tyr Gly Asp Val Val Met Asn His Lys Gly Gly Ala Asp  
 100 105 110

Gly Thr Glu Ile Val Asn Ala Val Glu Val Asn Arg Ser Asn Arg Asn  
 115 120 125

Gln Glu Thr Ser Gly Glu Tyr Ala Ile Glu Ala Trp Thr Lys Phe Asp  
 130 135 140

Phe Pro Gly Arg Gly Asn Asn His Ser Ser Phe Lys Trp Arg Trp Tyr  
 145 150 155 160

His Phe Asp Gly Thr Asp Trp Asp Gln Ser Arg Gln Leu Gln Asn Lys  
 165 170 175

Ile Tyr Lys Phe Arg Gly Thr Gly Lys Ala Trp Asp Trp Glu Val Asp  
 180 185 190

Thr Glu Asn Gly Asn Tyr Asp Tyr Leu Met Tyr Ala Asp Val Asp Met  
 195 200 205

Asp His Pro Glu Val Ile His Glu Leu Arg Asn Trp Gly Val Trp Tyr  
 210 215 220

Thr Asn Thr Leu Asn Leu Asp Gly Phe Arg Ile Asp Ala Val Lys His  
 225 230 235 240

Ile Lys Tyr Ser Phe Thr Arg Asp Trp Leu Thr His Val Arg Asn Thr  
 245 250 255

Thr Gly Lys Pro Met Phe Ala Val Ala Glu Phe Trp Lys Asn Asp Leu  
 260 265 270

## SEQUENCE LISTING

Gly Ala Ile Glu Asn Tyr Leu Asn Lys Thr Ser Trp Asn His Ser Val  
 275 280 285  
 Phe Asp Val Pro Leu His Tyr Asn Leu Tyr Asn Ala Ser Asn Ser Gly  
 290 295 300  
 Gly Tyr Tyr Asp Met Arg Asn Ile Leu Asn Gly Ser Val Val Gln Lys  
 305 310 315 320  
 His Pro Thr His Ala Val Thr Phe Val Asp Asn His Asp Ser Gln Pro  
 325 330 335  
 Gly Glu Ala Leu Glu Ser Phe Val Gln Gln Trp Phe Lys Pro Leu Ala  
 340 345 350  
 Tyr Ala Leu Val Leu Thr Arg Glu Gln Gly Tyr Pro Ser Val Phe Tyr  
 355 360 365  
 Gly Asp Tyr Tyr Gly Ile Pro Thr His Gly Val Pro Ala Met Lys Ser  
 370 375 380  
 Lys Ile Asp Pro Leu Leu Gln Ala Arg Gln Thr Phe Ala Tyr Gly Thr  
 385 390 395 400  
 Gln His Asp Tyr Phe Asp His His Asp Ile Ile Gly Trp Thr Arg Glu  
 405 410 415  
 Gly Asn Ser Ser His Pro Asn Ser Gly Leu Ala Thr Ile Met Ser Asp  
 420 425 430  
 Gly Pro Gly Gly Asn Lys Trp Met Tyr Val Gly Lys Asn Lys Ala Gly  
 435 440 445  
 Gln Val Trp Arg Asp Ile Thr Gly Asn Arg Thr Gly Thr Val Thr Ile  
 450 455 460  
 Asn Ala Asp Gly Trp Gly Asn Phe Ser Val Asn Gly Gly Ser Val Ser  
 465 470 475 480  
 Val Trp Val Lys Gln  
 485

<210> 3  
 <211> 1455  
 <212> DNA  
 <213> Bacillus sp.

<220>  
 <221> CDS  
 <222> (1)..(1455)  
 <223> SP722

<400> 3  
 cat cat aat ggg aca aat ggg acg atg atg caa tac ttt gaa tgg cac 48  
 His His Asn Gly Thr Asn Gly Thr Met Met Gln Tyr Phe Glu Trp His  
 1 5 10 15  
 ttg cct aat gat ggg aat cac tgg aat aga tta aga gat gat gct agt 96  
 Leu Pro Asn Asp Gly Asn His Trp Asn Arg Leu Arg Asp Asp Ala Ser  
 20 25 30  
 aat cta aga aat aga ggt ata acc gct att tgg att ccg cct gcc tgg 144  
 Asn Leu Arg Asn Arg Gly Ile Thr Ala Ile Trp Ile Pro Pro Ala Trp  
 35 40 45

## SEQUENCE LISTING

aaa ggg act tcg caa aat gat gtg ggg tat gga gcc tat gat ctt tat 192  
 Lys Gly Thr Ser Gln Asn Asp Val Gly Tyr Gly Ala Tyr Asp Leu Tyr  
 50 55 60

gat tta ggg gaa ttt aat caa aag ggg acg gtt cgt act aag tat ggg 240  
 Asp Leu Gly Glu Phe Asn Gln Lys Gly Thr Val Arg Thr Lys Tyr Gly  
 65 70 75 80

aca cgt agt caa ttg gag tct gcc atc cat gct tta aag aat aat gcc 288  
 Thr Arg Ser Gln Leu Glu Ser Ala Ile His Ala Leu Lys Asn Asn Gly  
 85 90 95

gtt caa gtt tat ggg gat gta gtg atg aac cat aaa gga gga gct gat 336  
 Val Gln Val Val Gly Asp Val Val Met Asn His Lys Gly Gly Ala Asp  
 100 105 110

gct aca gaa aac gtt ctt gct gtc gag gtg aat cca aat aac cgg aat 384  
 Ala Thr Glu Asn Val Leu Ala Val Glu Val Asn Pro Asn Asn Arg Asn  
 115 120 125

caa gaa ata tct ggg gac tac aca att gag gct tgg act aag ttt gat 432  
 Gln Glu Ile Ser Gly Asp Thr Thr Ile Glu Ala Trp Thr Lys Phe Asp  
 130 135 140

ttt cca ggg agg ggt aat aca tac tca gac ttt aaa tgg cgt tgg tat 480  
 Phe Pro Gly Arg Gly Asn Thr Tyr Ser Asp Phe Lys Trp Arg Trp Tyr  
 145 150 155 160

cat ttc gat ggt gta gat tgg gat caa tca cga caa ttc caa aat cgt 528  
 His Phe Asp Gly Val Asp Trp Asp Gln Ser Arg Gln Phe Gln Asn Arg  
 165 170 175

atc tac aaa ttc cga ggt gat ggt aag gca tgg gat tgg gaa gta gat 576  
 Ile Tyr Lys Phe Arg Gly Asp Gly Lys Ala Trp Asp Trp Glu Val Asp  
 180 185 190

tcg gaa aat gga aat tat gat tat tta atg tat gca gat gta gat atg 624  
 Ser Glu Asn Gly Asn Tyr Asp Tyr Leu Met Tyr Ala Asp Val Asp Met  
 195 200 205

gat cat cgg gag gta gta aat gag ctt aga aga tgg gga gaa tgg tat 672  
 Asp His Pro Glu Val Val Asn Glu Leu Arg Arg Trp Gly Glu Trp Tyr  
 210 215 220

aca aat aca tta aat ctt gat gga ttt agg atc gat gcg gtg aag cat 720  
 Thr Asn Thr Leu Asn Leu Asp Gly Phe Arg Ile Asp Ala Val Lys His  
 225 230 235 240

att aaa tat agc ttt aca cgt gat tgg ttg acc cat gta aga aac gca 768  
 Ile Lys Tyr Ser Phe Thr Arg Asp Trp Leu Thr His Val Arg Asn Ala  
 245 250 255

acg gga aaa gaa atg ttt gct gtt gct gaa ttt tgg aaa aat gat tta 816  
 Thr Gly Lys Glu Met Phe Ala Val Ala Glu Phe Trp Lys Asn Asp Leu  
 260 265 270

ggt gcc ttg gag aac tat tta aat aaa aca aac tgg aat cat tct gtc 864  
 Gly Ala Leu Glu Asn Tyr Leu Asn Lys Thr Asn Trp Asn His Ser Val  
 275 280 285

ttt gat gtc ccc ctt cat tat aat ctt tat aac gcg tca aat agt gga 912  
 Phe Asp Val Pro Leu His Tyr Asn Leu Tyr Asn Ala Ser Asn Ser Gly  
 290 295 300

ggc aac tat gac atg gca aaa ctt ctt aat gga acg gtt gtt caa aag 960  
 Gly Asn Tyr Asp Met Ala Lys Leu Leu Asn Gly Thr Val Val Gln Lys  
 305 310 315 320

## SEQUENCE LISTING

cat cca atg cat gcc gta act ttt gtg gat aat cac gat tct caa cct 1008  
 His Pro Met His Ala Val Thr Phe Val Asp Asn His Asp Ser Gln Pro 325 330 335

ggg gaa tca tta gaa tca ttt gta caa gaa tgg ttt aag cca ctt gct 1056  
 Gly Glu Ser Leu Glu Ser Phe Val Gln Glu Trp Phe Lys Pro Leu Ala 340 345 350

tat gcg ctt att tta aca aga gaa caa gcc tat ccc tct gtc ttc tat 1104  
 Tyr Ala Leu Ile Leu Thr Arg Gln Gly Tyr Pro Ser Val Phe Tyr 355 360 365

ggt gac tac tat gga att cca aca cat agt gtc cca gca atg aaa gcc 1152  
 Gly Asp Tyr Tyr Gly Ile Pro Thr His Ser Val Pro Ala Met Lys Ala 370 375 380

aag att gat cca atc tta gag gcg cgt caa aat ttt gca tat gga aca 1200  
 Lys Ile Asp Pro Ile Leu Glu Ala Arg Gln Asn Phe Ala Tyr Gly Thr 385 390 395 400

caa cat gat tat ttt gac cat cat aat ata atc gga tgg aca cgt gaa 1248  
 Gln His Asp Tyr Phe Asp His His Asn Ile Ile Gly Trp Thr Arg Glu 405 410 415

gga aat acc acg cat ccc aat tca gga ctt gcg act atc atg tcg gat 1296  
 Gly Asn Thr Thr His Pro Asn Ser Gly Leu Ala Thr Ile Met Ser Asp 420 425 430

ggg cca ggg gga gag aaa tgg atg tac gta ggg caa aat aaa gca ggt 1344  
 Gly Pro Gly Gly Glu Lys Trp Met Tyr Val Gly Gln Asn Lys Ala Gly 435 440 445

caa gtt tgg cat gac ata act gga aat aaa cca gga aca gtt acg atc 1392  
 Gln Val Trp His Asp Ile Thr Gly Asn Lys Pro Gly Thr Val Thr Ile 450 455 460

aat gca gat gga tgg gct aat ttt tca gta aat gga gga tct gtt tcc 1440  
 Asn Ala Asp Gly Trp Ala Asn Phe Ser Val Asn Gly Gly Ser Val Ser 465 470 475 480

att tgg gtg aaa cga 1455  
 Ile Trp Val Lys Arg 485

<210> 4  
 <211> 485  
 <212> PRT  
 <213> Bacillus sp.

<400> 4  
 His His Asn Gly Thr Asn Gly Thr Met Met Gln Tyr Phe Glu Trp His  
 1 5 10 15  
 Leu Pro Asn Asp Gly Asn His Trp Asn Arg Leu Arg Asp Asp Ala Ser  
 20 25 30  
 Asn Leu Arg Asn Arg Gly Ile Thr Ala Ile Trp Ile Pro Ala Trp  
 35 40 45  
 Lys Gly Thr Ser Gln Asn Asp Val Gly Tyr Gly Ala Tyr Asp Leu Tyr  
 50 55 60  
 Asp Leu Gly Glu Phe Asn Gln Lys Gly Thr Val Arg Thr Lys Tyr Gly  
 65 70 75 80  
 Thr Arg Ser Gln Leu Glu Ser Ala Ile His Ala Leu Lys Asn Asn Gly  
 85 90 95

## SEQUENCE LISTING

Val Gln Val Tyr Gly Asp Val Val Met Asn His Lys Gly Gly Ala Asp  
 100 105 110  
 Ala Thr Glu Asn Val Leu Ala Val Glu Val Asn Pro Asn Asn Arg Asn  
 115 120 125  
 Gln Glu Ile Ser Gly Asp Tyr Thr Ile Glu Ala Trp Thr Lys Phe Asp  
 130 135 140  
 Phe Pro Gly Arg Gly Asn Thr Tyr Ser Asp Phe Lys Trp Arg Trp Tyr  
 145 150 155 160  
 His Phe Asp Gly Val Asp Trp Asp Gln Ser Arg Gln Phe Gln Asn Arg  
 165 170 175  
 Ile Tyr Lys Phe Arg Gly Asp Gly Lys Ala Trp Asp Trp Glu Val Asp  
 180 185 190  
 Ser Glu Asn Gly Asn Tyr Asp Tyr Leu Met Tyr Ala Asp Val Asp Met  
 195 200 205  
 Asp His Pro Glu Val Val Asn Glu Leu Arg Arg Trp Gly Glu Trp Tyr  
 210 215 220  
 Thr Asn Thr Leu Asn Leu Asp Gly Phe Arg Ile Asp Ala Val Lys His  
 225 230 235 240  
 Ile Lys Tyr Ser Phe Thr Arg Asp Trp Leu Thr His Val Arg Asn Ala  
 245 250 255  
 Thr Gly Lys Glu Met Phe Ala Val Ala Glu Phe Trp Lys Asn Asp Leu  
 260 265 270  
 Gly Ala Leu Glu Asn Tyr Leu Asn Lys Thr Asn Trp Asn His Ser Val  
 275 280 285  
 Phe Asp Val Pro Leu His Tyr Asn Leu Tyr Asn Ala Ser Asn Ser Gly  
 290 295 300  
 Gly Asn Tyr Asp Met Ala Lys Leu Leu Asn Gly Thr Val Val Gln Lys  
 305 310 315 320  
 His Pro Met His Ala Val Thr Phe Val Asp Asn His Asp Ser Gln Pro  
 325 330 335  
 Gly Glu Ser Leu Glu Ser Phe Val Gln Glu Trp Phe Lys Pro Leu Ala  
 340 345 350  
 Tyr Ala Leu Ile Leu Thr Arg Glu Gln Gly Tyr Pro Ser Val Phe Tyr  
 355 360 365  
 Gly Asp Tyr Tyr Gly Ile Pro Thr His Ser Val Pro Ala Met Lys Ala  
 370 375 380  
 Lys Ile Asp Pro Ile Leu Glu Ala Arg Gln Asn Phe Ala Tyr Gly Thr  
 385 390 395 400  
 Gln His Asp Tyr Phe Asp His His Asn Ile Ile Gly Trp Thr Arg Glu  
 405 410 415  
 Gly Asn Thr Thr His Pro Asn Ser Gly Leu Ala Thr Ile Met Ser Asp  
 420 425 430  
 Gly Pro Gly Gly Glu Lys Trp Met Tyr Val Gly Gln Asn Lys Ala Gly  
 435 440 445  
 Gln Val Trp His Asp Ile Thr Gly Asn Lys Pro Gly Thr Val Thr Ile

## SEQUENCE LISTING

450  
Asn Ala Asp Gly Trp Ala Asn Phe Ser Val Asn Gly Gly Ser Val Ser  
465 470 475 480

Ile Trp Val Lys Arg  
485

<210> 5  
<211> 1548  
<212> DNA  
<213> Bacillus stearothermophilus

<220>  
<221> CDS  
<222> (1)..(1548)  
<223> 85G

<400> 5  
gcc gca ccg ttt aac ggc acc atg atg cag tat ttt gaa tgg tac ttg 48  
Ala Ala Pro Phe Asn Gly Thr Met Met Gln Tyr Phe Glu Trp Tyr Leu  
1 5 10 15  
ccg gat gat ggc acg tta tgg acc aaa gtg gcc aat gaa gcc aac aac 96  
Pro Asp Asp Gly Thr Leu Trp Thr Lys Val Ala Asn Glu Ala Asn Asn  
20 25 30  
tta tcc agc ctt ggc atc acc gct ctt tgg ctg ccg ccc gct tac aaa 144  
Leu Ser Ser Leu Gly Ile Thr Ala Leu Trp Leu Pro Pro Ala Tyr Lys  
35 40 45  
gga aca agc cgc agc gac gta ggg tac gga gta tac gac ttg tat gac 192  
Gly Thr Ser Arg Ser Asp Val Gly Tyr Val Tyr Asp Leu Tyr Asp  
50 55 60  
ctc ggc gaa ttc aat caa aaa ggg acc gtc cgc aca aaa tac gga aca 240  
Leu Gly Glu Phe Asn Gln Lys Gly Thr Val Val Arg Thr Lys Tyr Gly Thr  
65 70 75 80  
aaa gct caa tat ctt caa gcc att caa gcc gcc cac gcc gct gga atg 288  
Lys Ala Gln Tyr Leu Gln Ala Ile Gln Ala Ala His Ala Ala Gly Met  
85 90 95  
caa gtg tac gcc gat gtc gtg ttc gac cat aaa ggc ggc gct gac gcc 336  
Gln Val Tyr Ala Asp Val Val Phe Asp His Lys Gly Glu Ala Asp Gly  
100 105 110  
acg gaa tgg gtg gac gcc gtc gaa gtc aat ccg tcc gac cgc aac caa 384  
Thr Trp Trp Val Asp Ala Val Glu Val Asn Pro Ser Asp Arg Asn Gln  
115 120 125  
gaa atc tcg ggc acc tat caa atc caa gca tgg acg aaa ttt gat ttt 432  
Glu Ile Ser Gly Thr Tyr Gln Ile Gln Ala Trp Thr Lys Phe Asp Phe  
130 135 140  
ccc ggg cgg ggc aac acc tac tcc agc ttt aag tgg cgc tgg tac cat 480  
Pro Gly Arg Gly Asn Thr Tyr Ser Ser Phe Lys Trp Arg Trp Tyr His  
145 150 155 160  
ttt gac ggc gtt gat tgg gac gaa agc cga aaa ttg agc cgc att tac 528  
Phe Asp Gly Val Asp Trp Asp Glu Ser Arg Lys Leu Ser Arg Ile Tyr  
165 170 175  
aaa ttc cgc ggc atc ggc aaa gcg tgg gat tgg gaa gta gac acg gaa 576  
Lys Phe Arg Gly Ile Gly Lys Ala Trp Asp Trp Glu Val Asp Thr Glu  
180 185 190

## SEQUENCE LISTING

aac gga aac tat gac tac tta atg tat gcc gac ctt gat atg gat cat Asn Gly Asn Tyr Asp Tyr Leu Met Tyr Ala Asp Leu Asp Met Asp His 195 200 205	624
ccc gaa gtc gtg acc gag ctg aaa aac tgg ggg aaa tgg tat gtc aac Pro Glu Val Val Thr Glu Leu Lys Asn Trp Gly Lys Trp Tyr Val Asn 210 215 220	672
aca acg aac att gat ggg ttc cgg ctt gat gcc gtc aag cat att aag Thr Thr Asn Ile Asp Gly Phe Arg Leu Asp Ala Val Lys His Ile Lys 225 230 235	720
ttc agt ttt ttt cct gat tgg ttg tgg tat gtc cgt tct cag act ggc Phe Ser Phe Phe Asp Trp Leu Ser Tyr Val Arg Ser Gln Thr Gly 245 250 255	768
aag ccg cta ttt acc gtc ggg gaa tat tgg agc tat gac atc aac aag Lys Pro Leu Phe Thr Val Gly Glu Tyr Trp Ser Tyr Asp Ile Asn Lys 260 265 270	816
ttg cac aat tac att acg aaa aca gac gga acg atg tct ttg ttt gat Leu His Asn Tyr Ile Thr Lys Thr Asp Gly Thr Met Ser Leu Phe Asp 275 280 285	864
gcc ccg tta cac aac aaa ttt tat acc gct tcc aaa tca ggg ggc gca Ala Pro Leu His Asn Lys Phe Tyr Thr Ala Ser Lys Ser Gly Gly Ala 290 295 300	912
ttt gat atg cgc acg tta atg acc aat act ctc atg aaa gat caa ccg Phe Asp Met Arg Thr Leu Met Thr Asn Thr Thr Met Lys Asp Gln Pro 305 310 315	960
aca ttg gcc gtc acc ttc gtt gat aat cat gac acc gaa ccc ggc caa Thr Leu Ala Val Thr Phe Val Asp Asn His Asp Thr Glu Pro Gly Gln 325 330 335	1008
gcg ctg cag tca tgg gtc gac cca tgg ttc aaa ccg ttg gct tac gcc Ala Leu Gln Ser Trp Val Asp Pro Trp Phe Lys Pro Leu Ala Tyr Ala 340 345 350	1056
ttt att cta act cgg cag gaa gga tac ccg tgc gtc ttt tat ggt gac Phe Ile Leu Thr Arg Gln Glu Gly Tyr Pro Cys Val Phe Tyr Gly Asp 355 360 365	1104
tat tat ggc att cca caa tat aac att cct tgc ctg aaa agc aaa atc Tyr Tyr Gly Ile Pro Gln Tyr Asn Ile Pro Ser Thr Lys Ser Lys Ile 370 375 380	1152
gat ccg ctc ctc atc gcg cgc agg gat tat gct tac gga acg caa cat Asp Pro Leu Leu Ile Ala Arg Arg Asp Tyr Ala Tyr Gly Thr Gln His 385 390 395	1200
gat tat ctt gat cac tcc gac atc atc ggg tgg aca agg gaa ggg ggc Asp Tyr Leu Asp His Ser Asp Ile Ile Gly Trp Thr Arg Glu Gly Gly 405 410 415	1248
act gaa aaa cca gga tcc gga ctg gcc gca ctg atc acc gat ggg ccg Thr Glu Lys Pro Gly Ser Gly Leu Ala Ala Leu Ile Thr Asp Gly Pro 420 425 430	1296
gga gga agc aaa tgg atg tac gtt ggc aaa caa cac gct gga aaa gtg Gly Gly Ser Lys Trp Met Tyr Val Gly Lys Gln His Ala Gly Lys Val 435 440 445	1344
ttc tat gac ctt acc ggc aac cgg agt gac acc gtc acc atc aac agt Phe Tyr Asp Leu Thr Gly Asn Arg Ser Asp Thr Val Thr Ile Asn Ser 450 455 460	1392

## SEQUENCE LISTING

gat gga tgg ggg gaa ttc aaa gtc aat ggc ggt tgc gtt tgc gtt tgg 1440  
 Asp Gly Trp Gly Glu Phe Lys Val Asn Gly Gly Ser Val Ser Val Trp 480  
 465 470 475

gtt cct aga aaa acg acc gtt tct acc atc gct cgg ccg atc aca acc 1488  
 Val Pro Arg Lys Thr Thr Val Ser Thr Ile Ala Arg Pro Ile Thr Thr 495  
 485 490

cga cgg tgg act ggt gaa ttc gtc cgt tgg acc gaa cca cgg ttg gtg 1536  
 Arg Pro Trp Thr Gly Glu Phe Val Arg Trp Thr Glu Pro Arg Leu Val 510  
 500 505 510

gca tgg cct tga 1548  
 Ala Trp Pro 515

<210> 6  
 <211> 515  
 <212> PRT  
 <213> Bacillus stearothermophilus

<400> 6  
 Ala Ala Pro Phe Asn Gly Thr Met Met Gln Tyr Phe Glu Trp Tyr Leu  
 1 5 10 15

Pro Asp Asp Gly Thr Leu Trp Thr Lys Val Ala Asn Glu Ala Asn Asn  
 20 25 30

Leu Ser Ser Leu Gly Ile Thr Ala Leu Trp Leu Pro Pro Ala Tyr Lys  
 35 40 45

Gly Thr Ser Arg Ser Asp Val Gly Tyr Gly Val Tyr Asp Leu Tyr Asp  
 50 55 60

Leu Gly Glu Phe Asn Gln Lys Gly Thr Val Arg Thr Lys Tyr Gly Thr  
 65 70 75 80

Lys Ala Gln Tyr Leu Gln Ala Ile Gln Ala Ala His Ala Ala Gly Met  
 85 90 95

Gln Val Tyr Ala Asp Val Val Phe Asp His Lys Gly Gly Ala Asp Gly  
 100 105 110

Thr Glu Trp Val Asp Ala Val Glu Val Asn Pro Ser Asp Arg Asn Gln  
 115 120 125

Glu Ile Ser Gly Thr Tyr Gln Ile Gln Ala Trp Thr Lys Phe Asp Phe  
 130 135 140

Pro Gly Arg Gly Asn Thr Tyr Ser Ser Phe Lys Trp Arg Trp Tyr His  
 145 150 155 160

Phe Asp Gly Val Asp Trp Asp Glu Ser Arg Lys Leu Ser Arg Ile Tyr  
 165 170 175

Lys Phe Arg Gly Ile Gly Lys Ala Trp Asp Trp Glu Val Asp Thr Glu  
 180 185 190

Asn Gly Asn Tyr Asp Tyr Leu Met Tyr Ala Asp Leu Asp Met Asp His  
 195 200 205

Pro Glu Val Val Thr Glu Leu Lys Asn Trp Gly Lys Trp Tyr Val Asn  
 210 215 220

Thr Thr Asn Ile Asp Gly Phe Arg Leu Asp Ala Val Lys His Ile Lys  
 225 230 235 240



## SEQUENCE LISTING

Phe Ser Phe Phe Pro Asp Trp Leu Ser Tyr Val Arg Ser Gln Thr Gly  
 245 250 255  
 Lys Pro Leu Phe Thr Val Gly Glu Tyr Trp Ser Tyr Asp Ile Asn Lys  
 260 265 270  
 Leu His Asn Tyr Ile Thr Lys Thr Asp Gly Thr Met Ser Leu Phe Asp  
 275 280 285  
 Ala Pro Leu His Asn Lys Phe Tyr Thr Ala Ser Lys Ser Gly Gly Ala  
 290 295 300  
 Phe Asp Met Arg Thr Leu Met Thr Asn Thr Leu Met Lys Asp Gln Pro  
 305 310 315 320  
 Thr Leu Ala Val Thr Phe Val Asp Asn His Asp Thr Glu Pro Gly Gln  
 325 330 335  
 Ala Leu Gln Ser Trp Val Asp Pro Trp Phe Lys Pro Leu Ala Tyr Ala  
 340 345 350  
 Phe Ile Leu Thr Arg Gln Glu Gly Tyr Pro Cys Val Phe Tyr Gly Asp  
 355 360 365  
 Tyr Tyr Gly Ile Pro Gln Tyr Asn Ile Pro Ser Leu Lys Ser Lys Ile  
 370 375 380  
 Asp Pro Leu Leu Ile Ala Arg Arg Asp Tyr Ala Tyr Gly Thr Gln His  
 385 390 395 400  
 Asp Tyr Leu Asp His Ser Asp Ile Ile Gly Trp Thr Arg Glu Gly Gly  
 405 410 415  
 Thr Glu Lys Pro Gly Ser Gly Leu Ala Ala Leu Ile Thr Asp Gly Pro  
 420 425 430  
 Gly Gly Ser Lys Trp Met Tyr Val Gly Lys Gln His Ala Gly Lys Val  
 435 440 445  
 Phe Tyr Asp Leu Thr Gly Asn Arg Ser Asp Thr Val Thr Ile Asn Ser  
 450 455 460  
 Asp Gly Trp Gly Glu Phe Lys Val Asn Gly Gly Ser Val Ser Val Trp  
 465 470 475 480  
 Val Pro Arg Lys Thr Thr Val Ser Thr Ile Ala Arg Pro Ile Thr Thr  
 485 490 495  
 Arg Pro Trp Thr Gly Glu Phe Val Arg Trp Thr Glu Pro Arg Leu Val  
 500 505 510  
 Ala Trp Pro  
 515

<210> 7  
 <211> 1920  
 <212> DNA  
 <213> *Bacillus licheniformis*

<220>  
 <221> CDS  
 <222> (421)..(1872)  
 <223> Terminus

<400> 7

## SEQUENCE LISTING

cggaagattg gaagtacaaa aataagcaaa agattgtcaa tcatgtcatg agccatgcgg 60  
 gagacggaaa aatcgtctta atgcacgata ttatgcaaac gtctgcagat gctgctgaag 120  
 agattatkaa aaagctgaaa gcaaaaggct atcaattggg aactgtatct cagcttgaag 180  
 aagtgaagaa gcagagaggc tattgaataa atgagtagaa gcgccatatc ggcgcttttc 240  
 ttttgaaga aatatataggg aaaatggtag ttgttaaaaa ttccgaatat ttatacaaca 300  
 tcattgtttt cacattgaaa ggggaggaga atcatgaaac aacaaaaacg gctttacgcc 360  
 cgattgtcga cgctgttaatt tgcgtctatc ttcttgctgc ctcatctgc agcagcggcg 420  
 gca aat ctt aat ggg acg ctg atg cag tat ttt gaa tgg tac atg ccc 468  
 Ala Asn Leu Asn Gly Thr Leu Met Gln Tyr Phe Glu Trp Tyr Met Pro  
 1 5 10 15  
 aat gac ggc caa cat tgg agg cgt ttg caa aac gac tcg gca tat ttg 516  
 Asn Asp Gly Gln His Trp Arg Arg Leu Gln Asn Asp Ser Ala Tyr Leu  
 20 25 30  
 gct gaa cac ggt att act gcc gtc tgg att ccc ccg gca tat aag gga 564  
 Ala Glu His Gly Ile Thr Ala Val Trp Ile Pro Pro Ala Tyr Lys Gly  
 35 40 45  
 acg agc caa gcg gat gtg ggc tac ggt gct tac gac ctt tat gat tta 612  
 Thr Ser Gln Ala Asp Val Gly Tyr Gly Ala Tyr Asp Leu Tyr Asp Leu  
 50 55 60  
 ggg gag ttt cat caa aaa ggg acg gtt cgg aca aag tac ggc aca aaa 660  
 Gly Glu Phe His Gln Lys Gly Thr Val Arg Thr Lys Tyr Gly Thr Lys  
 65 70 75 80  
 gga gag ctg caa tct gcg atc aaa agt ctt cat tcc cgc gac att aac 708  
 Gly Glu Leu Gln Ser Ala Ile Lys Ser Leu His Ser Arg Asp Ile Asn  
 85 90 95  
 gtt tac ggg gat gtg gtc atc aac cac aaa ggc ggc gct gat gcg acc 756  
 Val Tyr Gly Asp Val Val Ile Asn His Lys Gly Gly Ala Asp Ala Thr  
 100 105 110  
 gaa gat gta acc gcg gtt gaa gtc gat ccc gct gac cgc aac cgc gta 804  
 Glu Asp Val Thr Ala Val Glu Val Asp Pro Ala Asp Arg Asn Arg Val  
 115 120 125  
 att tca gga gaa cac cta att aaa gcc tgg aca cat ttt cat ttt ccg 852  
 Ile Ser Gly Glu His Leu Ile Lys Ala Trp Thr His Phe His Phe Pro  
 130 135 140  
 ggg cgc ggc agc aca tac agc gat ttt aaa tgg cat tgg tac cat ttt 900  
 Gly Arg Gly Ser Thr Tyr Ser Asp Phe Lys Trp His Trp Tyr His Phe  
 145 150 155 160  
 gac gga acc gat tgg gac gag tcc cga aag ctg aac cgc atc tat aag 948  
 Asp Gly Thr Asp Trp Asp Glu Ser Arg Lys Leu Asn Arg Ile Tyr Lys  
 165 170 175  
 ttt caa gga aag gct tgg gat tgg gaa gtt tcc aat gaa aac ggc aac 996  
 Phe Gln Gly Lys Ala Trp Asp Trp Glu Val Ser Asn Glu Asn Gly Asn  
 180 185 190  
 tat gat tat ttg atg tat gcc gac atc gat tat gac cat cct gat gtc 1044  
 Tyr Asp Tyr Leu Met Tyr Ala Asp Ile Asp Tyr Asp His Pro Asp Val  
 195 200 205  
 gca gca gaa att aag aga tgg ggc act tgg tat gcc aat gaa ctg caa 1092  
 Ala Ala Glu Ile Lys Arg Trp Gly Thr Trp Tyr Ala Asn Glu Leu Gln

210		215		SEQUENCE LISTING		220	
ttg gac ggt ttc cgt ctt gat gct gtc aaa cac att aaa ttt tct ttt	1140	Leu Asp Gly Phe Arg Leu Asp Ala Val Lys His Ile Lys Phe Ser Phe	225				
ttg cgg gat tgg gtt aat cat gtc agg gaa aaa acg ggg aag gaa atg	1188	Leu Arg Asp Trp Val Asn His Val Arg Glu Lys Thr Gly Lys Glu Met	245				
ttt acg gta gct gaa tat tgg cag aat gac ttg ggc gcg ctg gaa aac	1236	Phe Thr Val Ala Glu Tyr Trp Gln Asn Asp Leu Gly Ala Leu Glu Asn	260				
tat ttg aac aaa aca aat ttt aat cat tca gtg ttt gac gtg ccg ctt	1284	Tyr Leu Asn Lys Thr Asn Phe Asn His Ser Val Phe Asp Val Pro Leu	275				
cat tat cag ttc cat gct gca tcg aca cag gga ggc ggc tat gat atg	1332	His Tyr Gln Phe His Ala Ala Ser Thr Gln Gly Gly Tyr Asp Met	290				
agg aaa ttg ctg aac ggt acg gtc gtt tcc aag cat ccg ttg aaa tcg	1380	Arg Lys Leu Leu Asn Gly Thr Val Val Ser Lys His Pro Leu Lys Ser	305				
gtt aca ttt gtc gat aac cat gat aca cag ccg ggg caa tcg ctt gag	1428	Val Thr Phe Val Asn His Asp Thr Gln Pro Gly Gln Ser Leu Glu	325				
tcg act gtc caa aca tgg ttt aag ccg ctt gct tac gct ttt att ctc	1476	Ser Thr Val Gln Thr Trp Phe Lys Pro Leu Ala Tyr Ala Phe Ile Leu	340				
aca agg gaa tct gga tac cct cag gtt ttc tac ggg gat atg tac ggg	1524	Thr Arg Glu Ser Gly Tyr Pro Gln Val Phe Tyr Gly Asp Met Tyr Gly	355				
acg aaa gga gac tcc cag cgc gaa att cct gcc ttg aaa cac aaa att	1572	Thr Lys Gly Asp Ser Gln Arg Glu Ile Pro Ala Leu Lys His Lys Ile	370				
gaa ccg atc tta aaa gcg aga aaa cag tat gcg tac gga gca cag cat	1620	Glu Pro Ile Leu Lys Ala Arg Lys Gln Tyr Ala Tyr Gly Ala Gln His	385				
gat tat ttc gac cac cat gac att gtc ggc tgg aca agg gaa ggc gac	1668	Asp Tyr Phe Asp His His Asp Ile Val Gly Trp Thr Arg Glu Gly Asp	405				
agc tcg gtt gca aat tca ggt ttg gcg gca tta ata aca gac gga ccc	1716	Ser Ser Val Ala Asn Ser Gly Leu Ala Ala Leu Ile Thr Asp Gly Pro	420				
ggt ggg gca aag cga atg tat gtc ggc cgg caa aac gcc ggt gag aca	1764	Gly Gly Ala Lys Arg Met Tyr Val Gly Arg Gln Asn Ala Gly Glu Thr	435				
tgg cat gac att acc gga aac cgt tcg gag ccg gtt gtc atc aat tcg	1812	Trp His Asp Ile Thr Gly Asn Arg Ser Glu Pro Val Val Ile Asn Ser	450				
gaa ggc tgg gga gag ttt cac gta aac gcc ggg tcg gtt tca att tat	1860	Glu Gly Trp Gly Glu Phe His Val Asn Gly Gly Ser Val Ser Ile Tyr	465				
gtt caa aga tag aagagcagag aggacggatt tcctgaagga aatccgtrtt	1912	Val Gln Arg					

## SEQUENCE LISTING

tttttttt

1920

&lt;210&gt; 8

&lt;211&gt; 483

&lt;212&gt; PRT

<213> *Bacillus licheniformis*

&lt;400&gt; 8

Ala Asn Leu Asn Gly Thr Leu Met Gln Tyr Phe Glu Trp Tyr Met Pro  
 1 5 10 15

Asn Asp Gly Gln His Trp Arg Arg Leu Gln Asn Asp Ser Ala Tyr Leu  
 20 25 30

Ala Glu His Gly Ile Thr Ala Val Trp Ile Pro Pro Ala Tyr Lys Gly  
 35 40 45

Thr Ser Gln Ala Asp Val Gly Tyr Gly Ala Tyr Asp Leu Tyr Asp Leu  
 50 55 60

Gly Glu Phe His Gln Lys Gly Thr Val Arg Thr Lys Tyr Gly Thr Lys  
 65 70 75 80

Gly Glu Leu Gln Ser Ala Ile Lys Ser Leu His Ser Arg Asp Ile Asn  
 85 90 95

Val Tyr Gly Asp Val Val Ile Asn His Lys Gly Gly Ala Asp Ala Thr  
 100 105 110

Glu Asp Val Thr Ala Val Glu Val Asp Pro Ala Asp Arg Asn Arg Val  
 115 120 125

Ile Ser Gly Glu His Leu Ile Lys Ala Trp Thr His Phe His Phe Pro  
 130 135 140

Gly Arg Gly Ser Thr Tyr Ser Asp Phe Lys Trp His Trp Tyr His Phe  
 145 150 155 160

Asp Gly Thr Asp Trp Asp Glu Ser Arg Lys Leu Asn Arg Ile Tyr Lys  
 165 170 175

Phe Gln Gly Lys Ala Trp Asp Trp Glu Val Ser Asn Glu Asn Gly Asn  
 180 185 190

Tyr Asp Tyr Leu Met Tyr Ala Asp Ile Asp Tyr Asp His Pro Asp Val  
 195 200 205

Ala Ala Glu Ile Lys Arg Trp Gly Thr Trp Tyr Ala Asn Glu Leu Gln  
 210 215 220

Leu Asp Gly Phe Arg Leu Asp Ala Val Lys His Ile Lys Phe Ser Phe  
 225 230 235 240

Leu Arg Asp Trp Val Asn His Val Arg Glu Lys Thr Gly Lys Glu Met  
 245 250 255

Phe Thr Val Ala Glu Tyr Trp Gln Asn Asp Leu Gly Ala Leu Glu Asn  
 260 265 270

Tyr Leu Asn Lys Thr Asn Phe Asn His Ser Val Phe Asp Val Pro Leu  
 275 280 285

His Tyr Gln Phe His Ala Ala Ser Thr Gln Gly Gly Gly Tyr Asp Met  
 290 295 300

Arg Lys Leu Leu Asn Gly Thr Val Val Ser Lys His Pro Leu Lys Ser

[illegible]

```
<210> 9
<211> 2084
<212> DNA
<213> Bacillus amyloliquefaciens
```

```
<220>
<221> CDS
<222> (343)..(1794)
<223> BAN
```

```

400> 9
gccccgcaca tacgaaaaga ctggctgaaa acattgagcc tttgatgact gatgatttgg 60
ctgaagaagt ggatcgattg tttgagaaaa gaagaagacc ataaaaatcc ttgtctctgc 120
atcagacagg gtatttttta tgctgtccag actgtccgct gtgtaaaaaa aaggaataaa 180
gggggggtgt tattatttta ctgatatgta aaatataatt tgtataagaa aatgagaggg 240
agaggaaaca tgattcaaaa acgaaagcgg acagtttcgt tcagacttgt gcttatgtgc 300
acgctgttat ttgtcagttt gccgattaca aaaacatcag cc gta aat ggc acg 354
                        Val Asn Gly Thr
                        1
ctg atg cag tat ttt gaa tgg tat acg ccg aac gac ggc cag cat tgg 402
Leu Met Gln Tyr Phe Glu Trp Tyr Thr Pro Asn Asp Gly Gln His Trp
5 10 15 20
aaa cga ttg cag aat gat gcg gaa cat tta tcg gat atc gga atc act 450
Lys Arg Leu Gln Asn Asp Ala Glu His Leu Ser Asp Ile Gly Ile Thr
25 30 35

```

## SEQUENCE LISTING

gcc gtc tgg att cct ccc gca tac aaa gga ttg agc caa tcc gat aac Ala Val Trp Ile 40 Pro Pro Ala Tyr Lys Gly Leu Ser Gln Ser Asp Asn 50	498
gga tac gga cct tat gat ttg tat gat tta gga gaa ttc cag caa aaa Gly Tyr Gly 55 Pro Tyr Asp Leu Tyr Asp 60 Leu Gly Glu Phe 65 Gln Gln Lys	546
ggg acg gtc aga acg aaa tac ggc aca aaa tca gag ctt caa gat gcg Gly Thr Val Arg Thr Lys 70 Tyr Gly Thr Lys Ser Glu 80 Leu Gln Asp Ala	594
atc ggc tca ctg cat tcc cgg aac gtc caa gta tac gga gat gtg gtt Ile Gly Ser Leu His 85 Ser Arg Asn Val Gln Val 95 Tyr Gly Asp Val Val 100	642
ttg aat cat aag gct ggt gct gat gca aca gaa gat gta act gcc gtc Leu Asn His Lys 105 Gly Ala Asp Ala Thr 110 Glu Asp Val Thr 115 gtc Val	690
gaa gtc aat ccg gcc aat aga aat cag gaa act tcg gag gaa tat caa Glu Val Asn Pro 120 Ala Asn Arg Asn Gln 125 Glu Thr Ser Glu 130 Tyr Gln	738
atc aaa gcg tgg acg gat ttt cgt ttt ccg ggc cgt gga aac acg tac Ile Lys Ala Trp Thr Asp Phe 135 Arg Phe Pro Gly Arg 145 Asn Thr Tyr	786
agt gat ttt aaa tgg cat tgg tat cat ttc gac gga gcg gac tgg gat Ser Asp Phe Lys Trp His 150 Trp Tyr His Phe Asp Gly Ala Asp Trp Asp 160	834
gaa tcc ccg aag atc agc cgc atc ttt aag ttt cgt ggg gaa gga aaa Glu Ser Arg Lys Ile 165 Ser Arg Ile 170 Phe Ile Phe Lys 175 Arg Gly Glu Gly Lys 180	882
gcg tgg gat tgg gaa gta tca agt gaa aac ggc aac tat gac tat tta Ala Trp Asp Trp 185 Glu Val Ser Ser Glu Asn 190 Gly Asn Tyr Asp Tyr Leu 195	930
atg tat gct gat gtt gac tac gac cac cct gat gtc gtg gca gag aca Met Tyr Asp Val 200 Asp Tyr Asp His 205 Pro Asp Val Val 210 Glu Thr	978
aaa aaa tgg ggt atc tgg tat gcg aat gaa ctg tca tta gac gcc ttc Lys Lys Trp Gly Ile Trp Tyr 215 Ala Asn Glu Leu Ser 225 Leu Asp Gly Phe	1026
cgt att gat gcc gcc aaa cat att aaa ttt tca ttt ctg cgt gat tgg Arg Ile Asp Ala Ala Lys 230 His Ile Lys Phe Ser 240 Leu Arg Asp Trp	1074
gtt cag gcg gtc aga cag gcg acg gga aaa gaa atg ttt acg gtt gcg Val Gln Ala Val Arg Gln Ala Thr Gly Lys 250 Glu Met Phe Thr Val Ala 260	1122
gag tat tgg cag aat aat gcc ggg aaa ctc gaa aac tac ttg aat aaa Glu Tyr Trp Gln Asn Asn Ala Gly Lys 265 Leu Glu Asn Tyr Leu Asn Lys 275	1170
aca agc ttt aat caa tcc gtg ttt gat gtt ccg ctt cat ttc aat tta Thr Ser Phe Asn 280 Gln Ser Val Phe Asp 285 Val Pro Leu His Phe Asn Leu 290	1218
cag gcg gct tcc tca caa gga gcc gga tat gat atg agg cgt ttg ctg Gln Ala Ala Ser Ser Gln Gly Gly Gly Tyr Asp Met Arg Arg Leu Leu 305	1266

## SEQUENCE LISTING

gac ggt acc gtt gtg tcc agg cat ccg gaa aag gcg gtt aca ttt gtt 1314  
 Asp Gly Thr Val Val Ser Arg His Pro Glu Lys Ala Val Thr Phe Val  
 310 315 320

gaa aat cat gac aca cag ccg gga cag tca ttg gaa tcg aca gtc caa 1362  
 Glu Asn His Asp Thr Gln Pro Gly Gln Ser Leu Glu Ser Thr Val Gln  
 325 330 335 340

act tgg ttt aaa ccg ctt gca tac gcc ttt att ttg aca aga gaa tcc 1410  
 Thr Trp Phe Lys Pro Leu Ala Tyr Ala Phe Ile Leu Thr Arg Glu Ser  
 345 350 355

ggg tat cct cag gtg ttc tat ggg gat atg tac ggg aca aaa ggg aca 1458  
 Gly Tyr Pro Gln Val Phe Tyr Gly Asp Met Tyr Gly Thr Lys Gly Thr  
 360 365 370

tcg cca aag gaa att ccc tca ctg aaa gat aat ata gag ccg att tta 1506  
 Ser Pro Lys Glu Ile Pro Ser Leu Lys Asp Asn Ile Glu Pro Ile Leu  
 375 380 385

aaa gcg cgt aag gag tac gca tac ggg ccc cag cac gat tat att gac 1554  
 Lys Ala Arg Lys Glu Tyr Ala Tyr Gly Pro Gln His Asp Tyr Ile Asp  
 390 395 400

cac ccg gat gtg atc gga tgg acg agg gaa ggt gac agc tcc gcc gcc 1602  
 His Pro Asp Val Ile Gly Trp Thr Arg Glu Gly Asp Ser Ser Ala Ala  
 405 410 415 420

aaa tca ggt ttg gcc gct tta atc acg gac gga ccc ggc gga tca aag 1650  
 Lys Ser Gly Leu Ala Ala Leu Ile Thr Asp Gly Pro Gly Gly Ser Lys  
 425 430 435

cgg atg tat gcc ggc ctg aaa aat gcc ggc gag aca tgg tat gac ata 1698  
 Arg Met Tyr Ala Gly Leu Lys Asn Ala Gly Glu Thr Trp Tyr Asp Ile  
 440 445 450

acg ggc aac cgt tca gat act gta aaa atc gga tct gac ggc tgg gga 1746  
 Thr Gly Asn Arg Ser Asp Thr Val Lys Ile Gly Ser Asp Gly Trp Gly  
 455 460 465

gag ttt cat gta aac gat ggg tcc gtc tcc att tat gtt cag aaa taa 1794  
 Glu Phe His Val Asn Asp Gly Ser Val Ser Ile Tyr Val Gln Lys  
 470 475 480

ggtaataaaa aaacacctcc aagctgagtg cgggtatcag cttggagggt cgtttatttt 1854

ttcagccgta tgacaaggct ggcatacaggt gtgacaaata cggatatgctg gctgcatag 1914

gtgacaaatc cgggtttttgc gccgttttggc tttttcacat gtctgatttt tgrataatca 1974

acaggcacgg agccggaatc tttgccttg gaaaaataag cggcgatcgt agctgcttcc 2034

aatatggatt gttcatcggt atcgctgctt ttaatcacia cgtgggatcc 2084

<210> 10  
 <211> 483  
 <212> PRT  
 <213> Bacillus amyloliquefaciens

<400> 10  
 Val Asn Gly Thr Leu Met Gln Tyr Phe Glu Trp Tyr Thr Pro Asn Asp  
 1 5 10 15  
 Gly Gln His Trp Lys Arg Leu Gln Asn Asp Ala Glu His Leu Ser Asp  
 20 25 30

## SEQUENCE LISTING

Ile Gly Ile Thr Ala Val Trp Ile Pro Pro Ala Tyr Lys Gly Leu Ser  
 35 40 45  
 Gln Ser Asp Asn Gly Tyr Gly Pro Tyr Asp Leu Tyr Asp Leu Gly Glu  
 50 55 60  
 Phe Gln Gln Lys Gly Thr Val Arg Thr Lys Tyr Gly Thr Lys Ser Glu  
 65 70 75 80  
 Leu Gln Asp Ala Ile Gly Ser Leu His Ser Arg Asn Val Gln Val Tyr  
 85 90 95  
 Gly Asp Val Val Leu Asn His Lys Ala Gly Ala Asp Ala Thr Glu Asp  
 100 105 110  
 Val Thr Ala Val Glu Val Asn Pro Ala Asn Arg Asn Gln Glu Thr Ser  
 115 120 125  
 Glu Glu Tyr Gln Ile Lys Ala Trp Thr Asp Phe Arg Phe Pro Gly Arg  
 130 135 140  
 Gly Asn Thr Tyr Ser Asp Phe Lys Trp His Trp Tyr His Phe Asp Gly  
 145 150 155 160  
 Ala Asp Trp Asp Glu Ser Arg Lys Ile Ser Arg Ile Phe Lys Phe Arg  
 165 170 175  
 Gly Glu Gly Lys Ala Trp Asp Trp Glu Val Ser Ser Glu Asn Gly Asn  
 180 185 190  
 Tyr Asp Tyr Leu Met Tyr Ala Asp Val Asp Tyr Asp His Pro Asp Val  
 195 200 205  
 Val Ala Glu Thr Lys Lys Trp Gly Ile Trp Tyr Ala Asn Glu Leu Ser  
 210 215 220  
 Leu Asp Gly Phe Arg Ile Asp Ala Ala Lys His Ile Lys Phe Ser Phe  
 225 230 235 240  
 Leu Arg Asp Trp Val Gln Ala Val Arg Gln Ala Thr Gly Lys Glu Met  
 245 250 255  
 Phe Thr Val Ala Glu Tyr Trp Gln Asn Asn Ala Gly Lys Leu Glu Asn  
 260 265 270  
 Tyr Leu Asn Lys Thr Ser Phe Asn Gln Ser Val Phe Asp Val Pro Leu  
 275 280 285  
 His Phe Asn Leu Gln Ala Ala Ser Ser Gln Gly Gly Gly Tyr Asp Met  
 290 295 300  
 Arg Arg Leu Leu Asp Gly Thr Val Val Ser Arg His Pro Glu Lys Ala  
 305 310 315 320  
 Val Thr Phe Val Glu Asn His Asp Thr Gln Pro Gly Gln Ser Leu Glu  
 325 330 335  
 Ser Thr Val Gln Thr Trp Phe Lys Pro Leu Ala Tyr Ala Phe Ile Leu  
 340 345 350  
 Thr Arg Glu Ser Gly Tyr Pro Gln Val Phe Tyr Gly Asp Met Tyr Gly  
 355 360 365  
 Thr Lys Gly Thr Ser Pro Lys Glu Ile Pro Ser Leu Lys Asp Asn Ile  
 370 375 380  
 Glu Pro Ile Leu Lys Ala Arg Lys Glu Tyr Ala Tyr Gly Pro Gln His  
 385 390 395 400



## SEQUENCE LISTING

Asp Tyr Ile Asp His Pro Asp Val Ile Gly Trp Thr Arg Glu Gly Asp  
 405 415  
 Ser Ser Ala Ala Lys Ser Gly Leu Ala Ala Leu Ile Thr Asp Gly Pro  
 420 425 430  
 Gly Gly Ser Lys Arg Met Tyr Ala Gly Leu Lys Asn Ala Gly Glu Thr  
 435 440 445  
 Trp Tyr Asp Ile Thr Gly Asn Arg Ser Asp Thr Val Lys Ile Gly Ser  
 450 455 460  
 Asp Gly Trp Gly Glu Phe His Val Asn Asp Gly Ser Val Ser Ile Tyr  
 465 470 475 480  
 Val Gln Lys

<210> 11  
 <211> 1458  
 <212> DNA  
 <213> Bacillus sp.

<220>  
 <221> CDS  
 <222> (1)..(1458)  
 <223> AA560

<400> 11  
 cac cat aat ggt acg aac ggc aca atg atg cag tac ttt gaa tgg tat 48  
 His His Asn Gly Thr Asn Gly Thr Met Met Gln Tyr Phe Glu Trp Tyr  
 1 5 10 15  
 cta cca aat gac gga aac cat tgg aat aga tta agg tct gat gca agt 96  
 Leu Pro Asn Asp Gly Asn His Trp Asn Arg Leu Arg Ser Asp Ala Ser  
 20 25 30  
 aac cta aaa gat aaa ggg atc tca cgc gtt tgg att cct cct gca tgg 144  
 Asn Leu Lys Asp Lys Gly Ile Ser Ala Val Trp Ile Pro Pro Ala Trp  
 35 40 45  
 aag ggt gcc tct caa aat gat gtg ggg tat ggt gct tat gat ctg tat 192  
 Lys Gly Ala Ser Gln Asn Asp Val Gly Tyr Gly Ala Tyr Asp Leu Tyr  
 50 55 60  
 gat tta gga gaa ttc aat caa aaa gga acc att cgt aca aaa tat gga 240  
 Asp Leu Gly Glu Phe Asn Gln Lys Gly Thr Ile Arg Thr Lys Tyr Gly  
 65 70 75 80  
 acg cgc aat cag tta caa gct gca gtt aac gcc ttg aaa agt aat gga 288  
 Thr Arg Asn Gln Leu Gln Ala Ala Val Asn Ala Leu Lys Ser Asn Gly  
 85 90 95  
 att caa gtg tat ggc gat gtt gta atg aat cat aaa ggg gga gca gac 336  
 Ile Gln Val Tyr Gly Asp Val Val Met Asn His Lys Gly Gly Ala Asp  
 100 105 110  
 gct acc gaa atg gtt agg gca gtt gaa gta aac ccg aat aat aga aat 384  
 Ala Thr Glu Met Val Arg Ala Val Glu Val Asn Pro Asn Asn Arg Asn  
 115 120 125  
 caa gaa gtg tcc ggt gaa tat aca att gag gct tgg aca aag ttt gac 432  
 Gln Glu Val Ser Gly Glu Tyr Thr Ile Glu Ala Trp Thr Lys Phe Asp  
 130 135 140  
 ttt cca gga cga ggt aat act cat tca aac ttc aaa tgg aga tgg tat 480

## SEQUENCE LISTING

Phe Pro Gly Arg Gly	Asn Thr His	Ser Asn Phe Lys Trp Arg Trp Tyr	
145	150	155	160
cac ttt gat gga gta gat tgg gat cag tca cgt aag ctg aac aat cga			528
His Phe Asp Gly Val	Asp Trp Asp Gln	Ser Arg Lys Leu Asn Asn Arg	
165	170	175	
att tat aaa ttt aga ggt gat gga aaa ggg tgg gat tgg gaa gtc gat			576
Ile Tyr Lys Phe Arg Gly Asp Gly Lys Gly	Trp Asp Trp Trp Glu Val Asp		
180	185	190	
aca gaa aac ggt aac tat gat tac cta atg tat gca gat att gac atg			624
Thr Glu Asn Gly Asn Tyr Asp Tyr Leu Met Tyr Ala Asp Ile Asp Met			
195	200	205	
gat cac cca gag gta gtg aat gag cta aga aat tgg ggt gtt tgg tat			672
Asp His Pro Glu Val Val Asn Glu Leu Arg Asn Trp Gly Val Trp Tyr			
210	215	220	
acg aat aca tta ggc ctt gat ggt ttt aga ata gat gca gta aaa cat			720
Thr Asn Thr Leu Gly Leu Asp Gly Phe Arg Ile Asp Ala Val Lys His			
225	230	235	240
ata aaa tac agc ttt act cgt gat tgg att aat cat gtt aga agt gca			768
Ile Lys Tyr Ser Phe Thr Arg Asp Trp Ile Asn His Val Arg Ser Ala			
245	250	255	
act ggc aaa aat atg ttt gcg gtt gcg gaa ttt tgg aaa aat gat tta			816
Thr Gly Lys Asn Met Phe Ala Val Ala Glu Phe Trp Lys Asn Asp Leu			
260	265	270	
ggc gct att gaa aac tat tta aac aaa aca aac tgg aac cat tca gtc			864
Gly Ala Ile Glu Asn Tyr Leu Asn Lys Thr Asn Trp Asn His Ser Val			
275	280	285	
ttt gat gtt ccg ctg cac tat aac ctc tat aat gct tca aaa agc gga			912
Phe Asp Val Pro Leu His Tyr Asn Leu Tyr Asn Ala Ser Lys Ser Gly			
290	295	300	
ggg aat tat gat atg agg caa ata ttt aat ggt aca gtc gtg caa aga			960
Gly Asn Tyr Asp Met Arg Gln Ile Phe Asn Gly Thr Val Val Gln Arg			
305	310	315	320
cat cca atg cat gct gtt aca ttt gtt gat aat cat gat tcg caa cct			1008
His Pro Met His Ala Val Thr Phe Val Asp Asn His Asp Ser Gln Pro			
325	330	335	
gaa gaa gct tta gag tct ttt gtt gaa gaa tgg ttc aaa cca tta gcg			1056
Glu Glu Ala Leu Glu Ser Phe Val Glu Glu Trp Lys Pro Leu Ala			
340	345	350	
tat gct ttg aca tta aca cgt gaa caa ggc tac cct tct gta ttt tat			1104
Tyr Ala Leu Thr Leu Thr Arg Glu Gln Gly Tyr Pro Ser Val Phe Tyr			
355	360	365	
gga gat tat tat ggc att cca acg cat ggt gta cca gcg atg aaa tcg			1152
Gly Asp Tyr Tyr Gly Ile Pro Thr His Gly Val Pro Ala Met Lys Ser			
370	375	380	
aaa att gac ccg att cta gaa gcg cgt caa aag tat gca tat gga aga			1200
Lys Ile Asp Pro Ile Leu Glu Ala Arg Gln Lys Tyr Ala Tyr Gly Arg			
385	390	395	400
caa aat gac tac tta gac cat cat aat atc atc ggt tgg aca cgt gaa			1248
Gln Asn Asp Tyr Leu Asp His His Asn Ile Ile Gly Trp Thr Arg Glu			
405	410	415	
ggg aat aca gca cac ccc aac tcc ggt tta gct act atc atg tcc gat			1296

SEQUENCE LISTING

Gly Asn Thr Ala His Pro Asn Ser	Gly Leu Ala Thr Ile Met Ser Asp	
420	425 430	
ggg gca gga gga aat aag tgg atg ttt gtt ggg cgt aat aaa gct ggt	1344	
Gly Ala Gly Gly Asn Lys Trp Met Phe Val Gly Arg Asn Lys Ala Gly		
435 440	445	
caa gtt tgg acc gat atc act gga aat cgt gca ggt act gtt acg att	1392	
Gln Val Trp Thr Asp Ile Thr Gly Asn Arg Ala Gly Thr Val Thr Ile		
450 455	460	
aat gct gat gga tgg ggt aat ttt tct gta aat gga gga tca gtt tct	1440	
Asn Ala Asp Gly Trp Gly Asn Phe Ser Val Asn Gly Gly Ser Val Ser		
465 470	475 480	
att tgg gta aac aaa taa	1458	
Ile Trp Val Asn Lys		
485		

&lt;210&gt; 12

&lt;211&gt; 485

&lt;212&gt; PRT

&lt;213&gt; Bacillus sp.

&lt;400&gt; 12

His His Asn Gly Thr Asn Gly Thr Met Met Gln Tyr Phe Glu Trp Tyr	
1 5 10 15	
Leu Pro Asn Asp Gly Asn His Trp Asn Arg Leu Arg Ser Asp Ala Ser	
20 25 30	
Asn Leu Lys Asp Lys Gly Ile Ser Ala Val Trp Ile Pro Ala Trp	
35 40 45	
Lys Gly Ala Ser Gln Asn Asp Val Gly Tyr Gly Ala Tyr Asp Leu Tyr	
50 55 60	
Asp Leu Gly Glu Phe Asn Gln Lys Gly Thr Ile Arg Thr Lys Tyr Gly	
65 70 75 80	
Thr Arg Asn Gln Leu Gln Ala Ala Val Asn Ala Leu Lys Ser Asn Gly	
85 90 95	
Ile Gln Val Tyr Gly Asp Val Val Met Asn His Lys Gly Gly Ala Asp	
100 105 110	
Ala Thr Glu Met Val Arg Ala Val Glu Val Asn Pro Asn Asn Arg Asn	
115 120 125	
Gln Glu Val Ser Gly Glu Tyr Thr Ile Glu Ala Trp Thr Lys Phe Asp	
130 135 140	
Phe Pro Gly Arg Gly Asn Thr His Ser Asn Phe Lys Trp Arg Trp Tyr	
145 150 155 160	
His Phe Asp Gly Val Asp Trp Asp Gln Ser Arg Lys Leu Asn Asn Arg	
165 170 175	
Ile Tyr Lys Phe Arg Gly Asp Gly Lys Gly Trp Asp Trp Glu Val Asp	
180 185 190	
Thr Glu Asn Gly Asn Tyr Asp Tyr Leu Met Tyr Ala Asp Ile Asp Met	
195 200 205	
Asp His Pro Glu Val Val Asn Glu Leu Arg Asn Trp Gly Val Trp Tyr	
210 215 220	

## SEQUENCE LISTING

Thr Asn Thr Leu Gly Leu Asp Gly Phe Arg Ile Asp Ala Val Lys His  
 225 230 235 240  
 Ile Lys Tyr Ser Phe Thr Arg Asp Trp Ile Asn His Val Arg Ser Ala  
 245 250 255  
 Thr Gly Lys Asn Met Phe Ala Val Ala Glu Phe Trp Lys Asn Asp Leu  
 260 265 270  
 Gly Ala Ile Glu Asn Tyr Leu Asn Lys Thr Asn Trp Asn His Ser Val  
 275 280 285  
 Phe Asp Val Pro Leu His Tyr Asn Leu Tyr Asn Ala Ser Lys Ser Gly  
 290 295 300  
 Gly Asn Tyr Asp Met Arg Gln Ile Phe Asn Gly Thr Val Val Gln Arg  
 305 310 315 320  
 His Pro Met His Ala Val Thr Phe Val Asp Asn His Asp Ser Gln Pro  
 325 330 335  
 Glu Glu Ala Leu Glu Ser Phe Val Glu Glu Trp Phe Lys Pro Leu Ala  
 340 345 350  
 Tyr Ala Leu Thr Leu Thr Arg Glu Gln Gly Tyr Pro Ser Val Phe Tyr  
 355 360 365  
 Gly Asp Tyr Tyr Gly Ile Pro Thr His Gly Val Pro Ala Met Lys Ser  
 370 375 380  
 Lys Ile Asp Pro Ile Leu Glu Ala Arg Gln Lys Tyr Ala Tyr Gly Arg  
 385 390 395 400  
 Gln Asn Asp Tyr Leu Asp His His Asn Ile Ile Gly Trp Thr Arg Glu  
 405 410 415  
 Gly Asn Thr Ala His Pro Asn Ser Gly Leu Ala Thr Ile Met Ser Asp  
 420 425 430  
 Gly Ala Gly Gly Asn Lys Trp Met Phe Val Gly Arg Asn Lys Ala Gly  
 435 440 445  
 Gln Val Trp Thr Asp Ile Thr Gly Asn Arg Ala Gly Thr Val Thr Ile  
 450 455 460  
 Asn Ala Asp Gly Trp Gly Asn Phe Ser Val Asn Gly Gly Ser Val Ser  
 465 470 475 480  
 Ile Trp Val Asn Lys  
 485

<210> 13  
 <211> 485  
 <212> PRT  
 <213> Bacillus sp. 707

<400> 13  
 His His Asn Gly Thr Asn Gly Thr Met Met Gln Tyr Phe Glu Trp Tyr  
 1 5 10 15  
 Leu Pro Asn Asp Gly Asn His Trp Asn Arg Leu Asn Ser Asp Ala Ser  
 20 25 30  
 Asn Leu Lys Ser Lys Gly Ile Thr Ala Val Trp Ile Pro Pro Ala Trp  
 35 40 45  
 Lys Gly Ala Ser Gln Asn Asp Val Gly Tyr Gly Ala Tyr Asp Leu Tyr

## SEQUENCE LISTING

50  
 Asp Leu Gly Glu Phe Asn Gln Lys Gly Thr Val Arg Thr Lys Tyr Gly  
 65 70 75 80  
 Thr Arg Ser Gln Leu Gln Ala Ala Val Thr Ser Leu Lys Asn Asn Gly  
 85 90  
 Ile Gln Val Tyr Gly Asp Val Val Met Asn His Lys Gly Gly Ala Asp  
 100 105 110  
 Ala Thr Glu Met Val Arg Ala Val Glu Val Asn Pro Asn Asn Arg Asn  
 115 120 125  
 Gln Glu Val Thr Gly Glu Tyr Thr Ile Glu Ala Trp Thr Arg Phe Asp  
 130 135 140  
 Phe Pro Gly Arg Gly Asn Thr His Ser Ser Phe Lys Trp Arg Trp Tyr  
 145 150 155 160  
 His Phe Asp Gly Val Asp Trp Asp Gln Ser Arg Arg Leu Asn Asn Arg  
 165 170 175  
 Ile Tyr Lys Phe Arg Gly His Gly Lys Ala Trp Asp Trp Glu Val Asp  
 180 185 190  
 Thr Glu Asn Gly Asn Tyr Asp Tyr Leu Met Tyr Ala Asp Ile Asp Met  
 195 200 205  
 Asp His Pro Glu Val Val Asn Glu Leu Arg Asn Trp Gly Val Trp Tyr  
 210 215 220  
 Thr Asn Thr Leu Gly Leu Asp Gly Phe Arg Ile Asp Ala Val Lys His  
 225 230 235 240  
 Ile Lys Tyr Ser Phe Thr Arg Asp Trp Ile Asn His Val Arg Ser Ala  
 245 250 255  
 Thr Gly Lys Asn Met Phe Ala Val Ala Glu Phe Trp Lys Asn Asp Leu  
 260 265 270  
 Gly Ala Ile Glu Asn Tyr Leu Gln Lys Thr Asn Trp Asn His Ser Val  
 275 280 285  
 Phe Asp Val Pro Leu His Tyr Asn Leu Tyr Asn Ala Ser Lys Ser Gly  
 290 295 300  
 Gly Asn Tyr Asp Met Arg Asn Ile Phe Asn Gly Thr Val Val Gln Arg  
 305 310 315 320  
 His Pro Ser His Ala Val Thr Phe Val Asp Asn His Asp Ser Gln Pro  
 325 330 335  
 Glu Glu Ala Leu Glu Ser Phe Val Glu Glu Trp Phe Lys Pro Leu Ala  
 340 345 350  
 Tyr Ala Leu Thr Leu Thr Arg Glu Gln Gly Tyr Pro Ser Val Phe Tyr  
 355 360 365  
 Gly Asp Tyr Tyr Gly Ile Pro Thr His Gly Val Pro Ala Met Arg Ser  
 370 375 380  
 Lys Ile Asp Pro Ile Leu Glu Ala Arg Gln Lys Tyr Ala Tyr Gly Lys  
 385 390 395 400  
 Gln Asn Asp Tyr Leu Asp His His Asn Ile Ile Gly Trp Thr Arg Glu  
 405 410 415

## SEQUENCE LISTING

Gly Asn Thr Ala His Pro Asn Ser Gly Leu Ala Thr Ile Met Ser Asp  
 420 425 430

Gly Ala Gly Gly Ser Lys Trp Met Phe Val Gly Arg Asn Lys Ala Gly  
 435 440 445

Gln Val Trp Ser Asp Ile Thr Gly Asn Arg Thr Gly Thr Val Thr Ile  
 450 455 460

Asn Ala Asp Gly Trp Gly Asn Phe Ser Val Asn Gly Gly Ser Val Ser  
 465 470 475 480

Ile Trp Val Asn Lys  
 485

<210> 14  
 <211> 27  
 <212> DNA  
 <213> Artificial Sequence  
 <220>  
 <223> Primer 22149  
 <400> 14  
 CGATTGCTGA CGCTGTTATT TGCG  
 24

<210> 15  
 <211> 29  
 <212> DNA  
 <213> Artificial Sequence  
 <220>  
 <223> Primer 24814  
 <400> 15  
 GATCACCCGC GATACCGTC  
 29

<210> 16  
 <211> 31  
 <212> DNA  
 <213> Artificial Sequence  
 <220>  
 <223> Primer #24  
 <400> 16  
 GAATGTATGT CGGCCGGCAA AACGCCGGTG A  
 31

<210> 17  
 <211> 30  
 <212> DNA  
 <213> Artificial Sequence  
 <220>  
 <223> Primer #27  
 <400> 17  
 GCCGCCGCTG CTGCAGAATG AGGCAGCAAG  
 30

<210> 18  
 <211> 48  
 <212> DNA  
 <213> Artificial Sequence  
 <220>  
 <223> Primer #312  
 <400> 18

CCCGAAAGCT GAACCGCATC TATAGGTTTC AAGGGAAGAC TTGGGATT

48

<210> 19  
 <211> 23  
 <212> DNA  
 <213> Artificial Sequence  
 <220>

## SEQUENCE LISTING

<223> Primer #290  
 <400> 19  
 AGGATGGTCA TAATCAAAGT CGG  
 23

<210> 20  
 <211> 52  
 <212> DNA  
 <213> Artificial Sequence  
 <220>  
 <223> Primer #313  
 <400> 20  
 CCGACTTTGA TTATGACCAT CCGTTGTGCG TAGCAGAGAT TAAGAGATGG GG 52

<210> 21  
 <211> 45  
 <212> DNA  
 <213> Artificial Sequence  
 <220>  
 <223> Primer #314  
 <400> 21  
 CGACAATGTC ATGGTGGTCG AAAAAATCAT GCTGTGCTCC GTACG 45

<210> 22  
 <211> 23  
 <212> DNA  
 <213> Artificial Sequence  
 <220>  
 <223> Primer #296  
 <400> 22  
 TTTCGACCAC CATGACATTG TCG  
 23

<210> 23  
 <211> 24  
 <212> DNA  
 <213> Artificial Sequence  
 <220>  
 <223> Primer #305  
 <400> 23  
 TATAGATGCG GTTCAGCTTT CGGG  
 24

<210> 24  
 <211> 1650  
 <212> DNA  
 <213> Bacillus sp.  
 <220>  
 <221> CDS  
 <222> (65)..(1567)  
 <220>  
 <221> mat\_peptide  
 <222> (128)..()

<220>  
 <221> sig\_peptide  
 <222> (65)..(128)  
 <400> 24  
 ctggaatcat tatttaaagc tgggtatgat atatgtaagc gttatcatta aaaggaggta 60  
 ttgt atg aaa aga tgg gta gta gca atg ctg gca gtg tta ttt tta ttt 109  
 Met Lys Arg Trp Val Val Ala Met Leu Ala Val Leu Phe Leu Phe  
 -20 -15 -10

cct tcg gta gta gtt gca gat ggc ttg aat gga acg atg atg cag tat 157  
 Pro Ser Val Val Val Ala Asp Gly Leu Asn Gly Thr Met Met Gln Tyr  
 -5 -1 1 5 10

tat gag tgg cat cta gag aat gat ggg caa cac tgg aat cgg ttg cat 205  
 Page 25

SEQUENCE LISTING																			
Tyr	Glu	Trp	His	Leu	Glu	Asn	Asp	Gly	Gln	His	Trp	Asn	Arg	Leu	His				
				15					20					25					
gat	gat	gcc	gaa	gct	tta	agt	aat	gcg	ggt	att	aca	gct	att	tgg	ata				
Asp	Asp	Ala	Glu	Ala	Leu	Ser	Asn	Ala	Gly	Ile	Thr	Ala	Ile	Trp	Ile			253	
				30					35					40					
ccc	cca	gcc	tac	aaa	gga	aat	agt	cag	gct	gat	gtt	ggg	tat	ggt	gca				
Pro	Pro	Ala	Tyr	Lys	Gly	Asn	Ser	Gln	Ala	Asp	Val	Gly	Tyr	Gly	Ala			301	
				45					50					55					
tac	gac	ctt	tat	gat	tta	ggg	gag	ttt	aat	caa	aaa	ggt	acc	gtt	cga				
Tyr	Asp	Leu	Tyr	Asp	Leu	Gly	Glu	Phe	Asn	Gln	Lys	Gly	Thr	Val	Arg			349	
				60					65					70					
acg	aaa	tac	ggg	aca	aag	gct	cag	ctt	gag	cga	gct	ata	ggg	tcc	cta				
Thr	Lys	Tyr	Gly	Thr	Lys	Ala	Gln	Leu	Glu	Arg	Ala	Ile	Gly	Ser	Leu			397	
															90				
aag	tcg	aat	gat	atc	aat	gtt	tat	ggg	gat	gtc	gta	atg	aat	cat	aaa				
Lys	Ser	Asn	Asp	Ile	Asn	Val	Tyr	Gly	Asp	Val	Val	Met	Asn	His	Lys			445	
															105				
tta	gga	gct	gat	ttc	acg	gag	gca	gtg	caa	gct	gtt	caa	gta	aat	cct				
Leu	Gly	Ala	Asp	Phe	Thr	Glu	Ala	Val	Gln	Ala	Val	Gln	Ala	Asn	Pro			493	
															120				
tcg	aac	cgt	tgg	cag	gat	att	tca	ggt	gtc	tac	acg	att	gat	gca	tgg				
Ser	Asn	Arg	Trp	Gln	Asp	Ile	Ser	Gly	Val	Thr	Thr	Ile	Asp	Ala	Trp			541	
															135				
acg	gga	ttt	gac	ttt	cca	ggg	cgc	aac	aat	gcc	tat	tcc	gat	ttt	aaa				
Thr	Gly	Phe	Asp	Phe	Pro	Gly	Arg	Asn	Asn	Ala	Tyr	Ser	Asp	Phe	Lys			589	
															150				
tgg	aga	tgg	ttc	cat	ttt	aat	ggc	gtt	gac	tgg	gat	caa	cgc	tat	caa				
Trp	Arg	Trp	Phe	Phe	Asn	Gly	Val	Asp	Trp	Asp	Gln	Arg	Tyr	Gln				637	
															170				
gaa	aac	cat	ctt	ttt	cgc	ttt	gca	aat	acg	aac	tgg	aac	tgg	cga	gtg				
Glu	Asn	His	Leu	Phe	Arg	Phe	Ala	Asn	Thr	Asn	Trp	Asn	Trp	Arg	Val			685	
															185				
gal	gaa	gag	aat	ggt	aat	tat	gac	tat	tta	tta	gga	tcg	aac	att	gac				
Asp	Glu	Glu	Asn	Gly	Asn	Tyr	Asp	Tyr	Leu	Leu	Gly	Ser	Asn	Ile	Asp			733	
															200				
ttt	agc	cac	cca	gag	gtt	caa	gag	gaa	tta	aag	gat	tgg	ggg	agc	tgg				
Phe	Ser	His	Pro	Glu	Val	Gln	Glu	Glu	Leu	Lys	Asp	Trp	Gly	Ser	Trp			781	
															215				
ttt	acg	gat	gag	cta	gat	tta	gat	ggg	tat	cga	tgg	gat	gct	att	aag				
Phe	Thr	Asp	Glu	Leu	Asp	Gly	Tyr	Arg	Gly	Arg	Leu	Asp	Ala	Ile	Lys			829	
															220				
cat	att	cca	ttc	tgg	tat	acg	tca	gat	tgg	gtt	agg	cat	cag	cga	agt				
His	Ile	Pro	Phe	Trp	Tyr	Thr	Ser	Asp	Trp	Val	Arg	His	Gln	Arg	Ser			877	
															250				
gaa	gca	gac	caa	gat	tta	ttt	gtc	gta	ggg	gag	tat	tgg	aag	gat	gac				
Glu	Ala	Asp	Gln	Asp	Leu	Phe	Val	Val	Gly	Glu	Tyr	Trp	Lys	Asp	Asp			925	
															265				
gta	ggt	gct	ctc	gaa	ttt	tat	tta	gat	gaa	atg	aat	tgg	gag	atg	tct				
Val	Gly	Ala	Leu	Glu	Phe	Tyr	Leu	Asp	Glu	Met	Asn	Trp	Glu	Met	Ser			973	
															270				
cta	ttc	gat	gtt	ccg	ctc	aat	tat	aat	ttt	tac	cgg	gct	tca	aag	caa				
																		1021	



## SEQUENCE LISTING

Leu Phe Asp Val Pro Leu Asn Tyr Asn Phe Tyr Arg Ala Ser Lys Gln  
 285 290 295  
 ggc gga agc tat gat atg. cgt aat att tta cga gga tct tta gta gaa 1069  
 Gly Gly Ser Tyr Asp Met Arg Asn Ile Leu Arg Gly Ser Leu Val Glu  
 300 305 310  
 gca cat ccg att cat gca gtt acg ttt gtt gat aat cat gat act cag 1117  
 Ala His Pro Ile His Ala Val Thr Phe Val Asp Asn His Asp Thr Gln  
 315 320 325 330  
 cca gga gag tca tta gaa tca tgg gtc gct gat tgg ttt aag cca ctt 1165  
 Pro Gly Glu Ser Leu Glu Ser Trp Val Ala Asp Trp Phe Lys Pro Leu  
 335 340 345  
 gct tat gcg aca atc ttg acg cgt gaa ggt ggt tat cca aat gta ttt 1213  
 Ala Tyr Ala Thr Ile Leu Thr Arg Glu Gly Tyr Pro Asn Val Phe  
 350 355 360  
 tac ggt gac tac tat ggg att cct aac gat aac att tca gct aag aag 1261  
 Tyr Gly Asp Tyr Tyr Gly Ile Pro Asn Asp Asn Ile Ser Ala Lys Lys  
 365 370 375  
 gat atg att gat gag ttg ctt gat gca cgt caa aat tac gca tat ggc 1309  
 Asp Met Ile Asp Glu Leu Asp Ala Arg Gln Asn Tyr Ala Tyr Gly  
 380 385 390  
 aca caa cat gac tat ttt gat cat tgg gat atc gtt gga tgg aca aga 1357  
 Thr Gln His Asp Tyr Phe Asp His Trp Asp Ile Val Gly Trp Thr Arg  
 395 400 405 410  
 gaa ggt aca tcc tca cgt cct aat tgg ggt ctt gct act att atg tcc 1405  
 Glu Gly Thr Ser Ser Arg Pro Asn Ser Gly Leu Ala Thr Ile Met Ser  
 415 420 425  
 aat ggt cct gga gga tca aaa tgg atg tac gta gga cag caa cat gca 1453  
 Asn Gly Pro Gly Gly Ser Lys Trp Met Tyr Val Gly Gln Gln His Ala  
 430 435 440  
 gga caa acg tgg aca gat tta act ggc aat cac gcg gcg tgg gtt acg 1501  
 Gly Gln Thr Trp Thr Asp Leu Thr Gly Asn His Ala Ala Ser Val Thr  
 445 450 455  
 att aat ggt gat ggc tgg ggc gaa ttc ttt aca aat gga gga tct gta 1549  
 Ile Asn Gly Asp Gly Trp Gly Glu Phe Phe Thr Asn Gly Gly Ser Val  
 460 465 470  
 tcc gtg tat gtg aac caa taataaaaag ccttgagaag ggattcctcc 1597  
 Ser Val Tyr Val Asn Gln  
 475 480  
 ctaactcaag gctttcttta tgcgttttag ctcaacgctt ctacgaagct tta 1650  
  
 <210> 25  
 <211> 501  
 <212> PRT  
 <213> Bacillus sp.  
 <400> 25  
 Met Lys Arg Trp Val Val Ala Met Leu Ala Val Leu Phe Leu Phe Pro  
 -20 -15 -10  
 Ser Val Val Val Ala Asp Gly Leu Asn Gly Thr Met Met Gln Tyr Tyr  
 -5 -1 1 5 10  
 Glu Trp His Leu Glu Asn Asp Gly Gln His Trp Asn Arg Leu His Asp  
 15 20 25

## SEQUENCE LISTING

Asp Ala Glu Ala Leu Ser Asn Ala Gly Ile Thr Ala Ile Trp Ile Pro  
 30 35 40  
 Pro Ala Tyr Lys Gly Asn Ser Gln Ala Asp Val Gly Tyr Gly Ala Tyr  
 45 50 55  
 Asp Leu Tyr Asp Leu Gly Glu Phe Asn Gln Lys Gly Thr Val Arg Thr  
 60 65 70 75  
 Lys Tyr Gly Thr Lys Ala Gln Leu Glu Arg Ala Ile Gly Ser Leu Lys  
 80 85 90  
 Ser Asn Asp Ile Asn Val Tyr Gly Asp Val Val Met Asn His Lys Leu  
 95 100 105  
 Gly Ala Asp Phe Thr Glu Ala Val Gln Ala Val Gln Val Asn Pro Ser  
 110 115 120  
 Asn Arg Trp Gln Asp Ile Ser Gly Val Tyr Thr Ile Asp Ala Trp Thr  
 125 130 135  
 Gly Phe Asp Phe Pro Gly Arg Asn Asn Ala Tyr Ser Asp Phe Lys Trp  
 140 145 150 155  
 Arg Trp Phe His Phe Asn Gly Val Asp Trp Asp Gln Arg Tyr Gln Glu  
 160 165 170  
 Asn His Leu Phe Arg Phe Ala Asn Thr Asn Trp Asn Trp Arg Val Asp  
 175 180 185  
 Glu Glu Asn Gly Asn Tyr Asp Tyr Leu Leu Gly Ser Asn Ile Asp Phe  
 190 195 200  
 Ser His Pro Glu Val Gln Glu Glu Leu Lys Asp Trp Gly Ser Trp Phe  
 205 210 215  
 Thr Asp Glu Leu Asp Leu Asp Gly Tyr Arg Leu Asp Ala Ile Lys His  
 220 225 230 235  
 Ile Pro Phe Trp Tyr Thr Ser Asp Trp Val Arg His Gln Arg Ser Glu  
 240 245 250  
 Ala Asp Gln Asp Leu Phe Val Val Gly Glu Tyr Trp Lys Asp Asp Val  
 255 260 265  
 Gly Ala Leu Glu Phe Tyr Leu Asp Glu Met Asn Trp Glu Met Ser Leu  
 270 275 280  
 Phe Asp Val Pro Leu Asn Tyr Asn Phe Tyr Arg Ala Ser Lys Gln Gly  
 285 290 295

## SEQUENCE LISTING

Gly Ser Tyr Asp Met Arg Asn Ile Leu Arg Gly Ser Leu Val Glu Ala  
300 305 310 315

His Pro Ile His Ala Val Thr Phe Val Asp Asn His Asp Thr Gln Pro  
320 325 330

Gly Glu Ser Leu Glu Ser Trp Val Ala Asp Trp Phe Lys Pro Leu Ala  
335 340 345

Tyr Ala Thr Ile Leu Thr Arg Glu Gly Gly Tyr Pro Asn Val Phe Tyr  
350 355 360

Gly Asp Tyr Tyr Gly Ile Pro Asn Asp Asn Ile Ser Ala Lys Lys Asp  
365 370 375

Met Ile Asp Glu Leu Leu Asp Ala Arg Gln Asn Tyr Ala Tyr Gly Thr  
380 385 390 395

Gln His Asp Tyr Phe Asp His Trp Asp Ile Val Gly Trp Thr Arg Glu  
400 405 410

Gly Thr Ser Ser Arg Pro Asn Ser Gly Leu Ala Thr Ile Met Ser Asn  
415 420 425

Gly Pro Gly Gly Ser Lys Trp Met Tyr Val Gly Gln Gln His Ala Gly  
430 435 440

Gln Thr Trp Thr Asp Leu Thr Gly Asn His Ala Ala Ser Val Thr Ile  
445 450 455

Asn Gly Asp Gly Trp Gly Glu Phe Phe Thr Asn Gly Gly Ser Val Ser  
460 465 470 475

Val Tyr Val Asn Gln  
480

<210> 26

<211> 1745

<212> DNA

<213> Bacillus sp.

<220>

<221> CDS

<222> (190)..(1692)

<220>

<221> mat\_peptide

<222> (253)..O

<220>

<221> sig\_peptide

<222> (190)..(253)

<400> 26

aactaagtaa catcgattca ggataaaagt atgcgaaacg atgcgcaaaa ctgcgcaact 60

actagcactc tticagggact aaaccacctt ttttccaaaa atgacatcat ataacaat 120

## SEQUENCE LISTING

ttgtctaccaa atcactatit aaagctgttt atgatatatg taagcggttat cattaaaagg 180

aggatatttg atg aga aga tgg gta gta gca atg ttg gca gtg tta ttt tta 231  
Met Arg Arg Trp Val Val Ala Met Leu Ala Val Leu Phe Leu  
-20 -15 -10

ttt cct tcg gta gta gtt gca gat gga ttg aac ggt acg atg atg cag 279  
Phe Pro Ser Val Val Val Ala Asp Gly Leu Asn Gly Thr Met Met Gln  
-5 -1 1 5

tat tat gag tgg cat ttg gaa aac gac ggg cag cat tgg aat cgg ttg 327  
Tyr Tyr Glu Trp His Leu Glu Asn Asp Gly Gln His Trp Asn Arg Leu  
10 15 20 25

cac gat gat gcc gca gct ttg agt gat gct ggt att aca gct att tgg 375  
His Asp Asp Ala Ala Ala Leu Ser Asp Ala Gly Ile Thr Ala Ile Trp  
30 35 40

att cgg cca gcc tac aaa ggt aat agt cag cgg gat gtt ggg tac ggt 423  
Ile Pro Pro Ala Tyr Lys Gly Asn Ser Gln Ala Asp Val Gly Tyr Gly  
45 50 55

gca tac gat ctt tat gat tta gga gag ttc aat caa aag ggt act gtt 471  
Ala Tyr Asp Leu Tyr Asp Leu Glu Phe Asn Gln Lys Gly Thr Val  
60 65 70

cga acg aaa tac gga act aag gca cag ctt gaa cga gct att ggg tcc 519  
Arg Thr Lys Tyr Gly Thr Lys Ala Gln Leu Glu Arg Ala Ile Gly Ser  
75 80 85

ctt aaa tct aat gat atc aat gta tac gga gat gtc gtg atg aat cat 567  
Leu Lys Ser Asn Asp Ile Asn Val Tyr Gly Asp Val Val Met Asn His  
90 95 100 105

aaa atg gga gct gat ttt acg gag gca gtg caa gct gtt caa gta aat 615  
Lys Met Gly Ala Asp Phe Thr Glu Ala Val Gln Ala Val Gln Val Asn  
110 115 120

cca acg aat cgt tgg cag gat att tca ggt gcc tac acg att gat cgg 663  
Pro Thr Asn Arg Trp Gln Asp Ile Ser Gly Ala Tyr Thr Ile Asp Ala  
125 130 135

tgg acg ggt ttc gac ttt tca ggg cgt aac aac gcc tat tca gat ttt 711  
Trp Thr Gly Phe Asp Phe Ser Gly Arg Asn Asn Ala Tyr Ser Asp Phe  
140 145 150

aag tgg aga tgg ttc cat ttt aat ggt gtt gac tgg gat cag cgc tat 759  
Lys Trp Arg Trp Phe His Phe Asn Gly Val Asp Trp Asp Gln Arg Tyr  
155 160 165

caa gaa aat cat att ttc cgc ttt gca aat acg aac tgg aac tgg cga 807  
Gln Glu Asn His Ile Phe Arg Phe Ala Asn Thr Asn Trp Asn Trp Arg  
170 175 180 185

gtg gat gaa gag aac ggt aat tat gat tac ctg tta gga tcg aat atc 855  
Val Asp Glu Glu Asn Gly Asn Tyr Asp Tyr Leu Leu Gly Ser Asn Ile  
190 195 200

gac ttt agt cat cca gaa gta caa gat gag ttg aag gat tgg ggt agc 903  
Asp Phe Ser His Pro Glu Val Gln Asp Gly Leu Lys Asp Trp Gly Ser  
205 210 215

tgg ttt acc gat gag tta gat ttg gat ggt tat cgt tta gat gct att 951  
Trp Phe Thr Asp Glu Leu Asp Leu Asp Gly Tyr Arg Leu Asp Ala Ile  
220 225 230

aaa cat att cca ttc tgg tat aca tct gat tgg gtt cgg cat cag cgc 999  
Lys His Ile Pro Phe Trp Tyr Thr Ser Asp Trp Val Arg His Gln Arg  
235 240 245

235		240		SEQUENCE LISTING		245	
aac gaa gca gat caa gat tta ttt gtc gta ggg gaa tat tgg aag gat	1047	asn glu ala asp gln asp 255	leu phe val val gly 260	gaa glu tyr trp lys asp 265			
gac gta ggt gct ctc gaa ttt tat tta gat gaa atg aat tgg gag atg	1095	asp val gly ala leu glu phe tyr leu asp 270	glu met asn trp glu met 280				
tct cta ttc gat gtt cca ctt aat tat aat ttt tac cgg gct tca caa	1143	ser leu phe asp 285	val pro leu asn tyr 290	asn phe tyr arg ala ser gln 295			
caa ggt gga agc tat gat atg cgt aat att tta cga gga tct tta gta	1191	gln gly 300	ser tyr asp met arg 305	asn ile leu arg gly ser leu val 310			
gaa gcg cat ccg atg cat gca gtt acg ttt gtt gat aat cat gat act	1239	glu ala his pro met his 320	ala val thr phe val 325	asn his asp thr 330			
cag cca ggg gag tca tta gag tca tgg gtt gct gat tgg ttt aag cca	1287	gln pro gly glu ser leu 335	glu ser trp val 340	asp trp phe lys pro 345			
ctt gct tat gcg aca att ttg acg cgt gaa ggt ggt tat cca aat gta	1335	leu ala tyr ala thr 350	ile leu thr arg 355	glu gly gly tyr pro asn val 360			
ttt tac ggt gat tac tat ggg att cct aac gat aac att tca gct aaa	1383	phe tyr gly asp 365	tyr tyr gly ile pro 370	asn asp asn ile ser ala lys 375			
aaa gat atg att gat gag ctg ctt gat gca cgt caa aat tac gca tat	1431	lys asp met ile asp glu leu 380	leu asp ala arg 385	gln asn tyr ala tyr 390			
ggc acg cag cat gac tat ttt gat cat tgg gat gtt gta gga tgg act	1479	gly thr 395	gln his asp tyr phe asp 400	his trp asp 405	val val gly trp thr 410		
agg gaa gga tct tcc tcc aga cct aat tca ggc ctt gcg act att arg	1527	arg glu gly ser ser ser 415	arg pro asn ser 420	gly leu ala thr ile met 425			
tcg aat gga cct ggt ggt tcc aag tgg atg tat gta gga cgt cag aat	1575	ser asn gly pro gly gly ser lys 430	trp met tyr val gly arg 435	asn gly ala ser val 440			
gca gga caa aca tgg aca gat tta act ggt aat aac gga gcg tcc gtt	1623	ala gly gln thr 445	trp thr asp leu thr 450	gly asn asn gly ala ser val 455			
aca att aat ggc gat gga tgg ggc gaa ttc ttt acg aat gga gga tct	1671	thr ile 460	asn gly asp gly trp gly glu phe 465	phe thr asn gly gly ser 470			
gta tcc gtg tac gtg aac caa taacaaaaag ccttgagaag ggattcctcc	1722	val ser val tyr val asn 475	gln 480				
ctaactcaag gcttcttta tgt	1745						

<210> 27  
 <211> 501  
 <212> PRT

## SEQUENCE LISTING

&lt;213&gt; Bacillus sp.

&lt;400&gt; 27

Met Arg Trp Val Val Ala Met Leu Ala Val Leu Phe Leu Phe Pro  
-20 -15 -10Ser Val Val Val Ala Asp Gly Leu Asn Gly Thr Met Met Gln Tyr Tyr  
-5 -1 1 5 10Glu Trp His Leu Glu Asn Asp Gly Gln His Trp Asn Arg Leu His Asp  
15 20 25Asp Ala Ala Ala Leu Ser Asp Ala Gly Ile Thr Ala Ile Trp Ile Pro  
30 35 40Pro Ala Tyr Lys Gly Asn Ser Gln Ala Asp Val Gly Tyr Gly Ala Tyr  
45 50 55Asp Leu Tyr Asp Leu Gly Glu Phe Asn Gln Lys Gly Thr Val Arg Thr  
60 65 70 75Lys Tyr Gly Thr Lys Ala Gln Leu Glu Arg Ala Ile Gly Ser Leu Lys  
80 85 90Ser Asn Asp Ile Asn Val Tyr Gly Asp Val Val Met Asn His Lys Met  
95 100 105Gly Ala Asp Phe Thr Glu Ala Val Gln Ala Val Gln Val Asn Pro Thr  
110 115 120Asn Arg Trp Gln Asp Ile Ser Gly Ala Tyr Thr Ile Asp Ala Trp Thr  
125 130 135Gly Phe Asp Phe Ser Gly Arg Asn Asn Ala Tyr Ser Asp Phe Lys Trp  
140 145 150 155Arg Trp Phe His Phe Asn Gly Val Asp Trp Asp Gln Arg Tyr Gln Glu  
160 165 170Asn His Ile Phe Arg Phe Ala Asn Thr Asn Trp Asn Trp Arg Val Asp  
175 180 185Glu Glu Asn Gly Asn Tyr Asp Tyr Leu Leu Gly Ser Asn Ile Asp Phe  
190 195 200Ser His Pro Glu Val Gln Asp Glu Leu Lys Asp Trp Gly Ser Trp Phe  
205 210 215Thr Asp Glu Leu Asp Leu Asp Gly Tyr Arg Leu Asp Ala Ile Lys His  
220 225 230 235Ile Pro Phe Trp Tyr Thr Ser Asp Trp Val Arg His Gln Arg Asn Glu  
240 245 250

## SEQUENCE LISTING

Ala Asp Gln Asp Leu Phe Val Val Gly Glu Tyr Trp Lys Asp Asp Val  
 255 260 265

Gly Ala Leu Glu Phe Tyr Leu Asp Glu Met Asn Trp Glu Met Ser Leu  
 270 275 280

Phe Asp Val Pro Leu Asn Tyr Asn Phe Tyr Arg Ala Ser Gln Gln Gly  
 285 290 295

Gly Ser Tyr Asp Met Arg Asn Ile Leu Arg Gly Ser Leu Val Glu Ala  
 300 305 310 315

His Pro Met His Ala Val Thr Phe Val Asp Asn His Asp Thr Gln Pro  
 320 325 330

Gly Glu Ser Leu Glu Ser Trp Val Ala Asp Trp Phe Lys Pro Leu Ala  
 335 340 345

Tyr Ala Thr Ile Leu Thr Arg Glu Gly Gly Tyr Pro Asn Val Phe Tyr  
 350 355 360

Gly Asp Tyr Tyr Gly Ile Pro Asn Asp Asn Ile Ser Ala Lys Lys Asp  
 365 370 375

Met Ile Asp Glu Leu Leu Asp Ala Arg Gln Asn Tyr Ala Tyr Gly Thr  
 380 385 390 395

Gln His Asp Tyr Phe Asp His Trp Asp Val Val Gly Trp Thr Arg Glu  
 400 405 410

Gly Ser Ser Ser Arg Pro Asn Ser Gly Leu Ala Thr Ile Met Ser Asn  
 415 420 425

Gly Pro Gly Gly Ser Lys Trp Met Tyr Val Gly Arg Gln Asn Ala Gly  
 430 435 440

Gln Thr Trp Thr Asp Leu Thr Gly Asn Asn Gly Ala Ser Val Thr Ile  
 445 450 455

Asn Gly Asp Gly Trp Gly Glu Phe Phe Thr Asn Gly Gly Ser Val Ser  
 460 465 470 475

Val Tyr Val Asn Gln  
 480

<210> 28  
 <211> 1920  
 <212> DNA  
 <213> Bacillus licheniformis  
 <220>  
 <221> CDS  
 <222> (421)..(1872)

## SEQUENCE LISTING

<400> 28  
 cggaaagattg gaagtacaaa aataagcaaa agattgtcaa tcatgtcatg agccatgcgg 60  
 gagacggaaa aatcgtctta atgcacgata tttatgcaac gticgcagat gctgctgaag 120  
 agattattaa aaagctgaaa gcaaaaggct atcaattggt aactgtatct cagcttgaag 180  
 aagtgaagaa gcagagaggg tattgaataa atgagtagaa gcgccatatt ggcgcttttc 240  
 ttttggaga aatatagggg aaaaatgtac ttgttaaaaa ttcggaatat ttatacaaca 300  
 tcatatgttt cacattgaaa ggggaggaga atcatgaaac aacaaaaacg gctttacgcc 360  
 cgattgctga cgctgttatt tgcgtctcat tcttctgcgc ctcttctgc agcagcggcg 420  
 gca aat ctt aat ggg acg ctg atg cag tat ttt gaa tgg tac atg ccc 468  
 Ala Asn Leu Asn Gly Thr Leu Met Gln Tyr Phe Glu Trp Tyr Met Pro  
 1 5 10 15  
 aat gac ggc caa cat tgg agg cgt ttg caa aac gac tgg gca tat ttg 516  
 Asn Asp Gly Gln His Trp Arg Arg Leu Gln Asn Asp Ser Ala Tyr Leu  
 20 25 30  
 gct gaa cac ggt att act gcc gtc tgg att ccc ccg gca tat aag gga 564  
 Ala Glu His Gly Ile Thr Ala Val Trp Ile Pro Pro Ala Tyr Lys Gly  
 35 40 45  
 acg agc caa gcg gat gtg gcc tac ggt gct tac gac ctt tat gat tta 612  
 Thr Ser Gln Ala Asp Val Gly Tyr Gly Ala Tyr Asp Leu Tyr Asp Leu  
 50 55 60  
 ggg gag ttt cat caa aaa ggg acg gtt cgg aca aag tac gcc aca aaa 660  
 Gly Glu Phe His Gln Lys Gly Thr Val Arg Thr Lys Tyr Gly Thr Lys  
 65 70 75 80  
 gga gag ctg caa tct gcg atc aaa agt ctt cat tcc cgc gac att aac 708  
 Gly Glu Leu Gln Ser Ala Ile Lys Ser Leu His Ser Arg Asp Ile Asn  
 85 90 95  
 gtt tac ggg gat gtg gtc atc aac cac aaa gcc gcc gct gat gcg acc 756  
 Val Tyr Gly Asp Val Val Ile Asn His Lys Gly Gly Ala Asp Ala Thr  
 100 105 110  
 gaa gat gta acc gcg gtt gaa gtc gat ccc gct gac cgc aac cgc gta 804  
 Glu Asp Val Thr Ala Val Glu Val Asp Pro Ala Asp Asn Asn Arg Val  
 115 120 125  
 att tca gga gaa cac cta att aaa gcc tgg aca cat ttt cat ttt ccg 852  
 Ile Ser Gly Glu His Leu Ile Lys Ala Trp Thr His Phe His Phe Pro  
 130 135 140  
 ggg cgc gcc agc aca tac agc gat ttt aaa tgg cat tgg tac cat ttt 900  
 Gly Arg Gly Ser Thr Ser Ser Phe Lys Thr His Trp Tyr His Phe  
 145 150 155 160  
 gac gga acc gat tgg gac gag tcc cga aag ctg aac cgc atc tat aag 948  
 Asp Gly Thr Asp Trp Asp Glu Ser Arg Lys Leu Asn Arg Ile Tyr Lys  
 165 170 175  
 ttt caa gga aag gct tgg gat tgg gaa gtt tcc aat gaa aac gcc aac 996  
 Phe Gln Gly Lys Ala Trp Asp Trp Glu Val Ser Asn Glu Asn Gly Asn  
 180 185 190  
 tat gat tat ttg atg tat gcc gac atc gat tat gac cat cct gat gtc 1044  
 Tyr Asp Tyr Leu Met Tyr Asp Ile Asp Tyr Asp His Pro Asp Val  
 195 200 205  
 gca gca gaa att aag aga tgg gcc act tgg tat gcc aat gaa ctg caa 1092



SEQUENCE LISTING															
Ala	Ala	Glu	Ile	Lys	Arg	Trp	Gly	Thr	Trp	Tyr	Ala	Asn	Glu	Leu	Gln
210						215					220				
ttg	gac	ggg	ttc	cgt	ctt	gat	gct	gtc	aaa	cac	att	aaa	ttt	tct	ttt
Leu	Asp	Gly	Phe	Arg	Leu	Asp	Ala	Val	Lys	His	Ile	Lys	Phe	Ser	Phe
225					230				235					240	
1140															
ttg	cgg	gat	tgg	gtt	aat	cat	gtc	agg	gaa	aaa	acg	ggg	aag	gaa	atg
Leu	Arg	Asp	Trp	Val	Asn	His	Val	Arg	Glu	Lys	Thr	Gly	Lys	Glu	Met
245				250					255				260		
1188															
ttt	acg	gta	gct	gaa	tat	tgg	cag	aat	gac	ttg	ggc	gcg	ctg	gaa	aac
Phe	Thr	Val	Ala	Glu	Tyr	Trp	Gln	Asn	Asp	Leu	Gly	Ala	Leu	Glu	Asn
260				265					270				275		
1236															
tat	ttg	aac	aaa	aca	aat	ttt	aat	cat	tca	gtg	ttt	gac	gtg	ccg	ctt
Tyr	Leu	Asn	Lys	Thr	Asn	Phe	Asn	His	Ser	Val	Phe	Asp	Val	Pro	Leu
275				280					285						
1284															
cat	tat	cag	ttc	cat	gct	gca	tcg	aca	cag	gga	ggc	ggc	tat	gat	atg
His	Tyr	Gln	Phe	His	Ala	Ser	Thr	Gln	Gly	Gly	Gly	Tyr	Asp	Met	
290				295					300						
1332															
agg	aaa	ttg	ctg	aac	ggg	acg	gtc	gtt	tcc	aag	cat	ccg	ttg	aaa	tcg
Arg	Lys	Leu	Leu	Asn	Gly	Thr	Val	Val	Ser	Lys	His	Pro	Leu	Lys	Ser
305				310					315				320		
1380															
gtt	aca	ttt	gtc	gat	aac	cat	gat	aca	cag	ccg	ggg	caa	tcg	ctt	gag
Val	Thr	Phe	Val	Asp	Asn	His	Asp	Thr	Gln	Pro	Gly	Gln	Ser	Leu	Glu
325				330					335				340		
1428															
tcg	act	gtc	caa	aca	tgg	ttt	aag	ccg	ctt	gct	tac	gct	ttt	att	ctc
Ser	Thr	Val	Gln	Thr	Trp	Phe	Lys	Pro	Leu	Ala	Tyr	Ala	Phe	Ile	Leu
340				345					350						
1476															
aca	agg	gaa	tct	gga	tac	cct	cag	gtt	ttc	tac	ggg	gat	atg	tac	ggg
Thr	Arg	Glu	Ser	Gly	Tyr	Pro	Gln	Val	Phe	Tyr	Gly	Asp	Met	Tyr	Gly
355				360					365						
1524															
acg	aaa	gga	gac	tcc	cag	cgc	gaa	att	cct	gcc	ttg	aaa	cac	aaa	att
Thr	Lys	Gly	Asp	Ser	Gln	Arg	Glu	Ile	Pro	Ala	Leu	Lys	His	Lys	Ile
370				375					380						
1572															
gaa	ccg	atc	tta	aaa	gcg	aga	aaa	cag	tat	gcg	tac	gga	gca	cag	cat
Glu	Pro	Ile	Leu	Lys	Ala	Arg	Lys	Gln	Tyr	Ala	Tyr	Gly	Ala	Gln	His
385				390					395				400		
1620															
gat	tat	ttc	gac	cac	cat	gac	att	gtc	ggc	tgg	aca	agg	gaa	ggc	gac
Asp	Tyr	Phe	Asp	His	His	Asp	Ile	Val	Gly	Trp	Thr	Arg	Glu	Gly	Asp
405				410					415				420		
1668															
agc	tcg	gtt	gca	aat	tca	ggg	ttg	gcg	gca	tta	ata	aca	gac	gga	ccc
Ser	Ser	Val	Ala	Asn	Ser	Gly	Leu	Ala	Ala	Leu	Ile	Thr	Asp	Gly	Pro
420				425					430						
1716															
ggg	ggg	gca	aag	cga	atg	tat	gtc	ggc	cgg	caa	aac	gcc	ggg	gag	aca
Gly	Gly	Ala	Lys	Arg	Met	Tyr	Val	Gly	Arg	Gln	Asn	Ala	Gly	Glu	Thr
435				440					445						
1764															
tgg	cat	gac	att	acc	gga	aac	cgt	tcg	gag	ccg	gtt	gtc	atc	aat	tcg
Trp	His	Asp	Ile	Thr	Gly	Asn	Arg	Ser	Glu	Pro	Val	Val	Ile	Asn	Ser
450				455					460						
1812															
gaa	ggc	tgg	gga	gag	ttt	cac	gta	aac	ggc	ggg	tcg	gtt	tca	att	tat
Glu	Gly	Trp	Gly	Glu	Phe	His	Val	Asn	Gly	Ser	Val	Ser	Ile	Tyr	
465				470					475				480		
1860															
gtt	caa	aga	tag	aagacgagag	aggacggatt	tcttgaagga	aatccgtrrrt								
490															
1912															

Val Gln Arg

## SEQUENCE LISTING

tttttttt

1920